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Post-translational modification (PTM) of proteins is known to be a method by which 
protein function can be regulated.  The addition of selected chemical groups at specific 
amino acid residues can act as a switch by which the function of a modified protein can 
be attenuated.  Histones are a group of proteins which are found in the nucleus of 
eukaryotic cells and interact with DNA, providing it with a structural foundation upon 
which the chromosome is built.  Histone proteins have numerous sequence variants and 
are known to be extensively post-translationally modified in a dynamic manner.  These 
modifications have a direct effect on the interacting DNA resulting in increasing or 
decreasing levels of gene transcription. 
 
Advancements in analytical instrumentation, when coupled to high resolution separation 
techniques permit the analysis of increasingly complex biological mixtures.  Fourier 
transform ion cyclotron resonance mass spectrometry (FT-ICR MS) offers unrivalled 
mass resolving power and mass measurement accuracy, allowing the detailed study of 
mixtures of intact proteins and their post-translational modifications.  These features have 
been exploited to provide a global view of the PTMs of histone proteins. 
 
The work contained within this thesis is a study, by FT-ICR MS, of the modifications of 
one of the most extensively modified histone proteins; histone H4.  Firstly, the 
modifications of histone H4 were examined after treatment with a potent histone de-
acetylase inhibitor across several cell lines.  The cell lines chosen showed a varying 
response to treatment with the inhibitor.  From the cell lines tested, two which responded 
differently were further interrogated to elucidate the order in which acetylation occurs in 
the N-terminal region. 
 
Secondly, the modifications of histone H4 were analyzed after exposure to lactic acid 
over multiple treatment times.  Lactic acid is a metabolic by-product, and is of interest 
when considering the Warburg effect and its role in tumorigenesis.  Exposure of cells to 
levels of lactic acid which can be present under anaerobic conditions (i.e. during intense 
vi 
 
exercise) showed that lactate is able to inhibit histone de-acetylation.  The resulting 
increase in hyper-acetylated forms of histone H4 could be potentially linked to increased 
gene expression, a typical observation in tumorigenic cells. 
 
Finally, using a mouse model for the neurological condition Rett Syndrome, the post-
translational modifications of histone H4 were investigated.  The primary cause of Rett 
Syndrome is mutation of the DNA binding protein methyl CpG binding protein 2 
(MeCP2).  MeCP2 has been associated with multiple intracellular functions, one of which 
is chromatin remodelling.  The work carried out showed a link between MeCP2 mutation 
and tri-methylation of histone H4.  In addition, the tri-methylation was not solely 
identified through the presence of tri-methylated fragments in fragmentation mass spectra.  
Interestingly, the neutral loss of a methylene group was observed extensively during 
fragmentation of tri-methylated species. This unreported phenomenon made 















The main purpose of this work was to demonstrate that mass spectrometry, while 
primarily a technique used in analytical chemistry, could be used as a valuable tool in 
medical investigation; used here in the study of epigenetics. 
Chapter 3 of this thesis demonstrated that mass spectrometry could be used to establish 
the order in which epigenetic modifications occurred on histone H4, and that while the 
response of multiple cell lines was different to drug administration, the order in which 
modifications occurred was consistent. 
Chapter 4 showed that lactic acid, a compound produced by the body, could affect  
histone acetylation and that this could be linked to changes in acetylation profile seen in 
tumorigenic tissues.  The changes in acetylation were observed and quantified by mass 
spectrometry. 
Chapter 5 was a study of the acetylation profile of histone H4seen in patients suffering 
from the neurological condition Rett Syndrome.  It was shown that specific markers for 
the condition could be observed by mass spectrometry and that these markers could be of 
diagnostic value. 
Each experimental chapter of this thesis demonstrates that mass spectrometry could be a 
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This introduction provides background information relevant to the work presented in this 
thesis.  A description of the complex biological language of protein post-translational 
modifications is given, along with detailed information on the proteins chosen for this 
study; histone proteins.  A discussion of various aspects of protein mass spectrometry is 
given, as well as a full description of the physical principles underlying the instruments 
used throughout the work.  The ultimate aims of the work are listed at the end of the 
introduction. 
The focus of this work was the investigation of the post-translational modifications 
(PTMs) of histone H4, a protein which plays a crucial role in the process of DNA 
packaging within the cell.  Specifically, this work aims to utilise the many advantages 
associated with  Fourier transform ion cyclotron resonance mass spectrometry to 
investigate histone PTMs.   
Chapter 2 of this thesis describes the materials, methods and instrumentation used 
throughout the work, and each subsequent chapter presents experimental results. 
Chapter 3 examines how acetylation of histone H4 (a common post-translational 
modification) is altered after exposure to a potent de-acetylase inhibitor.  In addition to 
testing the potency of the compound over numerous cell lines, the order in which N-
terminal residues are acetylated is determined. 
Chapter 4 of this thesis builds on the results presented in Chapter 3, and focuses on the 
changes to PTMs after cells were exposed to an endogenous metabolic by-product.   The 
final experimental chapter, Chapter 5, demonstrates the application of high resolution 
mass spectrometry to investigate the PTMs linked to a neurological condition from 
2 
 
samples which were derived from a primary tissue source, as opposed to the cell cultures 
used in the work described in the previous chapters. 
 
1.1 Epigenetics 
The storage and transmission of information within organisms is critical to the survival of 
the organism, and affects many of the tasks involved in respiration, damage repair and 
replication.  A common feature across all eukaryotes and many prokaryotes is the method 
by which information is stored.  Macromolecules are used exclusively for information 
transmission through generations, and for high fidelity storage.  While there are several 
classes of biological macromolecules, only two are used in the transmission and storage 
of heritable information; nucleic acids and proteins.   
When the human genome was fully published in the last decade, it was thought that the 
key to understanding many diseases lay in the genetic sequence.  This has not been the 
case, and it appeared that information could be passed through generations without 
altering an organism’s genome.  This area of study, the heritable transmission of 
information leading to altered phenotype of an organism without changes to the genome, 
is called epigenetics and focuses almost exclusively on modifications to deoxy-ribose 
nucleic acids (DNA) and proteins; the two main components used to store biological 
information.   
The central dogma (shown in Figure 1.1) initially described by Francis Crick
1
, addressed 
how biological information was transferred through different classes of macromolecules.  
At the time, little was known about the inheritance of a phenotype, without altering the 
genotype.  As such, the central dogma could be considered incomplete due to its omission 
of DNA and protein post-translational modifications.  To some extent, every protein 





Figure 1.1:  Illustration of the position of Epigenetics as part of the central dogma.  Epigenetics deals 
with modifications of biopolymers: DNA, RNA and proteins. 
 
1.1.1 DNA Structure and Modification 
A common feature of eukaryotes is that heritable information is localised to a specific 
compartment of the cell (the nucleus), and the genome is encoded in DNA.  DNA is 
structured as a double helix
2
 (illustrated in Figure 1.2 (a)) and multiple forms are known 
to exist e.g  α-, β- and z- etc
3
.  The concept of the central dogma postulated by Crick 
suggested a direction to the passage of information contained in nucleic acids, and that 
once information was captured as a protein, it could not subsequently be released.  The 
intermediate steps (DNA     RNA) and (RNA     protein) are termed transcription and 
translation respectively.  Crick also recognised that DNA replication was a special 
process which did not involve RNA.  Transcription is the process where the information 
contained in the single letter nucleotide sequence is re-written from DNA to RNA, and 
translation is the process where the newly transcribed information (contained in the single 
letter RNA sequence) is translated into protein, from three letter codons into single amino 
acids.   
In the nucleus, DNA is found in discrete units called chromosomes, composed of DNA 
and proteins (collectively called chromatin) which provide their structure.  Since the 
entire genome of an organism is contained in each cell, DNA must be heavily compacted, 
yet still accessible to carry out the processes of gene expression and replication.  Proteins 
provide the means by which the genome can be packaged to fit into the nucleus of each 
cell and still be accessible for transcription.  Figure 1.2 (below) illustrates how DNA is 
stored in the cell.   
DNA RNA Protein Biological Function  
PTMs 
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Figure 1.2: The organisation of DNA in the cell.  The DNA double helix (a) is wound around the core 
histones to form beads of nucleosomes (b).  The nucleosome beads are packed into 30 nm fibres (c), 




While the DNA sequence can be considered a blueprint for building a cell, it gives little 
quantitative information on the amount of each protein required, their interactions and the 
order in which large protein complexes are assembled.  It has emerged that DNA can be 
modified by the addition of small moieties at a specific locations.  Of the four DNA bases, 
cytosine is known to be modified by the addition of methyl and hydroxy-methyl groups at 
carbon-5 of the pyrimidine ring, only when present in a CG dinucleotide (referred to 
hereafter as CpG), and can be modified on both strands or on a single strand (hemi-
modified).  Figure 1.3 below shows modified forms of cytosine. 
                                                     
Figure 1.3:  Modified forms of the DNA base cytosine.  The site and nature of the modification is 
highlighted in red. (a) cytosine, (b) 5 methyl-cytosine, (c) 5 hydroxymethyl-cytosine. 
 
DNA methylation is one mechanism by which genetic information potential can be 
extended, and is associated with a condensed chromatin structure (termed 
heterochromatin), leading to reduced gene expression
5
.  Early studies into DNA 
methylation suggested a link with the distribution of active and inactive chromatin in the 
nucleus.  This link was subsequently refined to show that methylation was often found at 
the promoters of inactive genes, suggesting involvement of DNA methylation in gene 
(f) (e) (d) (c) (b) (a) 





.  Methylation is essential in parental imprinting, X chromosome inactivation 
and development
9,10
.  Although the mechanism by which methylated DNA represses gene 
activation is still under debate, one widely accepted view is that gene silencing is 
achieved through direct interference of the methyl group with the binding of transcription 
factors
11
.  Another possibility is that modified DNA is able to recruit methyl CpG binding 
proteins which mediate repression through altering chromatin structure
12,13
.   
Modifications are added to the DNA molecule by groups of enzymes; DNA methyl 
transferases and hydroxy-methyl transferases, which fall into several classes based on 
their mode of action.  There are three primary DNA methyl transferase (DNMT) enzymes 
in eukaryotes; DNMT1, DNMT3a and DNMT3b, which fall into two classes, namely 
maintenance and de novo methyl transferases.  It is known that after fertilization, the 
methylation pattern is completely erased from the gametes, followed by establishment of 
a new pattern by de novo methylation 
14
.  DNMT3a and DNMT3b are de novo methyl 
transferase enzymes which are able to methylate CpG dinucleotides in un-methylated and 
hemi-methylated DNA.  They are present at high levels in embryonic stem cells, but at 
much lower levels in adult tissues.  DNMT1 is a maintenance methyl transferase enzyme 
with high affinity for hemi-methylated DNA.  This was the first methyl transferase 
enzyme characterised, and due to its specificity for hemi-methylated DNA it is most 
active during DNA replication, when it is recruited to reproduce the methylation of the 
parent DNA strand to the daughter strand 
15,16
.   
The function of hydroxy-methylated DNA is not well understood.  Few genes have been 
identified which code for enzymes able to modify DNA with this group, but hydroxy-
methylation may play an important epigenetic role.   
The possibilities for DNA modification represent a means by which genes can be 
activated or silenced without altering DNA sequence, i.e. epigenetically.  The other 
primary mode of epigenetic gene control is through alteration of chromatin structure, 





1.1.2 Histone Proteins and Nucleosome Structure 
The nucleosome can be described as the smallest repeating unit which makes up the bulk 
chromatin material, and is an octamer of four histones (2 dimers of H2a and H2b, and a 
tetramer of H3 and H4), which bind roughly 146 bp of DNA
17
.  Histones are the main 
protein component of chromatin and interact directly with DNA.  There are five histones 
in total; four of which make up the nucleosome core particle (shown in Figure 1.2), and 
one which resides out-with the nucleosome and acts as a sliding link with DNA.  The 
histone proteins share similar structural features; each has a C-terminal globular domain 
and an N-terminal tail.  Only the globular domains form the nucleosome core, while the 
N-terminal tails project out from the nucleosome.  Initial studies of nucleosome 
composition carried out in the 1970’s were performed using reconstitution, sedimentation 
and gel electrophoresis and showed that equimolar amounts of each core histone were 
required for nucleosome formation.  Much of the work by Roger Kornberg focused 
specifically on the structure and components of the nucleosome.  In 2006 he was awarded 
the Nobel Prize in Chemistry for his studies of genetic information transmission. 
The focus of this initial work was the elucidation of the structure of the nucleosome.  
Analysis of bands visualised through gel electrophoresis suggested that the components 
must associate into larger complexes (dimers or trimers), while nuclease digestion was 
used to reveal the size of the core particle, and the amount of DNA associated with each 
nucleosome
18-20
.  This work served to confirm data from X-ray diffraction studies of the 
nucleosome carried out previously, and helped to establish a model suggesting that 
chromatin structure was formed through a repeating unit of histones and DNA
21
.  Studies 
which employed cross-linking of histone amino groups showed that nucleosome structure 
was similar in native chromatin, and in solution (denatured), and suggested a packing 
ratio (the level of compaction of unravelled DNA in relation to the spacing of 
nucleosome particles) of roughly 7:1
22
.  These studies also showed that the nucleosome 
particle was composed of hetero-dimers and a tetramer of histones; two H2a-H2b dimers 
associated with an H3-H4 tetramer, without H1 present
23
.  Further studies would focus on 
higher order chromatin structure.  Electron microscopy of chromatin was used to 
visualize linear arrays of particles
24,25
, confirm the circular form of the nucleosome, and 
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show that nucleosomes were present as ‘beads on a flexibly jointed chain’ in chromatin.   
This work also confirmed the earlier idea that DNA was associated to the perimeter of the 
nucleosome, rather than the core
26
, and that the overall size of the repeating unit (the 
nucleosome and associated DNA) was roughly 100 Ǻ
27
.  The nucleosome core particle is 
illustrated in Figure 1.4 below. 
 
 
Figure 1.4:  Structure of the nucleosome (RSC PDB:  1KX5).  (a) front view and (b) side view.  
Histones are H2a-Yellow, H2b-Green, H3-Red and H4-Blue.  147 bp DNA (orange chain) are 
wrapped around the nucleosome core. 
Nucleosome formation occurs through initial binding of DNA to the H3-H4 tetramer, 
followed by encapsulation by two H2a-H2b dimers.  Histones H3 and H4 are the prime 
directors of nucleosome structure, while the H2a-H2b dimers appear to add stability
28
.  
Interestingly, charge reduction of the histone tails appeared to play a crucial role in 
assembly of the nucleosome, however it was shown that substitution of the H3 and H4 
tails permitted nucleosome assembly, but had a detrimental effect on the transcription of 
specific genes
29,30
.   
In the 1980’s, with nucleosome structure well understood, there was a shift in the focus 
of study to what would become the subject of epigenetics.  The pioneers of this work 
were C. David Allis and Brian D. Strahl who chose to focus more on histone proteins and 
their post-translational modifications.  While Kornberg showed that nucleosomes inhibit 
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transcription when gene promoters are located on nucleosomes, but that transcription 
could proceed when promoters were positioned away from histones
31
, the interplay 
between histone PTMs was demonstrated in several studies by Allis.  The majority of 
their work was conducted using the organism Tetrahymena thermophila.  This organism 
has a different cell compartment organization compared to most eukaryotes, specifically 
it contains two nuclei; a macronucleus which houses genes transcribed during normal 
cellular function, and a micronucleus which is transcriptionally silent, but which is 
involved in the organisms duplication.  This segregation of function allowed Allis and co-
workers to study in great detail how PTMs were localised when associated with specific 
biological functions.   
Originally, histones were thought to exclusively play a structural role, providing a 
scaffold around which DNA can wrap and be compacted.  It has emerged, however, that 
histones are extensively post-translationally modified and that these modifications are 
able to disrupt interactions with DNA and alter chromatin structure.  Two popular 
theories attempt to explain how histone PTMs affect transcription; the first suggests that 
modifications physically disrupt DNA/histone interactions leading to unwinding of DNA 
from the nucleosome.  This disruption could be the result of post-translational 
modifications occupying space which is necessary for transcription factor binding, or 
through localized charge alteration due to the modification.  The presence of negatively 
charged phosphate groups (as PTMs) would repel a DNA backbone and the neutralization 
of basic amino acids present in the histone N-terminal region would have a similar effect.  
The second theory postulates that histone modifications serve as substrates which recruit 
chromatin modifying enzymes.  Histone PTMs include methylation, acetylation, 
phosphorylation, ubiquitination and sumoylation, and the majority are observed on the N-
terminal tail where they induce structural changes to the globular domains which affect 
nucleosome stability
22
.   
Initially through studying nucleosome assembly, it was shown that newly synthesized 
histones H3 and H4 were acetylated at specific residues, and that although acetylation 
sites varied between histones in transcriptionally active regions, and newly formed 
nucleosomes, the acetylation was performed by a single histone acetyl-transferase (HAT) 
enzyme
32
.    It was also shown that during nucleosome assembly, histone acetylation 
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occurred at the time of synthesis, and not after formation of the nucleosome.  These 
acetyl groups are subsequently removed by de-acetylase enzymes
33
.  In contrast to 
acetylation during assembly, proteolytic cleavage of N-terminal residues was also 
identified as a PTM which affected localization of newly formed nucleosomes.  This 
PTM, apparently specific to H3, was found associated with transcriptionally silent 
chromatin, and possibly serves to direct compartmentalization of chromatin with specific 
biological functions
34,35
.  Evidence supporting the idea that specific histone isoforms 
were involved in different biological functions was further reinforced with the discovery 
that a variant of H2a is enriched in the nucleoli of mammalian cells, and that a similar 
variant (in Tetrahymena) was found only in the transcriptionally active macronucleus
36,37
.  
Further study of H2a found that these variants were highly conserved, specifically that 
the H2a core domain, shown in Figure 1.4(a) was conserved and that the level of 
conservation suggested an important biological role
38
.  These findings suggested that the 
location of these variants may be linked to their function.  With the theory that histone 
isoforms are linked to specific biological events well established, multiple studies began 
to focus on the role of dynamically regulated post translational modifications.  While 
histone families H2a and H2b include many sequence variants, histones H3 and H4 do 
not.  However, the density of modifiable residues in their N-terminal regions, coupled to 
their intimate interaction with DNA in the intact nucleosome presents opportunities for 
the regulation of DNA templated events through post-translational modification. 
L. G. Chicoine (while working for Allis) showed that different residues were 
preferentially modified (in H4) between transcriptionally active and silent chromatin
39
.  
This finding suggested that each modification site may be functionally distinct from the 
others; in addition they found that PTMs seldom appeared isolated, but in fact various 
combinations of modifications appeared together during biological events.  They noted 
that there was an inter-dependence between modifications; i.e. that the presence of one 
specific modification could interfere with the addition of PTMs at other locations
40
.  This, 
along with the observation that acetylated H4 played a critical role in transcription factor 







While a single modification can affect the entire structure, typically a combination of 
modifications is observed. The large number of modifiable residues in the N-terminal 
tails presents multiple opportunities for epigenetic control; in addition three of the core 
histones have multiple sequence variants, some of which are associated with specific 
cellular events.  Figure 1.5 (below) shows the four core histones, their most commonly 
observed sequence variants, and highlights the sites of modification. 
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H2a-1           SGRGKQGGKA RAKAKTRSSR AGLQFPVGRV HRLLRKGNYS ERVGAGAPVY LAAVLEYLTA 60 
H2a-1h          SGRGKQGGKA RAKAKTRSSR AGLQFPVGRV HRLLRKGNYS ERVGAGAPVY LAAVLEYLTA  
H2a-1f          SGRGKQGGKA RAKAKTRSSR AGLQFPVGRV HRLLRKGNYS ERVGAGAPVY LAAVLEYLTA  
H2a-1k          SGRGKQGGKA RAKAKTRSSR AGLQFPVGRV HRLLRKGNYS ERVGAGAPVY LAAVLEYLTA  
H2a-3           SGRGKQGGKA RAKAKSRSSR AGLQFPVGRV HRLLRKGNYS ERVGAGAPVY LAAVLEYLTA  
  
H2a-1           EILELAGNAA RDNKKTRIIP RHLQLAIRND EELNKLLGRV TIAQGGVLPN IQAVLLPKKT 120 
H2a-1h          EILELAGNAA RDNKKTRIIP RHLQLAIRND EELNKLLGRV TIAQGGVLPN IQAVLLPKKT  
H2a-1f          EILELAGNAA RDNKKTRIIP RHLQLAIRND EELNKLLGRV TIAQGGVLPN IQAVLLPKKT  
H2a-1k          EILELAGNAA RDNKKTRIIP RHLQLAIRND EELNKLLGRV TIAQGGVLPN IQAVLLPKKT  
H2a-3           EILELAGNAA RDNKKTRIIP RHLQLAIRND EELNKLLGRV TIAQGGVLPN IQAVLLPKKT  
 
H2a-1           ESHHKAKGK 129 
H2a-1h          ESHHKAK-- 127 
H2a-1f          ESHHKPKGK 129 
H2a-1k          ETHHKAKGK 129 
H2a-3           ESHHKAKGK 129 
                   
    
 
Figure 1.5 (a): Structure of H2a (RSC PDB:  1KX5) with sequence alignment of commonly observed H2a isoforms.  Shaded residues indicate sites of 
post-translational modification in N-terminal regions where (_) indicates phosphorylation or acetylation, (_) methylation or acetylation, (_) acetylation 
and (_) methylation. 
N-terminal tail 




                                                                               
 
H2b-1b          PEPS-KSAPA PKKGSKKAIS KAQKKDGKKR KRSRKESYSV YVYKVLKQVH PDTGISSKAM 59 
H2b-3a          PEPS-RSTPA PKKGSKKAIT KAQKKDGKKR KRGRKESYSI YVYKVLKQVH PDTGISSKAM  
H2b-1c          PEPA-KSAPA PKKGSKKAVT KAQKKDGKKR KRSRKESYSV YVYKVLKQVH PDTGISSKAM  
H2b-2b          PDPA-KSAPA PKKGSKKAVT KVQKKDGKKR KRSRKESYSV YVYKVLKQVH PDTGISSKAM  
H2b-1a          PEVAVKGATI SKKGFKKAVT KTQKKEGRKR KRCRKESYSI YIYKVLKQVH PDTGISSKAM 60 
                 
 
H2b-1b          GIMNSFVNDI FERIASEASR LAHYNKRSTI TSREIQTAVR LLLPGELAKH AVSEGTKAVT 119 
H2b-3a          GIMNSFVNDI FERIASEASR LAHYNKRSTI TSREVQTAVR LLLPGELAKH AVSEGTKAVT  
H2b-1c          GIMNSFVNDI FERIAGEASR LAHYNKRSTI TSREIQTAVR LLLPGELAKH AVSEGTKAVT  
H2b-2b          GIMNSFVNDI FERIAGEASR LAHYNKRSTI TSREIQTAVR LLLPGELAKH AVSEGTKAVT  
H2b-1a          SIMNSFVTDI FERIASEASR LAHYNKRSTI TSREIQTAVR LLLPGELAKH AVSEGTKAVT 120 
                 
 
H2b-1b          KYTSSK 125 
H2b-3a          KYTSSK  
H2b-1c          KYTSSK  
H2b-2b          KYTSSK  
H2b-1a          KYTSSK 126 
                 
Figure 1.5 (b): Structure of H2b (RSC PDB:  1KX5) with sequence alignment of commonly observed H2b isoforms.  Shaded residues indicate sites of 
post-translational modification in N-terminal regions where (_) indicates phosphorylation, (_) methylation or acetylation, (_) acetylation and (_) 
methylation. 




                                                                        
 
 
H3.1            ARTKQTARKS TGGKAPRKQL ATKAARKSAP ATGGVKKPHR YRPGTVALRE IRRYQKSTEL 60 
H3.2            ARTKQTARKS TGGKAPRKQL ATKAARKSAP ATGGVKKPHR YRPGTVALRE IRRYQKSTEL  
H3.3            ARTKQTARKS TGGKAPRKQL ATKAARKSAP STGGVKKPHR YRPGTVALRE IRRYQKSTEL  
               
 
H3.1            LIRKLPFQRL VREIAQDFKT DLRFQSSAVM ALQEACEAYL VGLFEDTNLC AIHAKRVTIM 120 
H3.2            LIRKLPFQRL VREIAQDFKT DLRFQSSAVM ALQEASEAYL VGLFEDTNLC AIHAKRVTIM  
H3.3            LIRKLPFQRL VREIAQDFKT DLRFQSAAIG ALQEASEAYL VGLFEDTNLC AIHAKRVTIM  
                 
 
H3.1            PKDIQLARRI RGERA 135 
H3.2            PKDIQLARRI RGERA  
H3.3            PKDIQLARRI RGERA  
 
                 
Figure 1.5 (c): Structure of H3 (RSC PDB:  1KX5) with sequence alignment of H3 isoforms.  Shaded residues indicate sites of post-translational 













                                    
 
 
H4      SGRGKGGKGL GKGGAKRHRK VLRDNIQGIT KPAIRRLARR GGVKRISGLI YEETRGVLKV 60 
 
 
      FLENVIRDAV TYTEHAKRKT VTAMDVVYAL KRQGRTLYGF GG  102 
 
 
Figure 1.5 (d): Structure and sequence of H4 (RSC PDB:  1KX5).  Shaded residues indicate sites of post-translational modification in N-terminal 
regions where (_) indicates acetylation and (_) methylation. 
 





Examination of each core histone (Figure 1.4 above) reveals structural features are 
conserved.  Each has an N-terminal tail projecting out from the nucleosome core, and 
each has a helical core domain (composed of at least three α-helices).  H2a has an 
additional C-terminal projection, not found on the other histones.  Other conserved 
features include the density of basic amino acid residues (lysine and arginine) in all four 
histones, concentrated in the N-terminal regions.  There is striking similarity in the 
sequences of two of the core histones: H2a and H4.  Not only do they share similar N-
terminal sequences, but the spacing between modifiable residues is conserved.  Since the 
histone tails are accessible to the nuclear environment, the finding that several 
transcriptional activators contain two bromo-domains suggests that HATs may have 
multiple targets. 
The N-terminal domain of H3 contains several modifiable residues, and studies have 
linked these modifications to biological events, e.g. methylation of lysine 9 is observed 
during transcriptional repression, while tri-methylation at lysine 4 has been suggested as 
a marker for active transcription
43-45
.  Phosphorylation at serines 10 and 28 have been 
linked to chromosome condensation during mitosis, and appears in conjunction with 
acetylation
46
.  Similarly, acetylation of the N-terminal of H4 at lysines 8 and 16 has been 
linked to a transcriptionally active state
47,48
, while further acetylation of all H4 N-
terminal lysines  has been linked to higher order chromatin structure showing correlations 
with cell cycle progression
49
.   
Histone protein H1 (which is not found within the nucleosome) serves as a sliding ‘linker’ 
at the entry and exit points of the bound DNA chain.  The flexibility in the positioning of 
H1 allows easier interaction between histone proteins and DNA.  The positioning of H1 
relative to the nucleosome was proposed as a result of X-ray patterns generated by 
Richards and Pardon in 1970
50
.  They observed that removal of histone H1 from 
chromatin preparations did not alter the diffraction pattern.  In addition, it was shown by 
Kornberg
19
 that the other histone proteins were present in relatively equal amounts, while 
roughly half as much of histone H1 was present.  Subsequent work on H1 focused on its 
interaction with DNA, and revealed that the extent of this interaction was dependent on 




sedimentation analyses revealed H1 was involved in the link between nucleosome 
beads
51
.  A hypothesis for the function of H1 suggested that it served to stabilize 
nucleosome structure, based on its preferential interaction for double stranded DNA and 
the regular spacing between core nucleosome complexes, shown to be roughly 43 bp of 
DNA but which can vary between organisms
52-54
. 
The presence of multiple modifications on the same histone tail, or in different histones, 
suggests that they may work in synergy as part of a larger framework to exert some 
regulatory control.  Current research suggests that the combination of modifications 
present on the histone N-terminal tails forms a ‘histone code’, indicating the level of gene 
transcription, and that an intimate association between histone modifications exists
55
.  In 
the absence of these post-translational modifications, when the nucleosome is tightly 
wound, and the chromosome is compact, transcription does not occur
56,57
.  Each 
methylation and acetylation is able to recruit or disrupt binding of transcription factors or 
chromatin remodelling proteins, possibly by serving as a substrate for chromo-domain or 
bromo-domain containing proteins respectively.  The bromo-domain is a structural motif; 
110 amino acids long which binds to acetylated lysine as a substrate.  Multiple bromo-
domains have been found in many transcriptional activators, however its function is not 
well understood
58
.    
Figure 1.6 (below) shows the most common histone post translational modifications. 
While the array of histone PTMs includes phosphorylation, acetylation, methylation and 
to a lesser extent ADP-ribosylation (primarily found on H1
59,60
), the majority of 
modifications present are acetyl and methyl groups (including N-terminal acetylation), 
and so are primarily found on lysine and arginine residues.  Histone acetylation is a 
dynamic modification, and is mediated through the action of acetyl transferase and 
deacetylase enzymes.  The most widely accepted theory suggests that disruption of 
electrostatic forces permits unwinding of DNA from the nucleosome allowing enough 
space for transcription factors to bind.  In contrast, histone methylation is regulated by 
methyl transferase enzymes (distinct from those involved in DNA methylation), and 







    
 
    
 
 




Figure 1.6:  The most commonly observed histone post-translational modifications of lysine and 
arginine; (a) acetyl lysine, (b) methyl lysine, (c) di-methyl lysine, (d) tri-methyl lysine, (e) methyl 









Acetylation of histones is not limited to specific lysine residues in the N-terminal regions.  
Indeed, histone acetylation was first described as a modification of the N-terminal residue 
through experiments which attempted to sequence these proteins
61
.  This acetylation was 
different to that seen as a side chain modification in that it displayed a different rate of 
turnover, and it was shown that acetyl groups were N-linked, and not O-linked.  While all 
histone proteins can be acetylated, H4 and H3 are acetylated to greater levels than the 
others
62
.  The state of acetylation at any time can be thought of as a result of the action of 
two enzymatic activities.  Histone acetyl transferases (HATs) catalyse the addition of 
acetyl groups (using acetyl coenzyme-A as the acetyl donor), while histone de-acetylases 
(HDACs) catalyse the removal of acetyl groups.  Acetylation had been linked to active 
gene transcription, and the search for the enzymes responsible lead to the discovery that 
some transcription factors possessed HAT and HDAC activities
63-65
.  The studies into the 
process of histone acetylation also revealed that the model of a simple correlation 
between increased acetylation and active transcription was too simplistic.  In depth 
analysis of different HATs revealed that each had different targets, i.e. different residues 
would serves as binding substrates, possibly suggesting that each HAT is linked to a 
specific biological event
66
.  These studies also showed that while HATs contain 
bromodomains, these bromodomains are not required for acetyl transferase activity.  
Instead, the bromodomains may serve to stabilise binding of other chromatin associated 
proteins. 
The higher incidence of acetylation and methylation presents difficulties when 
investigating PTMs by mass spectrometry.  Since multiple modifications are typically 
present simultaneously, the identification of an acetyl group (by mass) can be mistaken 
for the presence of a tri-methyl group.  Both modifications are known to be present on 
lysine residues, a highly abundant amino acid in histone proteins.   
The current paradigm of the ‘histone code’ evolved from the work of Allis, and continues 
to be expanded upon.  Collectively, studies into histone PTMs support the hypothesis that 
a histone code exists.  The documentation of modification patterns lends evidence to the 
concept that the presence of PTMs, including their chemical nature and their number are 




combinatorial and sequential modification of histone tails to extend the information 
content of the genetic code.  Thus, histone post-translational modification is fundamental 
to all DNA directed processes.  Current studies are attempting to answer some 
fundamental questions.  Are specific PTMs associated with biological events?  Is there an 
order to the appearance of PTMs?  If so, are histone PTMs a cause or a consequence of 
biological processes?  Ultimately, what is the specific nature of the interaction between 
DNA and modified histones? (e.g. how are PTMs involved in regulating transcription?).      
Technological developments in the 1990’s and early years of the 21
st
 century led to 
increased use of mass spectrometry in epigenetics research.  With the emergence of 
proteomics as a major field of study, and improvements in analytical techniques, the 
study of epigenetics would embrace mass spectrometry as a tool for protein and PTM 
characterization.  In contrast to immunological based techniques, mass spectrometry is 
able to give a global view of the modification state of a protein, and has become the 
method of choice for PTM identification.  While the last ten years have seen an 
exponential increase in the application of mass spectrometry to histones, much of the 
output has been limited to a few research groups which have developed better tools to 
address the complex problems of protein PTMs.  These tools include improved 
instrumentation, sample separation methods and software. 
An intricate theory now exists which champions the ‘histone code’ hypothesis and links 
nucleosome structure, histone sequence variants and the presence of post-translational 
modifications.  The work described in this thesis has attempted to build on this theory 
through application of mass spectrometry, specifically focusing on the dynamic nature of 
histone post-translational modification.  In particular, 
 
• to determine if histone PTMs can be reproducibly altered due to chemical 
exposure across cell lines; 
• to investigate the effects of endogenous compounds on the PTM profile of 
histones; and 





1.2 Protein Mass Spectrometry 
 
The ability to form intact molecular ions of non-volatile macromolecules using either 
electrospray ionisation (ESI)
67
 or matrix assisted laser desorption/ionisation (MALDI)
68
 
led to a drive to improve mass spectrometry instrumentation and fragmentation methods.  
Today, mass spectrometry is an integral part of proteomics, the field concerned with the 
identification of proteins from complex biological mixtures.  The sequencing of the 
genome of an organism provides much information about the proteins which are present 
in the organism, but very little about their abundances, interactions and the presence of 
any post-translational modifications.  Mass spectrometry has allowed in depth studies of 
proteins through accurate mass measurement of intact species, and by using 
fragmentation techniques for the characterisation and localisation of post-translational 
modifications.  Traditionally proteomic studies were performed by separating a sample of 
interest using 2-dimensional gel electrophoresis, to identify changes in protein expression 
(visible as spots on a 2-D gel with varying intensities).  Spots of interest would then be 
excised from the gel, the protein extracted, and interrogated by amino acid sequencing
69
.  
Today three methodologies dominate the field of proteomics, which negate the use of gel 
electrophoresis; ‘Top-down’, ‘Middle-down’ and ‘Bottom-up’ mass spectrometry.   
 
1.2.1 Top-Down Mass Spectrometry 
Top-down mass spectrometry is the study of intact proteins exclusively through mass 
spectrometry
70-72
.  A typical top-down experiment involves infusion of a sample into the 
instrument, the isolation of a precursor followed by tandem mass spectrometry.  The 
fragment ion masses generated are searched against the amino acid sequence of the 
protein (if known), or against a database.  Calculation of the intact mass from the isolated 
precursor can be used to elucidate the mass of any PTMs present, while identification of 
fragment ions permits their localisation.  Top-down experiments can provide a global 
view of all modifications present on a protein, and their abundances.  In addition, stable 
isotope labelling techniques can also be used in top-down experiments.  The steps 




spectrometry can be a versatile tool for protein/PTM identification, it suffers from 
limitations related to protein size.  Fragmentation efficiency decreases with increasing 
protein size, in part due to the tertiary structure of gas-phase proteins.  Although there is 
no defined upper limit for protein mass in top-down experiments, above a molecular mass 
of roughly 50 kDa, top-down work becomes difficult
73
.  This can be overcome by 
reducing protein size through enzymatic or chemical digestion (i.e. by performing 




Figure 1.7:  Schematic workflow of a top-down mass spectrometry experiment.  A sample is infused 
into the instrument, an ion is selected for fragmentation, fragment ions are assigned and data is 
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1.2.2 Middle-Down Mass Spectrometry 
Middle-down mass spectrometry involves cleavage of the amino acid sequence at low 
abundance residues
74,75
.  Cleavage can be induced at Asp or Lys residues using 
endoproteinases AspN or LysC respectively, while Met residues can be cleaved using 
cyanogen bromide.  The result is generation of large peptides, which can be separated by 
LC or infused directly into the mass spectrometer.  Similar to top-down experiments, 
precursor ions are isolated and then fragmented.  Fragmentation of a large peptide is 
significantly easier to achieve than that of a large protein, which is especially useful if the 
peptide is a region of a protein which may be heavily modified.  In addition, middle-
down experiments can provide extensive sequence coverage over internal regions of a 
protein which may be difficult to fragment by top-down experiments.  A schematic 








Figure 1.8: Schematic workflow of a middle-down mass spectrometry experiment.  A sample is 
partially digested before infusion into the instrument (with optional LC).  Accurate peptide masses 
are recorded before isolation of a precursor and subsequent fragmentation. 
 
1.2.3 Bottom-Up Mass spectrometry 
Bottom-up mass spectrometry is the most routinely used strategy for PTM 
characterisation
76-78
.  The bottom-up method involves complete digestion of the protein 
by an enzyme at high abundance residues.  Trypsin is typically used in bottom-up work 
due to its high specificity for lysine and arginine, where it cleaves at the C-terminals.  
Enzymatic cleavage can optionally be followed by LC separation prior to sample infusion.  
The advantages of bottom-up experiments are that they are suitable for high-throughput 
work, can be automated, and since analysis is ultimately done on peptides, bottom-up 
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experiments are not limited by protein size.  A diagram of the steps involved in a bottom 




Figure 1.9: Schematic workflow of a bottom-up mass spectrometry experiment.  The sample is 
completely digested chemically or enzymatically before infusion into the instrument, with LC 
separation and fragmentation as optional steps.   
 
Traditional bottom-up experiments attempt to identify a protein through searching 
peptide masses against a database.  The peptides serve as a mass fingerprint for the 
protein, and there is still the possibility to use fragmentation on larger peptides.  However, 
the lack of an intact mass of the un-cleaved protein presents major problems when 
performing bottom-up experiments.  Without a precursor mass, there is no knowledge of 
the modification state of the protein, making PTM assignment extremely difficult.  In 
addition, complete sequence coverage is rarely achieved in bottom-up experiments 
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resulting in PTMs going undetected.  The combinatorial nature of PTMs on proteins 
which are heavily modified can be difficult to determine using bottom-up mass 
spectrometry.   
 
1.3 Ionisation Sources 
Extensive work in the 1980’s led to the development of two ionisation techniques which 
are in widespread use today.  The unique advantage of these techniques over older 
sample ionisation methods was that gas-phase ions could be generated without 
fragmentation of the sample.  This characteristic meant these methods were soon being 
applied to the study of peptides and intact proteins.  In recognition of this achievement, 
half of the 2002 Nobel Prize in Chemistry was given to those credited with discovering 
these techniques; John Fenn for his work on electrospray ionisation
67
(ESI), and Koichi 
Tanaka for his work on matrix assisted laser desorption/ionisation (MALDI)
68
.  While 
Tanaka and Fenn enjoyed great success for revolutionising biological mass spectrometry, 
it has emerged that their work was based on observations and theories which had been 
established years earlier
79-83
.  Both ionisation techniques were employed in this research, 
however most of the experiments utilised electrospray ionisation, and all the data 
presented utilised an electrospray source. 
The principle governing MALDI is that gas-phase ions are generated through the laser 
ablation of a mixture of sample which has been co-crystallised with a matrix.  The matrix 
itself is a saturated solution of a light absorbing molecule.  The energy absorbed by the 
matrix molecules creates a plume of ions which can then be detected in a mass 
spectrometer.  Contrary to ESI, ions generated by MALDI typically carry a single charge, 
which limits mass analysis to instruments with a suitably large mass range.  For this 
reason, MALDI sources are often coupled to time-of-flight (ToF) mass analysers.  Figure 







Figure 1.10:  Schematic diagram of the MALDI process.  Crystallized matrix (yellow spheres) and 
analyte (red spheres) are irradiated by a laser, and gas-phase ions are formed. 
 
While both MALDI and ESI are considered ‘soft’ ionisation techniques, MALDI is 
carried out at near vacuum conditions, while ESI is performed under atmospheric 
conditions.  Advantages of ESI over MALDI are that less sample preparation is required, 
and ESI is compatible with a wide range of mass spectrometers.   
Debate still exists over the process of ion formation during ESI.  In practice, ESI involves 
pumping a solution containing the analyte through a needle which is held at high 
potential relative to a counter electrode.  The large electric field at the capillary tip causes 
charging of the liquid, which emerges as a mist of charged droplets.  The droplets are 
attracted to the mass spectrometer inlet due to the potential and pressure gradients.  A 




















Figure 1.11: (a) Droplet formation during ESI, and (b) a representation of the competing theories 
describing gas-phase ion formation, where CRM is the charge reduction model and IEM is the ion 
evaporation model.   
 
During electrospray ionisation, the high electrical potential at the capillary tip distorts the 
meniscus into what is described as a Taylor cone
84
.  A fine stream emerges from the 
Taylor cone, and charge repulsion propagates the ejection of droplets once surface 
tension forces have been overcome.  Continued Coulombic repulsion drives the droplets 
into an expanding plume, while solvent continues to evaporate from the droplets.  At a 
critical point (the Rayleigh limit), the Coulombic forces overcome the surface tension of 
the droplet, which experiences a large drop in volume, but only a slight reduction in 













transfer of ions from liquid to gas-phase.    Two theories exist relating to the formation of 
gas-phase ions from the charged droplets.  The charge reduction model suggests that ions 
are formed by the evaporation of solvent until only gas-phase ions remain.  This model 
was attributed to Malcom Dole, a pioneer in the field of molecular beams
80
.  The 
competing model suggests the process of ion formation is the result of ions evaporating 
directly from a charged droplet
85-87
.  While arguments persist regarding the precise nature 
of gas-phase ion formation, there is compelling evidence supporting the ion evaporation 
model
88-90
.  ESI is typically operated at solvent flow rates up to 150 μl/min, which makes 
the technique compatible with high performance liquid chromatography (HPLC) for ‘on-
line’ analysis of samples requiring separation, without the need for any desalting steps.  
The multiple charge states generated by ESI also permits the interrogation of protein 
structure to a higher level.  The presence of basic amino acid side chains can result in 
multiple charges of a protein when in acidified solution, effecting the charge state 
distribution observed,  For example, a denatured protein displays a wide charge state 
distribution (at low m/z), while proteins in native conformation exhibit narrow 
distributions at high m/z.  The charge states observed can also be effected by solvent 
used; denaturing conditions (high organic content of the solvent and low pH) favour 
unfolded protein conformations.  Denaturing solvent conditions were used throughout 
this work as the presence of protein species carrying many charges facilitates further 
study of the species by fragmentation.   
 
 
1.4 Mass Analyzers 
While the principles of ToF and FT-ICR MS have not changed since the first publications 
by Wiley and McLaren, and Comisarow and Marshall
91-93
, continuous developments in 
instrumentation have led to higher sensitivity and resolution.  The fundamental aspects of 
ToF and FT-ICR MS are covered in this section; however several extensive reviews are 
available on the subject
94-96





1.4.1 Time of Flight Analyzers 
Time of flight mass analyzers measure the mass dependent time taken by ions of differing 
masses to travel from an ion source to a detector.  To accurately measure the flight time 
of such ions, a well defined starting time is needed which can be achieved by using a 
pulsed ion source (typically a MALDI source).   







Equation 1.1:  The equation describing the kinetic energy of an ion where Ek is the kinetic energy (in 
joules), m is the mass of the partice (in kg), v is the velocity of the partice (in ms
-1
), e is the elimentary 
charge and V is the applied voltage (in volts). 
 




v   
Equation 1.2:  The equation describing the velocity of an ion where v is the velocity of the partice (in 
ms
-1
), L is the length of the ion flight path (in metres) and t is the time (in seconds). 
 
Substituting this expression of ion velocity into the Equation 1.1, and rearranging to solve 







Equation 1.3:  The equation describing the flight time of an ion in a linear ion trap where t is the 
flight time (in seconds), m is the mass of the partice (in kg), V is the voltage applied  (in volts), e is the 





There is no true limit to the upper mass range of a ToF instrument, and since time can be 
measured with great accuracy the only real limitation of ToF instruments lies in the 
length of the flight tube (i.e. the physical dimensions of the instrument)
97
.  Time-of-flight 
instruments are known to have high ion transmission and the highest practical mass range 
of any type of mass analyser, but can be limited by the need of a pulsed ion source 
(making them impractical for coupling to high performance liquid chromatography) and 
have inferior precursor ion selectivity (a useful pre-requisite for MS/MS experiments). 
 
1.4.2 Principles of FT-ICR 
Accurate mass measurement of an intact protein is necessary for the confident assignment 
of post-translational modifications (PTMs).  FT-ICR instruments offer superior mass 
measurement accuracy, defined as   10 parts per million (ppm)
98
 and sufficiently high 
resolving power to distinguish isotopic variants (i.e. a difference in the number of 
13
C or 
other heavy isotopes) contained in the compound.  Fourier transform ion cyclotron 
resonance mass spectrometry routinely provides resolving power in excess of 1,000,000 
and sub-ppm mass accuracy.   
FT-ICR MS is based on the principle that an ion moving in a homogenous magnetic field 
will resonate at a cyclotron frequency depending on the mass and charge of the ion, and 
the magnetic field strength.  An ion travelling in a uniform magnetic field experiences a 
force proportional to its mass and the strength of the magnetic field, termed the Lorentz 
Force.  The Lorentz Force is a vector cross product of the magnetic field and the velocity 







Equation 1.4: The equation describing the Lorentz Force where F is the force (N), m is the mass of 
the particle (kg), [dv]/[dt] is acceleration (ms
-2
), q is the charge of the particle (C), v is the velocity of 
the particle (ms
-1
) and B is the magnetic field strength (Tesla). 
 
The path of a particle travelling in a uniform magnetic field is bent by the magnetic field 




magnetic field.  The direction of the cyclotron motion of the ion is dependent on the 





Figure 1.12:  (a) Diagram showing the Lorentz Force leading to cyclotron motion, and (b) cyclotron 
motions of positive and negative ions.  Figure adapted from Ref 
94
.   
 
At constant velocity (assuming no collisions occur), the ion follows a circular orbit.  The 
frequency with which the ion repeats its orbit (the cyclotron frequency) can be calculated 







Equation 1.5: Calculation of the cyclotron frequency vc (Hz) where q is the charge of the particle (C), 












Equation 1.5 can be expressed in the more convenient terms of mass to charge ratio (m/z), 
the unit used in mass spectrometry where m is in Daltons, and z is equal to q/e where e is 





















Equation 1.6:  The cyclotron frequency expressed in terms of mass to charge ratio (m/z) and 
magnetic field strength (B) 
 
To illustrate this, an ion with mass to charge ratio of 1000 m/z in a 9.4 T magnetic field 
would have a cyclotron frequency of 141 kHz, while the same ion being detected in a 
uniform magnetic field of 12 T would have a cyclotron frequency of 180 kHz.  The 
ability to measure frequency with great accuracy leads to the high mass accuracy 
associated with FT-ICR MS.  The cyclotron frequencies of ions routinely measured by 
FT-ICR lie in the range of kHz to MHz, which is a convenient detection range for 
modern electronics.  In addition, cyclotron frequency is not dependent on the kinetic 
energy of the ion, thus a spread in the K.E. distribution has no effect on the resolution of 
the instrument, which can affect ToF and magnetic sector instruments.   
Equation 1.3 can be rearranged to illustrate a fundamental relationship in FT-ICR mass 
spectrometry; mass to charge ratio is directly proportional to magnetic field strength and 






Equation 1.7:  The relationship between mass to charge ratio (m/z), magnetic field strength (B) and 







1.4.3 Excitation, Detection and Resolution of Ions 
Detection of a useful signal in FT-ICR requires confining the ions in the ICR cell, which 
enter through a trapping plate.  Modern instruments typically employ a cylindrical 
geometry for the ion trap configuration, however an assortment of configurations 
including cubic, hyperbolic and hybrids of these geometries also exist.  Guan and 
Marshall provide an extensive review of several FT-ICR trap configurations detailing 
how how various configurations can be optimised for ion trapping or detection
99
.  The 
cylindrical ICR cell is made up of six plates in total:  two trapping plates at opposite ends 
of the cell, two excitation plates and two detection plates.  The excitation and detection 
plates are located perpendicular to the trapping plates such that the intact cell is 
cylindrical in form.  During detection, the cell is positioned in a spatially uniform 
magnetic field (inside the bore of the magnet), the magnetic field serves to confine the 
ions radially, while a potential is applied to the trapping plates for axial confinement.  A 




Figure 1.13:  Schematic diagram of a cylindrical ICR cell.  The cylindrically shaped cell  is composed 
of six plates:  Front and back trapping plates (grey), excitation plates (yellow) and detection plates 
(blue).   
 
A meaningful signal can only be detected after excitation of the ions in the cell through 












the cyclotron radius of the ions is too small to detect a signal.  Upon excitation, the 
cyclotron radius of resonant ions is increased, if the excitation event continues the ion 
packet spirals from the centre of the cell until it collides with the cell electrodes.  As a 
result, excitation events are short, and the resonant frequency is applied as a pulse.  After 
excitation, the ion packet continues to orbit at a larger cyclotron radius.  Detection is 
achieved through measurement of an image current induced across the detection 
electrodes.  As the ion packet passes each detection plate, positive ions attract electrons to 
the plate, while negative ions repel electrons from the plate.  This movement of electrons 
creates an alternating current through an external circuit joining the detection plates.  
While the ion packet travels through a larger cyclotron orbit, the image current can only 
be detected for a short time as space-charge effects cause de-phasing of the ion packet.  
Furthermore, collisions between the ions and neutral molecules in the cell result in a loss 
of detectable signal.  The image current is amplified before being Fourier transformed to 
generate a frequency spectrum of the ions detected.  Unlike other mass spectrometers 
which use impact based detectors, detection by FT-ICR is non-destructive and permits 
further study of ions in the cell.  An illustration of the stages of an FT-ICR experiment is 










             
Figure 1.14: The stages of an FT-ICR experiment.  Ions trapped in the cell move with a small cyclotron 
radius (a).  An RF frequency sweep is applied to excite the ions to a larger cyclotron radius allowing 
detection (b and c).  Coherent ion packets are detected through an induced current across the detection 
plates (d).  The induced current is measured as a time domain transient which undergoes Fourier 
transformation into the frequency domain (e).  The frequency spectrum generated is calibrated into a 






















The resolution of acquired data is directly proportional to the length of the transient 
image current.  The transient signal is in constant decay due to collisions between ions 
and neutral molecules and de-phasing of the ion packet in the cell through space-charge 
effects.  For this reason, FT-ICR MS must be performed at high vacuum.  The 






cTfR   
Equation 1.8: The relationship between resolution and transient length in Fourier Transform data 
where R is the resolving power, fc is the cyclotron frequency (in Hz) and T is the transient length (in 
seconds). 
 
Axial confinement of the ions is achieved through the application of a voltage to the front 
and back trapping plates of the cell.  High trapping voltages can increase resolution, 
through increasing trapping efficiency, but this creates the undesirable effect of 
increasing the magnetron motion of ions within the cell.  Magnetron motion is introduced 
to the ions as a result of the trapping potentials; it is not a component of the Lorentz force 
and is of no analytical use.  The lower measured frequency of ions in the cell, an effect of 
the magnetron motion, can shift observed masses to higher m/z values
94
.   
 
1.5 Fragmentation of Ions 
While measurement of the intact mass of an ion can provide information such as the 
presence of post translational modifications, and in the case of proteins some insight 
about secondary structure (through observation of the charge state distribution), this alone 
is insufficient to fully characterise any PTMs, especially when PTMs of similar mass are 
present.  In these circumstances, the identification of any PTMs is limited by the 
resolving power and mass accuracy of the instrument.  Isolation of an ion, and its 




Several fragmentation techniques have been adapted for use in FT-ICR instruments, with 
developments constantly being made in this area.  Tandem mass spectrometry involves 
the fragmentation of a precursor ion (MS/MS), and provided that fragment ions are 
present in high abundance, this process can be repeated (MS
n
).  Modern FT-ICR 
instruments allow the comprehensive study of intact proteins by using multiple 
fragmentation techniques.  The most common techniques are described below.   
   
1.5.1 Fragment Ion Nomenclature 
When studying proteins and peptides by fragmentation, the peptide backbone can be 
cleaved in three possible places; each of the covalent bonds present in an amino acid.  
After dissociation, gas-phase re-arrangements take place to form more stable ions where 
the charge can be retained on the N-terminus or the C-terminus of the fragment.  
Depending on the type of fragments formed, N-terminal fragments carrying the charge 
are called a, b or c ions, while C-terminal fragments are called x, y or z ions
100
.  Fragment 
ions formed tend to be specific to the fragmentation method used, and usually appear in 
pairs; e.g. a ions are formed with x ions, b ions with y ions and c with z ions.  A 
numerical value is also assigned to each fragment generated, indicating the number of 
amino acids present in the fragment.  In addition to cleavage of peptide backbone bonds, 
it is also possible to break bonds of the amino acid side chain, termed d, v and w 
fragments; the presence of side chain fragments can greatly complicate interpretation of 
fragmentation spectra.  Figure 1.15 is an illustration of the different fragments formed 
through cleavage of the bonds in the peptide backbone.              





Figure 1.15:  Nomenclature of fragment ions formed from the cleavage of the peptide backbone.  
Typically a and x ions appear together (green), b and y (blue) and c and z ions (red) are formed 
depending on the fragmentation method used.   
 
1.5.2 Collision Induced Dissociation 
Collision Induced Dissociation (CID) is a routinely used fragmentation technique due to 
its reproducibility and simplicity of application.  This method works by increasing the 
internal energy of the precursor ion after collision with a neutral gas (typically helium, 
nitrogen or argon), which leads to bond dissociation in the precursor
101-104
.  CID can be 
classified as low energy or high energy, depending on the instrument used
105
.  Along with 
infra-red multi photon dissociation (IRMPD), low energy CID can be considered a slow 
heating technique, which relies on increasing the internal energy of the precursor 
resulting in bond cleavage
106,107
.  Fragmentation of proteins by slow heating methods 
primarily results in dissociation of the amide bonds of the protein or peptide, producing 
predominantly b and y fragment ions.  In addition, cleavage of amino acid side chains and 
loss of small neutral molecules can occur, which can make interpretation of CID spectra 
more difficult, especially when trying to localise PTMs.  However, CID alone is of 
limited use when characterizing PTMs of an intact protein, due to the relationship 
between fragmentation efficiency and molecular size.  An increase in molecular size is 
accompanied by an increase in the number of degrees of freedom, resulting in a greater 
number of channels through which energy can be dissipated.  In consequence, a decrease 
in yield of fragment ions formed through bond cleavage on the peptide backbone is 
observed with increasing precursor mass, resulting in lower sequence coverage.   
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1.5.3 Electron Capture Dissociation 
Electron capture dissociation is a relatively modern fragmentation technique which is 
implemented almost exclusively on FT-ICR instruments
108,109
.  ECD occurs through the 
recombination of an electron with a positively charged ion to induce N-Cα bond cleavage, 
preferentially giving c and z fragment ions.  The bond dissociation process has been 
described as ‘non-ergodic’; bond breaking occurs before the precursor can dissipate 
energy vibrationaly, resulting in random cleavage of specific bonds along the peptide 
backbone which is distinct from slow heating techniques
110,111
.  Most importantly, due to 
this fast fragmentation labile post-translational modifications and non-covalent bonds 
often remain intact after backbone bond dissociation.  As a result, more confident 
assignment of PTMs is possible, and internal fragments tend to be appear at much lower 
abundance in ECD spectra which simplifies their interpretation
112,113
.  During the capture 
event, a multiply charged precursor [M + nH]
n+ 
acquires an electron, and if sufficient 
energy is accumulated, the N-Cα bond of the peptide backbone is cleaved.  If bond 
dissociation does not occur, a charge reduced species is formed [M + nH]
n-1+
.    
Traditionally the electron source in ECD was thermal emission of electrons from a 
filament placed at the rear of the ICR cell.  Modern instruments employ a hollow 
dispenser cathode in the same position, with the added benefit that the hollow design of 
the cathode permits IRMPD as well as ECD.   
ECD has several drawbacks; its implementation is predominantly limited to FT-ICR 
instruments, which has limited its use for top-down mass spectrometry.  ECD is also an 
inefficient process; the recombination product of a positively charged precursor with an 
electron is primarily a charge-reduced ion
114,115
.  For this reason, ECD can only be used 
on multiply charged precursor ions; therefore it must be used in an instrument with an 
ESI source
116,117
.  The detailed mechanisms underlying bond cleavage during ECD are 
still subject to debate, however this area is explored in several publications
118-121
.  The 
two most popular theories on the mechanism of c and z fragment ion formation are the 
Cornell mechanism and the Utah-Washinton mechanism
122,123
.  The Cornell mechanism 
suggests that the electron is initially captured at a highly excited Rydberg state followed 




the formation of a hypervalent radical.  The Utah-Washington mechanism proposes that 
the electron is captured to a stabilised amide π orbital rendering the amide bond super-























Materials, Methods and Instrumentation 
 
This chapter describes the materials, methods and instrumentation employed in this 
research.  The materials section covers solvents and samples which were utilised.  The 
methods section describes the techniques used for sample generation (e.g. cell culture, 
protein extraction) and the high performance liquid chromatography used in the 
separation of the sample mixtures for the LC-MS analyses.  The instrumentation section 
provides a detailed discussion of the operation of the FT-ICR mass spectrometer. 
 
2.1 Materials 
The materials used in this work are listed in Table 2.1.  This list includes materials used 
for sample generation, along with samples which were purchased for study and 
consumables such as solvents.  The compound names are listed, along with the supplier 













Table 2.1:  Materials used in this work, together with purity and supplier information. 
Name Purity Supplier 
Acetonitrile LC-MS Fisher Scientific 
Methanol LC-MS Fisher Scientific 
Water LC-MS Fisher Scientific 
Formic Acid ~98 % Fluka Bio-
Chemika 
Trifluroacetic Acid ≥98 % Sigma 
Ammonium Acetate 99 + % HPLC Fisher Scientific 
NuPAGE MES Running Buffer N/A Invitrogen 
SeeBlue Gel Stain N/A Thermo 
Scientific 
NuPAGE Bis-Tris Gels (12%) N/A Invitrogen 
NuPAGE Sample Reducing Agent N/A Invitrogen 
Sulphuric Acid >95 % Fisher Scientific 
Trichloroacetic Acid ≥99.5 % Fisher Scientific 
Acetone Analytical Grade Fisher Scientific 
Hydrochloric Acid ~37 % Fisher Scientific 
Trichostatin A 0.2 μM filtered Sigma 




Fetal Calf Serum Sterile-filtered Sigma 
Penicillin/Streptomycin Mix Sterile-filtered Sigma 
Bradykinin Acetate ≥98 % (HPLC) Sigma 
Angiotensin I Acetate Hydrate ≥90 % (HPLC) Sigma 
Angiotensin II human Acetate ~98 % (HPLC) Sigma 
Bombesin Acetate Hydrate ≥97 % (HPLC) Fluka Bio-
Chemika 
Lutenising Hormone Releasing Hormone 
Human Acetate Salt 
≥98 % (HPLC) Sigma 
Ubiquitin from Bovine Erythrocytes ~98 % (SDS-PAGE) Sigma 
Myoglobin from Horse Heart ≥90 % (SDS-PAGE) Sigma 
Deuterium oxide (d2O) 99.9 % Sigma 
Deuterated Acetic Acid 99.5 % Arcos Organics 




Sinapic Acid ~98 % (GC) Sigma 
Deuterated Acetic Anhydride 98.5 % Arcos Organics 
Dimethyl Sulfoxide N/A Sigma 







The following section describes in detail the cell lines and techniques used for sample 
generation and purification in this research. 
 
2.2.1 Cell Lines 
Several cell lines were used to generate histone samples for LC-MS analysis, with some 
chosen for further fragmentation studies.  The cell lines used were as follows: 
K562, a human cell line of myeloid lineage derived from a 57 year old female subject 
suffering from chronic myeloid leukemia (CML)
124
. 
THP1, a human cell line of monocytic lineage derived from a male subject suffering 
from acute myeloid leukemia (AML)
125
. 
HCT-116, a human cell line of colon epithelial lineage derived from the primary colon 
carcinoma of a subject
126
. 
OCI-AML3, a human cell line of myeloid lineage derived from a 57 year old male 
subject suffering from AML
127
. 
MV411, a human cell line established from the blast cells of a male subject suffering 
from biphenotypic B-myelomonocytic leukemia
128
. 









2.2.2 Cell Culture Conditions 
Cells were grown in 75 cm
2
 culture flasks in RPMI medium supplemented with 10% fetal 
calf serum and 1% penicillin/streptomycin mix to inhibit bacterial growth.  Cells were 




confluence.  At 80% confluence the cells were harvested for acid extraction of histone 
proteins. 
 
2.2.3 Histone Extraction Procedure 
1 ml of nuclear isolation buffer (250 mM sucrose, 50 mM Tris-HCl, pH 7.5, 25 mM KCl, 
5 mM MgCl, 0.2 mM phenylmethylsulfonyl fluoride, 50 mM NaHSO3, 45 mM sodium 
butyrate, 10 mM 2-mercaptoethanol and 0.2% Triton X-100) was added to the cell 
culture and allowed to stand at room temperature for 5 minutes.  After 5 minutes, the 
cells were scraped manually from the bottom of the culture flask and the buffer 
containing the cells was aspirated from the flask and dispensed into a 1.5 ml Eppendorf 
tube.  The buffer was centrifuged at 13,000 rpm for 5 minutes to pellet the cells, which 
were then washed with phosphate buffered saline (PBS) and centrifuged again.  The 
following steps were performed on ice.  1 ml of 0.2 M H2SO4 was added to the cell pellet, 
which was then agitated to facilitate exposure to the acid.  The acid extraction was 
allowed to proceed for 60 minutes, after which the sample was centrifuged at 13,000 rpm 
for 15 minutes (at 4 °C).  The supernatant was transferred to a new Eppendorf tube and 
250 μl TCA (100%) was added and incubated for 30 minutes.  The sample was then 
centrifuged at 13,000 rpm for 15 minutes, after which the supernatant was aspirated and 
discarded.  The remaining pellet containing the histone proteins was washed in 1.3 ml 
acetone (with 50 mM HCl) and allowed to stand for 60 minutes.  The sample was then 
centrifuged at 13,000 rpm for 15 minutes, before the supernatant was aspirated and 
discarded.  The sample was then washed in 1.3 ml acetone and left at 4 °C overnight.  
After the overnight wash, the sample was centrifuged for 15 minutes at 13,000 rpm, the 








2.2.4 Gel Electrophoresis 
The presence of protein in the histone extracts was confirmed by gel electrophoresis 
using precast NuPAGE Bis-Tris Gels (12 %).  Samples were mixed with an equal volume 
of reducing agent and boiled for 5 minutes.  After boiling, samples were loaded into the 
gel lanes and run in MES buffer at 200 V for ~ 60 minutes.  After electrophoresis the gel 
was washed briefly in H2O before staining for 2 hours in SeeBlue Gel Stain Reagent.  
After staining, the gel was left to destain in H2O overnight. 
 
2.2.5 Reverse Phase High Performance Liquid Chromatography 
All chromatography carried out in this work was performed on a Dionex Ultimate 3000 
LC system which was equipped with a variety of reverse phase columns.  The reverse 
phase columns used for the majority of this work were a Dionex monolithic PS-DVB 
column (50 mm x 0.5 mm), and a Vydac C18 RP column (250 mm x 1 mm).  The buffers 
and gradients used are described below. 
The buffers used with the monolithic column were 98% H2O, 2% acetonitrile with 0.03% 
TFA (Buffer A), and 80% acetonitrile, 20% H2O with 0.03% TFA (Buffer B).  The 
column was heated to an operating temperature of 65 °C and equilibrated with 100% 
Buffer A at a flow rate of 20 μl min
-1
.  A linear gradient was applied over 25 minutes to 
57.1% Buffer B, at which point Buffer B was increased to 100%.  This was held for 3 
minutes and then reduced to 100% Buffer A and held for a further 7 minutes. 
The buffers used for the Vydac C18 column were similar to those used with the 
monolithic column, but 0.1% formic acid was substituted for the 0.03% TFA.  The 
column was operated at 25 °C at a flow rate of 100 μl min
-1
.  The percentage of Buffer B 
was increased to 44% as a linear gradient over 5 minutes.  From 5 to 22 minutes Buffer B 
was increased to 49%, and was held at 49% for a further 5 minutes.  At 27 minutes, 
Buffer B was increased to 100%, and held at this level for 5 minutes.  At 32 minutes, 






A primary aim of this work was to utilise a range of mass spectrometry techniques in the 
identification and characterisation of post-translational modifications (PTMs).  The main 
instruments used were an Applied Biosystems 4700 MALDI-ToF, a Bruker Apex Qe FT-
ICR and a Bruker solariX FT-ICR, both coupled to a 12 Tesla superconducting magnet.  
The solariX instrument is an upgrade of the Apex Qe and features enhanced ion optics 
which lead to greater sensitivity.  Both FT-ICR instruments are equipped with a mass 
resolving quadrupole which allows the selection of a single ion species for subsequent 
fragmentation work.  Additionally, both are capable of Collision Induced Dissociation 
(CID) and Electron Capture Dissociation (ECD) for increased sequence coverage and 
improved PTM localisation. 
 
2.3.1 MALDI-ToF MS 
MALDI-ToF was used in this work to confirm the presence of histone proteins in the 
samples generated.  The sensitivity and speed of data acquisition makes the use of this 
instrument a viable alternative to the use of SDS-PAGE to confirm the presence of 
protein in a sample.  MALDI-ToF mass spectrometry was performed on an Applied 
Biosystems 4700 Proteomics Analyzer in reflectron mode.  The matrix used was a 
saturated solution of sinapic acid in 50% acetonitrile with 0.1% formic acid.  Sample was 
applied to the MALDI plate by sequentially layering 0.3 μl of the matrix and allowing to 
dry, followed by 0.3 μl of the histone sample, allowing this to dry and adding a top layer 
of 0.3 μl matrix.  The laser was set to 70% maximum power and each spectrum acquired 
was the sum of 1000 scans.  Data was analysed using the Applied Biosystems Data 








2.3.2 FT-ICR MS 
Fourier Transform Ion Cyclotron Resonance mass spectrometry has several advantages 
over other mass spectrometry techniques including high resolution, increased mass 
accuracy and multiple fragmentation capabilities.  The FT-ICR instruments used in this 
work were either a Bruker Daltonics Apex Qe, or a Bruker Daltonics solariX system.  
During use, both instruments were equipped with a 12 Tesla ultra-shielded magnet with a 
stand-alone cryo-refrigeration system.  Electrospray ionisation was used as an ion source 
for the work, either by motor driven syringe, by using the TriVersa Nanomate for direct 
infusion, or by coupling the source to the Dionex LC system for online LC-MS analysis.  
All data was acquired in positive ion mode. 
The solariX FT-ICR MS instrument is shown in Figure 2.1, and a schematic overview of 
















Before proceeding with data acquisition, the instrument performance must be tuned for 
optimal sensitivity and resolution.  Tuning of the instrument is effectively done in two 
stages; the first parameters to be optimised are those of the source and the ion optics 
which are responsible for ion transmission.  These parameters must be tuned as the 
sensitivity of the instrument is dependent on them.  Each instrument uses an orthogonal 
source design, a significant improvement over older models.  The orthogonal positioning 
of the source drastically reduces the probability of neutral solvent molecules reaching the 
high vacuum regions, resulting in lower background pressure which aids detection in the 
ICR cell. Source tuning involves adjustment of capillary, funnel and skimmer voltages.  
The combined effect of these parameters allows for desolvated ions to travel through 
‘soft’ or ‘harsh’ conditions.  High source voltages can lead to in-source fragmentation, 
which under most circumstances is undesirable.  Ions which have travelled through the 
skimmers and ion funnels can then be accumulated in the storage multipole.  
Accumulation times can be adjusted to compensate for low ion abundance; while during 
normal operation ion accumulation typically lasts for less than 1 second, this can be 
extended to over 30 seconds if necessary.  This can bring with it a detrimental effect, the 
increase in accumulation time also increases the length of time required for each mass 
analysis, which makes coupling of the instrument to an LC system for online LC-MS 
analysis difficult.  Under these circumstances, shorter accumulation times must be used 
along with a more concentrated sample.  Once ions leave the storage multipole, species of 
interest can be selected in the mass resolving quadrupole before travelling through the 
transfer optics (focussing lenses and transfer lines) toward the ICR cell.  The major 
difference between the Apex Qe instrument and the solariX is improved ion transfer 
optics.  The solariX is equipped with a transfer line in front of the ICR cell, while in the 
Apex vacuum cart this was simply a drift tube.  The resulting increase in ion transmission 
leads to the greater sensitivity of the solariX instrument.   
Once a satisfactory level of sensitivity has been achieved, the remaining parameters to be 
optimised are those of the ICR cell which are responsible for the resolution of the 








Figure 2.3:  The Bruker Daltonics Infinity Cell used to trap, excite and detect ions.   
 
 
While it is possible to use various trapping techniques in each instrument, SIDEKICK 
trapping was used throughout this work.  The use of this technique alters the motion of 
the ions entering the cell, sending them off the central axis and closer to the 
excitation/detection plates.  Although this makes in-cell fragmentation more difficult, this 
issue can be overcome with careful tuning of the instrument parameters.     
 
2.3.2.1 On-line LC-MS 
When used for online LC-MS analysis, the instrument was set to record mass analyses for 
the full length of the chromatography run.  Each spectrum recorded was the sum of 2 
mass analyses.  The transient data size was 1M word for each acquisition and sine-bell 
squared multiplication (as windowing function) was applied during the acquisition.  Ion 
accumulation times were typically 0.7 seconds, the source capillary voltage was set to 
4500 V and the end plate offset to -500 V.  Ions were trapped in the Bruker Daltonics 
Infinity Cell and the front and back plate trapping potentials were typically 0.55 V and 










was processed using Data Analysis software (Bruker Daltonics), then exported and 
plotted in Microcal Origin 6.0. 
 
2.3.2.2 Direct Infusion 
The solariX instrument was used for acquiring data from infused samples when using the 
TriVersa Nanomate as the ESI source.  When performing optimally, the Nanomate could 
provide up to 90 minutes of continuous spray from a sample size of 10 µl, permitting 
extensive fragmentation work to be carried out.  The Nanomate was set to operate in 
‘infusion’ mode, the gas pressure was set to 0.65 psi and the spray voltage set to 1.65 kV. 
 
2.3.2.3 Top-Down Fragmentation 
Tandem mass spectrometry (both CID and ECD) was performed on the Bruker solariX 
instrument.  During the acquisition of MS/MS spectra, the ion accumulation time was 
increased, often to 20 s when performing ECD.  Spectra were the sum of up to 500 mass 
analyses, and data was acquired over a range of 500–3000 m/z.   
Before any fragmentation data was acquired, the fragmentation parameters were tuned by 
infusing a 5 µM solution of equine myoglobin (Sigma) in a mixture of methanol and H2O 
with 0.1% formic acid.  Typically, after the successful isolation of a selected precursor, 
the fragmentation parameters were adjusted such that the precursor ion abundance would 
drop to roughly 10% of its value before spectra were recorded.  These parameters (with 
the exception of ion accumulation times) were then applied to the sample of interest.  
CID involved adjusting the voltage at the collision cell to a value between 18 V and 26 V.  
ECD involved heating of the hollow dispenser cathode by applying a current, usually 1.8 
A, and adjusting the ECD pulse length until fragmentation was successful.  Pulse lengths 
were typically between 8 ms and 20 ms.  The ECD lens and bias voltages were set to 22.6 






2.3.2.4 Middle-Down Fragmentation 
Middle down fragmentation was performed on proteins of interest by fraction collection 
and enzymatic digestion.  Endoproteinase Asp-N was used for digestion.  Fractions of the 
selected protein were collected manually after LC separation and concentrated using a 
SpeedVac Plus (Savant).    After concentration the sample was resuspended in 100 mM 
NH4CO3 and the enzyme was added at a ratio of 20:1 (protein to enzyme).  The mixture 
was incubated in a water bath at 37°C for 18 hours, before desalting using C18 zip-tips.  
Once desalted, a 50:50 mixture of methanol and H2O with 0.1 % formic acid was added 
before the sample was infused.   
 
2.3.3 Data Processing 
All the data acquired was calibrated and processed before being plotted using Microcal 
Origin 6.0 for presentation. 
 
2.3.3.1 Calibration 
All LC-MS data and broadband infusion data were calibrated externally against Agilent 
low concentration ESI Tuning Mix.  Fragmentation data was calibrated internally using 
fragment ion lists generated manually by simulating a series of C-terminal ions and 
searching against their empirical formulae. 
 
2.3.3.2 Data Analysis 
All data acquired on the Apex Qe and the solariX instruments was analysed using Data 
Analysis software (Bruker Daltonics).  Isotope distributions were predicted using the 
IsotopePattern software and laid over experimentally acquired data.  Mass measurement 
error (expressed as parts per million) was calculated from the most abundant isotopic 
peak of a specific charge state using Equation 2.1
132
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Equation 2.1:  Mass Measurement Error (in parts per million) calculation, where mobs is the observed 
mass, and mexp is the expected mass. 
 
Fragmentation data was processed for mono-isotopic peak picking using the SNAP 2.0 
algorithm (Bruker Daltonics).  The fragment mass lists generated were searched for b and 
y or c and z ions using ProSight PTM
133
 by inputting the amino acid sequence and 
manually applying acetylation and mono-, di- and tri-methyl modifications to each 
modifiable lysine residue in all permutations.  Each permutation was then ranked 
according to the number of fragment ions matched, and mass errors were set to a 
maximum of 10 ppm. 
 
2.3.3.3 X-ray Crystal Structures 
All X-ray structures were obtained from the RCSB Protein Data Bank (PDB).  The 
structures were drawn using Pymol software (Delano Scientific), and PDB identification 
numbers are listed in the figure captions. 
 
2.3.3.4 Sequence Alignments 
All sequence alignments were performed with ClustalW2 software available online from 
the EBI web server
134
.  Protein sequences were obtained from the UniProt 












The Acetylation of Histone H4 
 
This chapter describes experimental work carried out to study the acetylation pattern of 
histone H4.  Although already described, a brief summary of H4 modifications is given 
along with their associated biological functions.  The aims of the experimental work are 




Eukaryotic histone H4 is known to have only one sequence variant.  The protein is 102 
amino acids long, and plays a critical role in nucleosome assembly as it forms half of the 
H3-H4 tetramer of the core particle
135
.  In common with the other core histones, it 
contains a central globular region formed of three α-helices, and contains an unstructured 
N-terminal region which contains roughly 25% of the amino acid content.  Also common 
with the other core histones, the N-terminal region is the primary site of PTMs, and 
similar to H2a, H4 is acetylated on the N-terminal residue.  However, this acetylation is 
not subject to regulation by acetyl-transferase and de-acetylase enzymes.  Figure 1.4(d) 
shows histone H4 with the sites of modification highlighted, while Table 3.1 lists the 

















Histone Modification Residues Modified Biological Function 
Acetylation K-Ac Transcription, repair, replication 
Methylation (Lysine) K-Me, K-Me2, K-Me3 Transcription, repair 
Methylation (Arginine) R-Me, R-Me2a, R-Me2s Transcription 
Phosphorylation S-Ph, T-Ph Transcription, repair, condensation 
Ubiquitylation K-Ub Transcription, repair 
Sumoylation K-Su Transcription 
ADP ribosylation E-Ar Transcription 
 
 
There are 18 known histone de-acetylase enzymes in humans, and as explained in Section 
1.1, each can have multiple acetyl lysine binding sites, and so may have a different 
associated function
48,66,137
.   
 
Since the modification state of the protein is the result of the interplay between HATs and 
HDACs, a relevant question to ask is how do PTMs change when one of these enzyme 
systems is inhibited?  Several histone de-acetylase inhibitors (HDACi’s) are now known 
and some show promise in the treatment of neural disorders, endometriosis and some 
cancers
56,138-143
, however little is known of their mode of action, and of how histone 
PTMs change other than on the global scale.  HDACi’s can broadly be divided into four 
classes; short chain fatty acids, hydroxamic acids, cyclic tetrapeptides and benzamides
56
.  
One HDACi in particular, trichostatin A (TSA), is known to completely alter the PTM 
profile of histone H4 after mild treatment (i.e. nM concentrations over 3 hours)
144,145
.  
Upon withdrawal of TSA, H4 modifications return to their base level.  The structure of 




                                 




While there are five lysine residues in the H4 N-terminal region, the distribution of PTMs 
is not uniform.  Figure 3.2 below shows the sequence of histone H4 with the most 
commonly modified N-terminal residues highlighted. 
 
SGRGKGGKGL GKGGAKRHRK VLRDNIQGIT KPAIRRLARR GGVKRISGLI  
 
YEETRGVLKV FLENVIRDAV TYTEHAKRKT VTAMDVVYAL KRQGRTLYGF GG   
 
Figure 3.2:  Amino acid sequence of histone H4 with modified N-terminal residues highlighted 
according to known modifications.  (_) indicates acetylation and (_) methylation.   
 
The N-terminal acetylation, which can be considered as the first PTM to occur, is not 
under the control of acetyl-transferase and de-acetylase enzymes.  As a result, H4 not 
carrying the N-terminal acetylation is typically not observed.  The next main sites of 
modification are lysines 5, 8, 12 and 16.  Each of these is known to be dynamically 
acetylated in response to biological stimuli, either alone or in combination. The final N-
terminal site of modification is lysine 20, which is primarily a site of methylation (mono-, 
di- or tri-methylation).  This site is not known to be acetylated, and in contrast to 
acetylation, methylation appears to be a more stable modification, with patterns changing 
little through cell cycle progression and duplication.  Histone methylation of H3 and H4 
has been linked to nucleosome stability; while acetylation is thought to play a regulatory 
role in gene transcription, methylation has been found associated with heterochromatin, 
suggesting a link to gene silencing
147
.  Turnover of H4 methylation is much lower than 
acetylation
148,149
.  Interestingly, while methylation appears to have a different biological 
role to acetylation, there appears to be little competition between these modifications on 
H4 
150
.  However, similar to the interplay known on H3, the appearance of methylation 




environmental exposure, and studies have shown that methylation can be the more 
dominant PTM when present before acetylation takes place, suggesting that for maximum 
effect each modification must be site specific and deposited in a temporally specific 
way
45,140
.  Further studies reinforced these links by focusing on changes in these PTMs 
after treating cells with de-acetylase inhibitors.  For example, it was shown that TSA 
treatment also alters H4 methylation state in addition to the level of acetylation, and that 




While many compounds are now known to affect histone acetylation, the first in-depth 
studies focused on the effects of butyrate treatment
35,152-154
.  Initially, it was shown that 
levels of acetylated H3 and H4 increased following butyrate treatment in HeLa cells, and 
that this accumulation was reversible upon withdrawal of treatment.  This treatment was 
also shown to alter differentiation patterns in Friend erythroleukaemia cells, suggesting a 
possible link between histone modification and cell cycle progression
153,155
.  Butyrate 
treatment was also shown to affect cell morphology and had varying effects on the 
activity of several enzymes, many of which are involved in metabolic pathways
152
.   
 
The acetylation levels of core histones are under the control of enzymes with opposing 
activities: histone de-acetylases (HDACs) and histone acetyl-transferases (HATs).  Gene 
transcription is regulated through the action of these enzymes at the level of nucleosomal 
DNA packaging.  Many histone de-acetylase inhibitors have now been described, 
typically short chain compounds such as butyrate and valproic acid, and hydroxamic 
acids such as trichostatin A.  One hypothesis explaining their use as anti-cancer drugs is 
that they are able to reactivate genes silenced by DNA hyper-methylation at promoter 
sites.  Treatment of cells with these compounds results in a characteristic accumulation of 
highly acetylated histone forms, and the associated changes in gene expression, cell cycle 
progression and apoptosis.    There is now significant interest in the natural microbial 
product TSA, which was initially isolated from Streptomyces hygroscopicus.  TSA is a 







In the present work, since naturally occurring modifications are known to occur at 
specific sites or combinations of sites,  the order of lysine acetylation was initially 
investigated through TSA treatment to determine how modifications would appear 
through inhibition of de-acetylase enzymes.  A study was also carried out to investigate 
the responses of different cell lines to TSA exposure.  The principal aims of the work 
described in this chapter were to investigate the effects of the HDAC inhibitor TSA 
across multiple cell lines, each of which carries mutations which may alter the PTM 
profile, and to use mass spectrometric fragmentation techniques to determine the order in 



























3.2.1 Cell Culture and TSA Treatment 
To determine whether or not de-acetylase inhibition was specific to a particular cell line, 
multiple human derived cell lines were cultured with a fixed concentration of TSA of 50 
nM.  The aim of this initial study was to confirm that TSA treatment resulted in a 
characteristic and reproducible increase in modified histone H4 isoforms.  Cell lines were 
cultured at 37 °C in an atmosphere of 5% CO2. RPMI culture medium was supplemented 
with fetal calf serum and penicillin/streptavidin to retard microbial growth.  Cells were 
removed from the culture medium at three time points before histone extraction was 
performed as described in section 2.5.  The culture times were 1h, 3h and 6h, and two 
controls were included for each cell line; 1h and 6h di-methyl sulfoxide (DMSO) 
treatment. 
 
3.2.2 Liquid Chromatography and Mass Spectrometry 
Histone extracts were separated by LC using a Vydac C18 reverse phase column, prior to 
FT-ICR mass spectrometry.  Each sample was separated over a 37 minute gradient using 
an Ultimate 3000 LC system (Dionex), which was coupled to the ESI inlet of the mass 
spectrometer.  The gradient was as follows:  Buffer A was 2% acetonitrile in 0.03% tri-
fluroacetic acid (TFA) and Buffer B was 80% acetonitrile with 0.03% TFA.  The gradient 
rose to 44% B over 5minutes, from 5 to 22 minutes to 49% B, and held at 49% for a 
further 5 minutes.  At 27 minutes Buffer B was increased to 100% and held for 5 minutes, 
before Buffer A was increased to 100% and held for 5 minutes.     
 
The data presented in this chapter was acquired on two FT-ICR mass spectrometers.  
Much of the data for the HDAC inhibitor study (for the HCT-116 cell line) was acquired 
on a Bruker Apex Qe mass spectrometer, while the data for all other cell lines and all of 
the tandem mass spectrometry work to identify the order of acetylation was carried out on 
a Bruker solariX mass spectrometer.  The solariX instrument offered greater sensitivity 




acquired in broadband mode with a mass range of 500-3000 m/z.  Each spectrum was the 
sum of 500 mass analyses whenever possible.  
 
For fragmentation work histone fractions were collected manually from each run and 
stored on ice.  Successful fragmentation involved selection of a high charge state 
precursor ion (typically 13
+
 or greater) followed by adjustment of the CID and ECD 
settings.  Precursor ions were isolated and ion accumulation times for CID were 1 second, 
with the collision voltage set to ~ 18 V.  ECD was performed with extended ion 
accumulation times, typically 20 seconds.  The dispenser cathode was set to a current of 
1.7 nA and the ECD pulse length was set to ~ 0.06 seconds.   
 
3.2.3 Data Analysis 
Data was analyzed using DataAnalysis software (Bruker Daltonics), before being 
exported and plotted in Microcal Origin (v 6.0).  Calculation of the level of acetylated 
species was performed using an in-house written program (written in Python), using the 
method described by Smith
159,160
, modified to suit the work performed.  Briefly, 
acetylation was quantified from the integrated ion abundances of modified species.  
Typically, the three most abundant charge states were used for this analysis.  Each 
integrated ion abundance was then weighted according to the number of modified Lysine 
residues.  These were then summed and divided by the total weighted ion abundance of 
all modified H4 species possible.  The levels of acetylation are presented as a percentage 













3.3.1 H4 Acetylation in Multiple Cell Lines 
Each cell line used in this study was analyzed under similar conditions.  Figure 3.3 below 
shows a total ion chromatogram of Histone H4.  Figure 3.4 shows the MALDI-ToF 
spectrum generated from the same sample prior to chromatographic separation while 
Figure 3.5 shows an extracted ion chromatogram for histone h4 from HCT-116 cells (1h 
control sample) with the LC gradient overlaid.  H4 eluted as a single peak separately 
from the other core histones.  A total ion chromatogram showing the elution of all 
histones during a typical chromatographic run is presented in Figure 3.3 below.  The 
broadband spectrum generated by summing across the eluted peak is shown in Figure 3.3 
with an inset of the 7
+




    
Figure 3.3: Total ion chromatogram of histone H4 from HCT-116 1h control cells.  The peaks 
















Figure 3.4:  MALDI-ToF mass spectrum of core histones from HCT-116 cells after 1 hour DMSO 
treatment. 
        
Figure 3.5: Extracted ion chromatogram of histone H4 from HCT-116 1h control cells.  H4 eluted as 









                     
 
                    
Figure 3.6:  Mass spectrum of H4 from HCT-116 cells after 1h DMSO treatment. (a) broadband 
spectrum with inset of 7
+
 charge state.  (b)  7
+
 charge state with inset of base peak corresponding to 
an intact mass of 11,299 Da.  The post-translational modifications of three peaks are labelled where, 
(N-Ac) means N-terminal acetylation, (Ac) means acetylation and (Me) means methylation.  A 
simulated isotope pattern is included (blue dots) corresponding to N-terminally acetylated di-
methylated H4 (11,299 Da). 
 
11,299 Da 
(N-Ac + 2 Me) 
11,341 Da 
(N-Ac + Ac + 2 Me) 
11,383 Da 
















SDS-PAGE followed by Coomassie Brilliant Blue staining revealed bands corresponding 
in molecular weight to the core histones (data not shown).  With their presence in the 
samples verified by electrophoresis, analysis was then performed by LC-MS.  The 
gradient conditions used allowed elution of histone H4, with little contamination of other 
core histones with similar retention to the column stationary phase, permitting the 
generation of mass spectra of good quality.  While the spectrum shown in Figure 3.6 
(above) is of H4, the first observation of note is the presence of multiple species in a 
single charge state.  This highlights an important feature of H4, it is rarely present in 
unmodified form, and as shown in subsequent figures, multiple modified forms are 
typically present.  The next feature to note is the regular spacing between modified forms, 
which correspond to regular mass shifts.  The most abundant peaks are shifted in mass by 
42 Da, while the minor peaks are separated by 14 Da.  A 42 Da mass shift is in agreement 
with the presence of an acetyl group, while a 14 Da mass shift corresponds to the 
presence of a methyl group; both modifications are known to occur on histone H4.  In 
addition, the 42 Da mass shift could also correspond to the presence of three methyl 
groups (present on a single lysine, or distributed over one, two or three residues).  
Ultimately, the identity and location of these modifications can only be confirmed 
through fragmentation studies which were also performed.   
 
In the untreated control cells, the dominant form of H4 corresponds in mass to the 
presence of a di-methylated species with a single acetyl group (with theoretical mass of 
11,299.383 Da, and measured mass of 11,299.520 Da giving a mass measurement error 
of 12 ppm.  The peaks of next highest abundance also correspond to di-methylated 
species, with varying numbers of acetyl groups, suggesting that methylation (in this case 









Table 3.2: Modified H4 isoforms and their theoretical masses.  All masses were calculated using 
Bruker Daltonics Isotope simulation software and only mono-isotopic neutral masses are displayed.  
Unmodified H4 is defined as H4 sequence (Uniprot P62805) with N-terminal methionine removed, 
acetylated at serine 1 and di-methylated at lysine 20. 
 
 
H4 Isoform Theoretical Mass (Da) 
H4 11,271.351 
H4 + Me 11,285.367 
H4 + 2Me 11,299.383 
H4 + 3Me 11,313.398 
H4 + Ac 11,313.362 
H4 + Ac + Me 11,327.378 
H4 + Ac + 2Me 11,341.393 
H4 + Ac + 3Me 11,355.409 
H4 + 2Ac 11,355.372 
H4 + 2Ac + Me 11,369.388 
H4 + 2Ac + 2Me 11,383.404 
H4 + 2Ac + 3Me 11,397.419 
H4 + 3Ac 11,397.383 
H4 + 3Ac + Me 11,411.399 
H4 + 3Ac + 2Me 11,425.414 
H4 + 3Ac + 3Me 11,439.430 
H4 + 4Ac 11,439.394 
H4 + 4Ac + Me 11,453.409 
H4 + 4Ac + 2Me 11,467.425 
H4 + 4Ac + 3Me 11,481.441 





Examination of the abundance of all peaks reveals that those corresponding to di-
methylated H4 species dominate the spectra, while other methylated forms account for 
the minority of H4 species observed.  This high proportion of di-methylated H4 species is 
in agreement with previous studies on H4 which describe the stable presence of di-
methylation (at lysine 20).   
 
To determine an effective concentration range of TSA to use in further studies, a dose 
response study was performed on HCT-116 cells.  Cells were cultured in medium 
identical to that used in the time course study, with the exception that a range of TSA 
concentrations were added to the medium.  The TSA concentrations used were 10, 100, 
250 and 500 nM, and the cells were cultured for a fixed time of thirty minutes before 
histone extraction and subsequent LC-MS analysis.  The results of the TSA dose response 


























Figure 3.7:  Dose response of HCT-116 cells after 30 minutes treatment to various TSA 
concentrations.  The mass spectrum for the 7
+
 charge state of the PTM profile is shown. 
 
The results of the TSA dose response indicate the following: when present in 
concentrations as low as 10 nM, TSA has an inhibitory effect on histone de-acetylase 
enzymes, and these enzymes appear completely inhibited at a TSA concentration of 250 
nM.  Above a concentration of 250 nM, no further change in histone PTM profile is seen.  













effect on histone H4 acetylation level.  The levels of acetylation calculated for the dose 
response treatment shown in Figure 3.4 were as follows; roughly 52% of N-terminal 
lysines were acetylated after the 10 nM treatment.  At 100 nM this value rose to almost 
61%.  At 250 nM, the acetylation level was calculated at roughly 75% and the level of 
acetylation after 500 nM TSA treatment was 80%.   
 
The effects of TSA time course treatment in HCT-116 cells are shown in Figure 3.8.  The 
50 nM treatment was applied for a range of times (between thirty minutes and six hours) 
before histone extraction.  Figure 3.8 shows the mass spectrum for a single charge state 
of H4, the 7
+
 charge, state following the various treatments.  The masses of the multiple 
species in the spectra potentially correspond to modified forms of histone H4, listed in 
Table 3.2. 
 
The TSA time course results demonstrate the effectiveness of TSA as a histone de-
acetylase inhibitor.  Analysis of the results reveals the following; although there is a shift 
in the abundance of modified H4 isoforms, the most dominant species still correspond in 
mass to di-methylated species.  This finding confirms the suggestion that while TSA is 
effective in altering acetylation of H4, it has little effect on methylation state.  The 
response to TSA treatment is also rapid, changes in acetylation state are seen after only 
thirty minutes of treatment with acetylation levels rising from 27% to 47%, and 
ultimately to 67% after 6 hours of TSA exposure.  The control samples reveal that the 
changing acetylation state is a result of the TSA treatment, and not due to the culture 
conditions or the presence of di-methyl sulfoxide (added to the control samples as it was 







Figure 3.8:  PTM profile in the mass spectrum for the 7
+
 charge state of histone H4 from HCT-116 
cells after 50 nM TSA treatment (30 mins, 3h and 6h).  Untreated cells were included as control 




















While the results demonstrate the efficacy of TSA as an HDACi in HCT-116 cells, they 
do not conclusively show that the action of TSA is universal across cell lines.  To test 
whether or not TSA treatment would reproducibly result in the accumulation of 
acetylated forms of H4, multiple cell lines were treated with a fixed concentration of TSA 
(50 nM) for various time lengths before histone extraction.  A brief description of the cell 
lines used is given in Chapter 2 (Section 2.2.1), however the cell lines used shared some 
common features.  All were human derived, and all potentially carry genetic 
modifications which may play a role in affecting histone post-translational modification.  
Cell lines implicated in similar disease states (e.g. THP1 and OCI-AML3 are both linked 
to Acute Myeloid Leukemia) were derived from different patients.   
 
The results of the cross cell line TSA time course study are shown in the following 
figures, Figures 3.9 to 3.14.  In all of these figures the mass spectrum for the 7
+
 charge 
state of histone H4 is shown to illustrate the PTM profile.  The most striking aspect of the 
data generated is that while TSA is a potent inhibitor of de-acetylation in HCT-116 cells, 
this feature is not consistent across the cell lines chosen.    The results of the OCI-AML3 
TSA time course are shown in Figure 3.9.  Acetylation in the control samples established 
a baseline level of roughly 23% (mean value of the two control samples).  After one hour 
of treatment, acetylation rose to 34%, and increased to almost 46% after three hours.  At 
six hours, acetylation is at a maximum of over 54%.  The acetylation levels in the two 
control samples are in good agreement with each other, indicating that changes in 
acetylation are due to TSA treatment and not cell culture time.  The acetylation seen in 
OCI-AML3 cells after TSA treatment is markedly different from that seen in HCT-116 





Figure 3.9:  Response of OCI-AML3 cells to 50 nM TSA time course over 6 hours.  The mass 
spectrum for the 7
+
 charge state of the PTM profile is shown. 
 
 
Treatment of the chosen cell lines with TSA did not result in a uniform acetylation profile, 
however, those that differed from the HCT-116 PTM profile displayed a similar 
distribution.   
 
Figure 3.10 below shows the results of TSA time course treatment on K562 cells.  In 
contrast with the results generated from HCT-116 cells, TSA treatment does not 
completely inhibit histone deacetylation.  The data also reveals that in K562 cells, there is 
little change in acetylation levels after three hours treatment.  Calculation of acetylation 















22% (the mean of the levels calculated from the two control samples).  After one hour of 
treatment, acetylation rose to over 36%, and peaks at three hours at over 48%.  At six 
hours of treatment, acetylation drops slightly to 45%. There is significant similarity in the 
acetylation of the two control samples, indicating that the different acetylation levels are 






Figure 3.10: Response of K562 cell line to 50 nM TSA time course over 6 hours.  The mass spectrum 
for the 7
+




















Figure 3.11:  Response of THP1 cell line to 50 nM TSA treatment over 6 hours.  The mass spectrum 
for the 7
+
 charge state of the PTM profile is shown. 
 
 
The baseline acetylation levels on the THP-1 cells are roughly 26% (generated from the 
values of the control samples).  After one hour of TSA treatment, acetylation rose to over 
41%, and reached 56% after three hours of treatment.  After three further hours of 
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results are also in contrast to the results of TSA treatment on HCT-116 cells, again 
demonstrating that the effect of TSA as a de-acetylase inhibitor is not ubiquitous.  There 
is good agreement in the acetylation levels of the control samples, indicating that changes 
in acetylation are due to the TSA treatment and not the length of cell culture time.   






Figure 3.12:  Response of RAJ1 cell line to 50 nM TSA time course over 6 hours.  The mass spectrum 
for the 7
+
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The results of TSA treatment on RAJ1 cells further demonstrates that different cell lines 
respond to treatment differently.  In comparison to other cell lines the baseline level of 
acetylation is slightly decreased at 20%.  After one hour of TSA treatment acetylation 
rises to over 35%, and reaches its peak at over 51% at three hours treatment.  By six 
hours, acetylation fell to 48%, and the six hour control sample displayed roughly 12% 
acetylation.  The calculated standard deviations of the acetylation levels are low, all 
below 4%, showing good agreement from the data generated. 
 
The results of TSA treatment on SN1 cells is shown in Figure 3.13 below.  The control 
samples used to determine baseline acetylation levels are in good agreement with each 
other at roughly 10% each.  After one hour TSA treatment, acetylation rose to almost 
28%, and continued to rise to over 48% after three hours treatment.  By six hours 
treatment, acetylation levels have reached their maximum at over 57%.  The standard 
deviations of the calculated acetylation levels are low, all under 6%, indicating good 
























Figure 3.13:  Response of SN1 cell line to 50 nM TSA time course over 6 hours.  The mass spectrum 
for the 7
+
 charge state of the PTM profile is shown. 
 
 
The results of TSA treatment on MV411 cells is shown in Figure 3.14 below.  Baseline 
acetylation, calculated from the control samples is low; at 12% after one hour, and at 
11% after six hours of DMSO exposure.  After one hour of TSA treatment acetylation 
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three hours of TSA treatment (six hours), acetylation has reached a maximum of 54%.  





Figure 3.14:  Response of MV411 cell line to 50 nM TSA time course over 6 hours.  The mass 
spectrum for the 7
+
 charge state of the PTM profile is shown. 
 
The results of the TSA time course treatments demonstrate that the response to this de-
acetylase inhibitor is similar across cell lines, but not identical.  Each cell line displays an 
altered PTM profile after TSA treatment, but to varying levels.  The different responses 














line.  The majority of the cell lines tested exhibited a similar response to the TSA 
treatment; i.e. culture medium supplemented with TSA would result in an increase in 
acetylated histone H4 species, but full hyper-acetylation was never realized.  The cells 
which displayed this response were all derived from various white blood cells and several 
are known to contain mutations which result in expression of fusion proteins.  The only 
cell line in which full hyper-acetylation was achieved was the HCT-116 cell line which is 
derived from colo-rectal carcinoma. 
 
3.3.2 Determination of the Order of Acetylation of Histone H4 
 
In order to further investigate the response of different cell lines to HDACi treatment, 
histones were extracted from two of the previously utilized cell lines and after separation 
through HPLC, fractions of histone H4 were collected, re-infused into the mass 
spectrometer and subsequently fragmented by CID and ECD.  The purpose of this 
investigation was to further characterize the changes induced by TSA treatment by 
focusing on the order of acetylation of the N-terminal lysine residues of H4, through 
comparing the results from two cell lines.  To achieve this, TSA was administered as a 
dose response instead of a time course treatment.  The cell lines chosen for the in depth 
study of H4 acetylation were HCT-116 and OCI-AML3.  Two different cell lines were 
investigated in order to exclude the possibility of any variation in the acetylation order 
between cell lines.  Cell cultures were exposed to TSA at the following concentrations: 
50 nM, 100 nM, 250 nM and 500nM, for a period of one hour.  The spectra presented 
below display the most extensive fragmentation data gathered. 
 
 
3.3.2.1 HCT-116 Cell Line 
 
At 50 nM, low levels of fragmentation were achieved on isolated modified forms of 
histone H4 from HCT-116 cells, most likely due to low quality of the extracted histone 
samples.  This was potentially due to the extraction procedure, but a smaller cell culture 




data was gathered from several of the isolated species.  Extensive fragmentation at this 
concentration was only achieved when a precursor of mass 11,467 Da was isolated and 
fragmented.  The CID and ECD spectra of this precursor ion are shown in Figures 3.15 
and 3.16 below, along with a combined fragment ion map (Figure 3.17) for this species of 
histone H4 generated from both the CID and ECD data. 













































                  
 
Figure 3.15:  Top-down CID spectrum of histone H4 from TSA treated HCT-116 cells (50 nM) for 
the 13
+
 charge state from the precursor ion at 883.6 m/z  . The complete list of the assigned fragment 
ions is attached as Appendix A1. 




























































































































                   
     
         
Figure 3.16:  Top-down ECD spectrum of histone H4 from TSA treated HCT-116 cells (50 nM) for 
the 13
+
 charge state from the precursor ion at 883.6 m/z.  A complete list of the assigned fragment 
ions is attached as Appendix A2.                
 
 
      
                  












Figure 3.17:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 















































































The fragment ion map confirmed acetylation of all N-terminal Lysine residues, along 
with di-methylation of lysine 20.  The location of these modifications also reveals that H4 
acetylation occurs exclusively in the N-terminal region, and not in the globular portion of 
the protein. 
 
TSA treatment of HCT-116 cells at other concentrations provided more extensive 
sequence coverage.  Figure 3.18 below, shows the CID spectrum obtained for the 13
+
 
charge state of the modified H4 isoform (100 nM TSA treatment) from the precursor ion 
at 870.6 m/z, corresponding to an isoform with an intact mass of 11,299 Da with a 
fragment ion map ( Figure 3.19) 















































                 
Figure 3.18:  Top-down CID spectrum of histone H4 from TSA treated HCT-116 cells (100 nM) for 
the 13
+
 charge state from the precursor at 870.6 m/z.  A complete list of the assigned fragment ions is 

















Figure 3.19:  Fragment ion map top-down CID spectrum of histone H4 from TSA treated HCT-116 
cells (100 nM) from the precursor at 870.6 m/z.     
 
CID provided sufficient sequence coverage to assist in the localization of the PTMs 
present.  The intact mass of the precursor suggests the presence of an acetyl group and di-

























first seven amino acids, excluding all other lysine residues.  The di-methylation is likely 
located at lysine 20 or a subsequent residue.  At 100 nM TSA treatment, no further 
fragmentation was achieved using CID or ECD.   
 
The CID spectrum of histone H4 from HCT-116 cells after 500 nM treatment exhibited 
good sequence coverage.  The CID spectrum for the 13
+
 charge state of the precursor ion 
at 883.6 m/z, corresponding to an isoform with an intact mass of 11,467 Da is shown in 
Figure 3.20 below, with a fragment ion map (Figure 3.21). 
 










































                  
Figure 3.20:  Top-down CID spectrum of histone H4 from TSA treated HCT-116 cells (500 nM) for 
the 13
+
 charge state from the precursor ion at 883.6 m/z.  A complete list of the assigned fragment 












Figure 3.21:  Fragment ion map of top-down CID spectrum of histone H4 from TSA treated HCT-
116 cells (500 nM) for the precursor ion at 883.6 m/z.   
 
The fragment ions observed after CID of the precursor at 883.6 m/z confirmed that this 
species was the fully hyper-acetylated form of histone H4, and that each acetyl group was 

















































































116 cell line provided only limited information on the acetylation order of histone H4.  
The cells from 250 nM TSA treatment provided no useful data, and each other 
concentration of TSA used yielded limited results.  This was most likely a result of low 
protein yield from the extraction process.   
 
3.3.2.2 OCI-AML3 Cell Line 
 
Similar experiments performed on TSA treated OCI-AML3 cells yielded much more in 
depth results.  Instrument settings and culture conditions were unchanged between the 
two cell lines, suggesting that the improved sequence coverage was largely due to a 
higher protein concentration in the samples.  The spectra shown in Figures 3.22 and 3.23 
below show the fragmentation data obtained for the 13
+
 charge state of histone H4 (after 
50 nM treatment) following CID and ECD of the precursor ion at 870.6 m/z 
corresponding to an isoform with an intact mass 11,299 Da, along with a combined 
fragment ion map for this species of histone H4 generated from both the CID and ECD 
data (Figure 3.24). 































































              
Figure 3.22:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML 3 cells (50 nM) for 
the 13
+
 charge state from the precursor ion at 870.6 m/z.  A complete list of the assigned fragment 
ions is attached as Appendix A5. 
 


































































































                
Figure 3.23:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML3 cells (50 nM) for 
the 13
+
 charge state from the precursor ion at 870.6 m/z.  A complete list of the assigned fragment 



















Figure 3.24:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 

































































































































































The fragmentation data enable the presence of a single acetyl group in this species to be 
conclusively localized to the N-terminal serine residue.  The other modification present is 
the di-methyl group located at lysine 20, a common post-translational modification. 
 
Figures 3.25 and 3.26 below show CID and ECD fragment spectra for the 13
+
 charge 
state of the modified form of histone H4 at 873.9 m/z. This precursor ion mass-to-charge 
ratio corresponds to an isoform with an intact mass of 11,341 Da, an  increase in mass of 
42 Daltons with respect to that of the precursor ion selected for fragmentation in the 
figures above. 
       
           

























































                  
 
Figure 3.25:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML3 cells (50 nM) for 
the 13
+
 charge state from the precursor ion at 873.9 m/z.  A complete list of the assigned fragment 
ions is attached as Appendix A7. 


























































                    
                      
Figure 3.26:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML3 cells (50 nM) for 
the 13
+
 charge state from the precursor ion at 873.9 m/z.  A complete list of the assigned fragment 























































































































































Figure 3.27:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 
treated OCI-AML3 cells (50 nM).   
 
 
Both the CID and ECD spectra confirm the presence of the N-terminal acetylation, and 
di-methylation at lysine 20 (shown in Figure 3.27).  In addition, the mass increase can be 
accounted for by the presence of a second acetyl group.  However the position of this 
acetyl group cannot be identified with complete confidence.  The CID data reveals that 
the PTM is located on lysine 12 while the ECD reveals the acetyl group is at lysine 16 
(shown as blue circles above the lysine residues in Figure 3.27).  The most likely 
explanation is that this modified form of H4 exists as a mixture of these two species.   
 
CID was then performed on the 12
+
 charge state of the modified form of H4 at 950.1 m/z 
(it was not possible to achieve clean isolation of the 13
+
 charge state). This precursor ion 
mass-to-charge ratio corresponds to an isoform with an intact mass of 11,383 Da.  The 










                  
 
                     
Figure 3.28: Top-down CID spectrum of histone H4 from TSA treated OCI-AML3 cells (50 nM) for 
the 12
+
 charge state from the precursor ion at 950.1 m/z.  A complete list of the assigned fragment 









































































Figure 3.29: Fragment ion map of top-down CID of histone H4 from TSA treated OCI-AML3 cells 
(50 nM). 
 
The fragmentation data shown in the figure above was sufficient to conclusively confirm 
that the first two sites of acetylation in histone H4 are lysines 16 and 12. 
 
At 100 nM TSA treatment, low sequence coverage was achieved on the modified forms 
of H4.  CID and ECD experiments were performed on the 13
+
 charge state of the 
precursor ion at 870.6 m/z, corresponding to an isoform with an intact mass of 11,299 Da, 
again confirming as for the 50 nM TSA treatment, that this is histone H4 carrying an N-
terminal acetylation and a di-methylation at lysine 20.  
 
Figures 3.30 and 3.31 below show CID and ECD spectra for the 13
+
 charge state of the 
precursor ion at 873.9 m/z, corresponding to an isoform with an intact mass of 11,341 Da, 





                 
 
                   
 
 
Figure 3.30:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML3 cells (100 nM) 
for the 13
+
 charge state from the precursor ion at 873.9 m/z.  A complete list of the assigned fragment 






































































































                 
                 
 
Figure 3.31:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML3 cells (100 nM) 
for the 13
+
 charge state from the precursor ion at 873.9 m/z.  A complete list of the assigned fragment 

































































































Figure 3.32:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 
treated OCI-AML3 cells (100 nM). 
 
As shown in the above figures, extensive sequence coverage was achieved using both 
fragmentation techniques.  When combined, the data reveal no discrepancies in the 
localization of PTMs.  This species of histone H4 ion is N-terminally acetylated, di-
methylated at lysine 20 and acetylated at lysine 16, confirmed by both methods of 
fragmentation.   
 
Attempts to perform fragmentation on the 12
+
 charge state of the modified form of H4 at 
950.1 m/z, corresponding to an isoform with an intact mass of 11,383 Da were of only 
limited success.  After multiple attempts at isolation and fragmentation, low sequence 
coverage was achieved and only the N-terminal acetylation and di-methylation could be 
conclusively localized.  The final species to be examined in the cells treated with 100 nM 
TSA was the 13
+
 charge state for the precursor ion at 880.4 m/z.  This precursor ion 
mass-to-charge ratio corresponds to an isoform with an intact mass of 11,425 Da.  The 
results of the CID and ECD experiments performed are shown in the spectra below, 







               
 
 
                
 
Figure 3.33:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML 3 cells (100 nM) 
for the 13
+
 charge state from the precursor ion at 880.4 m/z.  A complete list of the assigned fragment 













































































                
 
 
Figure 3.34:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML 3 cells (100 nM) 
for the 13
+
 charge state from the precursor ion at 880.4 m/z.  A complete list of the assigned fragment 







































Figure 3.35:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 
treated OCI-AML 3 cells (100 nM).  
 
The fragmentation data above shows that the N-terminal acetylation, and lysine 20 and 
lysine 16 modifications are as seen previously, while newer modifications are located on 
Lysine residues closer to the N-terminus, specifically the newly added acetyl groups are 
located at lysines 5 & 8.   
 
Little meaningful data was gained through fragmentation of multiple H4 species after 250 
nM TSA treatment.  This is most likely due to low yield of histone proteins during the 
extraction process.  Figure 3.36 below shows the only useful spectrum acquired.  This is 
the CID spectrum of the 13
+
 charge state from the precursor ion at 873.9 m/z, 
corresponding to an isoform with an intact mass of 11,341 Da.  A fragment ion map is 











                
                  
 
Figure 3.36:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML3 cells (250 nM) 
for the 13
+
 charge state from the precursor ion at 873.9 m/z.  A complete list of the assigned fragment 





































































































Figure 3.37:  Fragment ion map of top-down CID of histone H4 from TSA treated OCI-AML3 cells 
(250 nM). 
 
The fragment map shown above is in agreement with data presented earlier, in that the 
first lysine residue to be modified by acetylation is lysine 16.  While the 250 nM TSA 
treatment provided little information, the next treatment and extraction carried out 
provided extensive sequence coverage of all ions fragmented by both CID and ECD.  
While the reasons for the improved results after 500 nM TSA treatment are unclear, they 
are most likely to do with more protein extracted during the procedure.   
 
CID and ECD spectra of the 13
+
 charge state of H4 species at 873.9 m/z, corresponding to 
an isoform with an intact mass of 11,299 Da confirmed that this was the common form; 
acetylated at the N-terminus and di-methylated at lysine 20.  The CID and ECD spectra 












                 
 
                 
 
 
Figure 3.38:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML3 cells (500 nM) 
for the 13
+
 charge state from the precursor ion at 873.9 m/z.  A complete list of the assigned fragment 


















































































































                  
Figure 3.39:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML3 cells (500 nM) 
for the 13
+
 charge state from the precursor ion at 873.9 m/z.  A complete list of the assigned fragment 





































































Figure 3.40:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 
treated OCI-AML3 cells (500 nM). 
 
 
In agreement with similar data presented from other treatments, the first site of 
acetylation (excluding the N-terminal serine) is lysine 16.  The data presented in the 
above figure showed no ambiguity in the location of the acetyl group, i.e. the ion 
fragmented above was not a mixture of modified H4 acetylated at lysines 12 and 16. 
 
The next species investigated was the 13
+
 charge state for the precursor ion at 877.1 m/z, 
corresponding to an isoform with an intact mass of 11,383 Da.  This intact mass 
corresponds to N-terminally acetylated and di-methylated H4 with a mass increase of 84 
Da.  CID and ECD spectra of this precursor ion are shown in Figures 3.41 and 3.42 below, 















                 
 
                  
 
Figure 3.41:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML3 cells (500 nM) 
for the 13
+
 charge state of the precursor ion at 877.1 m/z.  A complete list of the assigned fragment 




































































                  
 
 
                   
 
Figure 3.42:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML3 cells (500 nM) 
for the 13
+
 charge state from the precursor ion at 877.1 m/z.  A complete list of the assigned fragment 
























































































































































































































































































Figure 3.43:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 
treated OCI-AML3 cells (500 nM).   
 
While the intact mass of this ion corresponded to N-terminally acetylated and di-
methylated H4 with two additional acetyl groups, the location of one of these groups 
could not be identified conclusively from the fragmentation data.  Acetylation was 
confirmed at lysine 16, and the data gathered suggest that the next acetyl group is located 
at either lysine 8 or lysine 12.  CID data suggested that lysine 8 was acetylated whereas 
ECD data suggested that the seondary site of acetylation was lysine 12.  Again, this 
implied that this isoform of H4 exists as a mixture of these possible combinations.   
 
The next species to be examined was the 13
+
 charge state for the precursor ion at 880.4 
m/z.  The intact mass of 11,425 Da for this precursor ion corresponds to a mass increase 
of 126 Da over the unmodified form of H4.  CID and ECD experiments were performed, 
and Figure 3.44 below shows the ECD spectrum obtained.  While CID was successful, a 
low number of fragment ions were generated so this spectrum is not shown; however a 






                  
 
                  
Figure 3.44:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML3 cells (500 nM) 
for the 13
+
 charge state from the precursor ion at 880.4 m/z.  A complete list of the assigned fragment 






































































































































































































































Figure 3.45:  Fragment ion map of combined top-down CID and ECD spectrum of histone H4 from 
TSA treated OCI-AML3 cells (500 nM). 
 
The fragmentation data confirmed acetylation at lysine 5 and lysine 16, while the position 
of the third acetylation could not be confirmed accurately; however its position can be 
narrowed down to either lysine 8 or lysine 12.  Again, this suggests that modified forms 
of H4 exist as a mixture containing modifications at various sites. 
 
The final species to be investigated from the 500 nM treated OCI-AML3 cell line was the 
13
+
 charge state for the precursor ion at 883.6 m/z.  This precursor ion has an intact mass 
of 11,467 Da, which corresponds to a mass increase of 168 Da over  the unmodified form 
of H4.  CID and ECD spectra are shown in Figures 3.46 and 3.47 below along with a 











                 
 
                   
Figure 3.46:  Top-down CID spectrum of histone H4 from TSA treated OCI-AML3 cells (500 nM) 
for the 13
+
 charge state from the precursor ion at 883.6 m/z.  A complete list of the assigned fragment 













































































































                 
 
                   
Figure 3.47:  Top-down ECD spectrum of histone H4 from TSA treated OCI-AML3 cells (500 nM) 
for the 13
+
 charge state from the precursor ion at 883.6 m/z.  A complete list of the assigned fragment 











































































































































































































































































Figure 3.48:  Fragment ion map of combined top-down CID and ECD of histone H4 from TSA 
treated OCI-AML3 cells (500 nM).  
 
The extensive fragmentation achieved confirmed that all the modifications observed were 
located in the N-terminal region, and that no lysine residues after lysine 20 carried a PTM.  
The fragment ion map above shows clearly that post-translational acetylation of H4 
occurs at lysines 5, 8, 12 and 16. 
 
3.4 Conclusions 
The data presented in Section 3.3.1 demonstrate that the response to the histone 
deacetylase inhibitor Trichostatin A is variable across cell lines.  This is evident in the 
different ion abundances of modified H4 in each of the cell lines.  This can potentially be 
explained by the nature of the mutations carried in each of the cell lines.  Each cell line 
was derived from various cancerous tissues, and it is logical to assume that due to the 
altered growth rates of cancerous cells that different mechanisms are at play in regulating 
transcription.  Since histone PTMs serve a pivotal role in gene expression, it follows that 





The two cell lines chosen to investigate the order of acetylation of H4 displayed very 
different responses to TSA treatment.  HCT-116 cells could reach full hyper-acetylation 
following TSA treatment, defining hyper-acetylation as the complete occupancy of all N-
terminal lysine residues which could be modified with the addition of an acetyl group 
(this definition is necessary to exclude lysine 20 from the other four modifiable Lysine 
residues).  A much lower proportion of OCI-AML3 cells reached full hyper-acetylation 
following TSA treatment, even after six hours.  While CID and ECD fragmentation data 
on histone H4 extracted from OCI-AML3 cells yielded much useful information, less was 
obtained from HCT-116 cells, most likely due to low protein yield from the histone 
extraction procedure.  From examination of the fragmentation spectra and the fragment 
ion maps presented above, the following conclusions can be drawn.   
 
In HCT-116 cells, the histone isoform with an intact mass of 11,467 Da which 
corresponds to N-terminally acetylated and di-methylated H4 together with a mass 
increase of 168 Da, is the completely hyper-acetylated form with lysines 5, 8, 12 and 16 
carrying acetyl groups.  This was seen in the 50 nM and 500 nM treatments. 
 
In OCI-AML3 cells, the histone isoform with an intact mass of 11,342 Da, which 
corresponded to N-terminally acetylated and di-methylated H4 with a mass increase of 42 
Da was mono-acetylated, primarily at lysine 16.  This was seen in spectra obtained from 
the 100 nM, 250 nM and 500 nM TSA treatments.  The results from the 50 nM treated 
cells suggested that the acetyl group could be present on either lysine 16 or lysine 12.  
Fragments from the CID and ECD spectra confirmed the presence of both modified 
forms suggesting that mono-acetylated H4 could exist as a mixture. 
 
The histone isoform with an intact mass of 11,383 Da, corresponding to N-terminally 
acetylated and di-methylated H4 together with a mass increase of 84 Da, had two 
additional acetyl groups.  In OCI-AML3 cells treated with 50 nM TSA the acetyl groups 
were mapped to lysine 16 and lysine 12.  In cells treated with 500 nM TSA the acetyl 





The histone isoform with an intact mass of 11,425 Da, corresponding to N-terminally 
acetylated and di-methylated H4 together with a mass increase of 126 Da, had three 
additional acetyl groups.  In OCI-AML3 cells treated with 100 nM TSA the acetyl groups 
were mapped to lysine 12, lysine 8 and lysine 5.  In cells treated with 500 nM TSA the 
acetyl groups were mapped to lysine 16, lysine 5 and either lysine 8 or lysine 12.  
Fragments observed confirmed the presence of the modification at both these sites 
suggesting that H4 carrying this number of PTMs could exist as a mixture of these 
modified forms. 
 
Similar to results gathered from HCT-116 cells, the histone isoform with an intact mass 
of 11,467 Da was tetra-acetylated H4, with each N-terminal lysine residue carrying an 
acetyl group.  This was seen in OCI-AML3 cells after 500 nM TSA treatment. 
 
From the data presented it is possible to suggest an order to the preferred site of H4 
acetylation, based on the occurrence of the modification at each lysine residue.  Lysine 
acetylation of histone H4 initially begins at lysine 16.  This is followed by acetylation at 
lysine 12 or lysine 8.  Lysine 5 is the last (and least observed) site of acetylation.  This is 
shown in Figure 3.33 below.  These results are in good agreement with work performed 










Figure 3.49:  Sequence of N-terminal region of H4.  Lysine residues with PTMs affected by TSA are 








3.5 Future Work 
While the present study has provided a good indication of the order of acetylation, future 
work could focus on determining whether or not the site of modification is dependent on 
the presence of other PTMs close to the residue of interest.  This work could begin with 
investigating histone H4 acetylation in the absence of the di-methyl group located at 
lysine 20, and using the methods employed here (treatment with a de-acetylase inhibitor 
and top-down FT-ICR MS).  The modifications present at each N-terminal lysine could 
then be characterized.   
 
In addition, this work could be extended to the other histone protein known to be 
extensively decorated by acetylation, histone H3.  However, the study of histone H3 
would be more challenging due to the large number of methyl groups known to modify 
arginine residues.  Nevertheless, a better understanding of the combinations of post-
translational modifications would increase the body of knowledge linking PTMs to 


























Chapter 4 describes a study carried out to investigate the effects of lactic acid exposure to 
the acetylation profile of histone H4.  An introduction is given which includes a brief 
description of how lactic acid is formed during energy metabolism in eukaryotes, along 
with the methods used in the work and results generated.  A summary and suggestions for 
future work are provided at the end of the chapter. 
 
4.1 Introduction 
Energy metabolism in eukaryotes can broadly be split into three stages: glycolysis, the 
citric acid cycle and oxidative phosphorylation.  The first stage, glycolysis, involves the 
uptake of glucose (the preferred source of energy) into the cell and its conversion to the 
end product pyruvic acid
164
.  Pyruvic acid enters the citric acid cycle, and through a series 
of reactions, adenosine tri-phosphate (ATP, the molecule which serves as the body’s 
energy currency) is generated.  Following the citric acid cycle, oxidative phosphorylation 
converts products of the citric acid cycle into water and carbon dioxide using a series of 
reactions which function as an electron transport chain.  Water and carbon dioxide are the 
ultimate products of metabolism and their formation signals the complete metabolism of 
a glucose molecule.  A single glucose molecule can yield up to 36 molecules of ATP
165
 
and Figure 4.1 below is a representation of glycolysis (a) and the citric acid cycle (b).   
 

















                       
 
 





Entry into each of the stages is dependent on the availability of the correct substrates e.g. 
glycolysis begins with the six carbon sugar glucose, but not with its isomer fructose.  
Regulating the availability of several such substrates are enzymes responsible for the 
inter-conversion of various isomers
167
.  Glucose is sourced from the diet, however the 
citric acid cycle begins with the three carbon keto-acid, pyruvic acid.  Under aerobic 
conditions, this is the end product of glycolysis, but under anaerobic conditions i.e. when 
oxygen is present in limited amounts, glycolysis favours the formation of lactic acid, 
which can be reversibly converted into pyruvic acid by the enzyme lactate de-







Figure 4.2: Reversible conversion of pyruvate to lactate by the enzyme lactate de-hydrogenase.   




During intense exercise, when insufficient oxygen is present for glycolysis to proceed as 
normal, lactic acid becomes the main end product, rising to levels of 55.9 mM.  These 
levels return to normal (around 2.8 mM
 
) once sufficient oxygen is available
169
.  It has 
been shown previously that pyruvate and butyrate have an effect on the acetylation of 
histone H4
153,155,170
, however little concrete evidence exists showing whether or not 
lactate can affect histone acetylation.  The relevance of considering the role of lactic acid 
as a histone de-acetylase inhibitor becomes apparent when considering the metabolism of 
cells which undergo altered growth rates; i.e. cells which have become cancerous.  
Replicating cells can be split broadly into three groups depending on growth rates and 
entry/exit of stages of the cell cycle.  Cells can be classed as non-tumourigenic, 
tumourigenic or metastatic.  While the majority of cells fall into the non-tumourigenic 
group, tumourigenic cells (which are pre-cancerous) are known to metabolise energy 
through different pathways.   
During respiration in healthy cells, lactate concentration is roughly ten times that of 
pyruvate
169
.  Otto Warburg reported in 1926 that tumourigenic cells relied heavily on 
glycolysis to generate ATP, while the citric acid cycle and oxidative phosphorylation 
were used to a much lesser extent.  This observation was manifested as an increase in the 
amount of lactic acid in the presence of oxygen, a result of the conversion of pyruvic acid 
into lactic acid by the enzyme lactate de-hydrogenase
171
.  This phenomenon, noted by 
Warburg, and has come to be known as the Warburg effect
172,173
.  While it is still 
CH3      C      COO
¯ 
O OH 
NADH + H+ NAD+ 







unknown if the Warburg effect is a cause or a result of tumourigenesis, the increase in 
glucose consumption and the elevated levels of lactic acid in cancerous cells is now well 
known
174,175
.   
 
 
The work performed in the previous chapter serves as a starting point for the material 
presented here. 
 
The effect of lactate as a histone de-acetylase inhibitor was tested against the activity of 
two histone modifying enzymes; histone de-acetylases one and two (HDAC 1 and HDAC 
2).  The HCT-116 cell line was shown to be sensitive to histone de-acetylase inhibitors, 
as such it was deemed suitable for the work described here.  Cells were cultured and 
supplemented with lactate, histones extracted and LCMS performed to investigate 
whether lactate could alter the acetylation of histone H4. 
 
The aims of this study were as follows: 
• To determine if lactate, a by-product of glycolytic metabolism, could affect 
histone H4 acetylation. 

















4.2.1 Cell Culture and Lactate Treatment 
HCT-116 cells were cultured as described previously and split into four groups; two 
groups received a supplement of histone de-acetylase 1 (HDAC 1) at 5 and 10 units, and 
the other two groups supplemented with HDAC 2.  The cells were divided further 
according to HDACi treatment.  Lactate (as sodium lactate) was added to the culture 
medium in either L- or D- form at a final concentration of 100 mM.  As negative control, 
sodium chloride was added to one group (100 mM) and as positive control TSA was 
added to another (100 nM).  The treatment was carried out as a time course, with 
exposure lasting thirty minutes, three hours or six hours.  After each of these periods cells 
were washed briefly in PBS before histone extraction was carried out (as described in 
















Figure 4.3:  Workflow of experiment to determine if lactate can affect histone acetylation.  The steps 
shown above were repeated for cells receiving HDAC2 treatment. 
 
 




4.2.2 Liquid Chromatography and Mass Spectrometry 
LC-MS was performed with a Dionex Ultimate 3000 system coupled to a Bruker 
Daltonics Apex Qe FT-ICR mass spectrometer equipped with either a 9.4 T or a 12 T 
superconducting magnet.  Data was acquired in broadband mode with an ion 
accumulation time of roughly 1 second.  Each spectrum acquired was the sum of 2 mass 
analyses.   
 
4.2.3 Data Analysis 
Data was analysed using Compass DataAnalysis software (Bruker) and ion abundances 
were calculated using in house software (written in Python), using a modified version of 
the method described by Smith et al 
159,160
.  Briefly, acetylation was quantified from the 
integrated ion abundances of modified species at the three highest abundance charge 
states.  Each integrated ion abundance was then weighted according to the number of 
modified lysine residues.  These were then summed and divided by the total weighted ion 
abundance of all modified H4 species possible.  The levels of acetylation are presented as 
a percentage (i.e. ((acetylation present)/(acetylation possible)) multiplied by 100).  All 
spectra were exported as simple ASCII files and plotted using Microcal Origin (version 
6.0).   
 
4.2.4 Statistical Analysis 
Statistical analysis of data was performed using Minitab Statistical Software, Version 16 
(Minitab Inc).  Ion abundance data was manually entered into Minitab and the on-board 
statistical analysis functions were used to perform either paired t-tests or analysis of 
variance.  A p- value of <0.05 indicated a difference between the data being compared 
(i.e. acceptance of the null hypothesis where a change in acetylation level was the result 
of the treatment administered to the cells) while a p- value >0.05 was interpreted as there 








4.3.1 HDAC 1 Treatment 
The LC-MS spectra shown in Figure 4.4 below display the 9
+
 charge state of histone H4 
extracted from HCT-116.  Cells were treated with 5 units HDAC 1 and either sodium 
chloride, L-lactate, D-lactate or TSA (shown in different colours) for thirty minutes. 
 
Figure 4.4:  LC-MS spectra for the 9
+  
charge state of histone H4 after 30 minutes treatment with L- 
or D-lactate (blue and green respectively).  NaCl (black) and TSA (red) were included as negative 
and positive controls respectively.  The di-methylated peaks are labelled and numbered in order of 
acetylation state where (N-Ac) means N-terminally acetylated and (2 Ac) means two acetyl groups 
are present etc. 
 
As would be expected for the NaCl treatment, little change is seen in the amount of 
acetylation.  The L-lactate treatment proved an effective histone deacetylase inhibitor 
(HDACi), as did the D-lactate treatment.  TSA is a known inhibitor of histone de-
acetylation and this treatment resulted in the expected rise in abundance of acetylated 
species.  The level of acetylation calculated for the NaCl treatment was 37%.  L-lactate, 









of 73%, 75% and 74% respectively.  The standard deviations from these values 
(calculated from the three highest abundance charge states) were all under 5%, giving 
good confidence in the results.   
 
The LC-MS spectra shown in Figure 4.5 below display the 9
+
 charge state of histone H4, 
with similar treatments to those described above, except that the treatments were applied 
for three hours.  Similar to Figure 4.4 above, the colours used in the spectra represent the 
various treatments. 
 
Figure 4.5:  LC-MS spectra for the 9
+
 charge state of histone H4 after 3 hours treatment with L- or 
D-lactate (blue and green respectively).  NaCl (black) and TSA (red) were included as negative and 
positive controls respectively.  The di-methylated peaks are labelled and numbered in order of 
acetylation state where (N-Ac) means N-terminally acetylated and (2 Ac) means two acetyl groups 
are present etc. 
 
Changes in the level of acetylation start to appear after three hours treatment time.  The 
level of acetylation in the NaCl treated cells rose, visible as the peaks at roughly 1270 m/z 









histone acetylation.  Contrary to this, and somewhat expected, the levels of acetylation in 
the three other treatments fell.  Acetylation in the L-lactate cells fell to 63%, D-lactate 
treated cells fell to 66% and acetylation of TSA treated cells fell to 66%.  The maximum 
standard deviation from these values was 5.81% (TSA treatment), again giving good 
confidence in the results.  The extension of treatment time resulted in a drop in 
acetylation for all treatments (except NaCl) which is most likely a result of the various 
treatments being matabolised by the cells.   
 
The LC-MS spectra shown in Figure 4.6 below show the 9
+
 charge state of histone H4 
after six hours treatment with the same four compounds. 
 
Figure 4.6:  LC-MS spectra for the 9
+
 charge state of histone H4 after 6 hours treatment with L- or 
D-lactate (blue and green respectively).  NaCl (black) and TSA (red) were included as negative and 
positive controls respectively.  The di-methylated peaks are labelled and numbered in order of 
acetylation state where (N-Ac) means N-terminally acetylated and (2 Ac) means two acetyl groups 










After six hours treatment there was little change in acetylation levels when compared to 
the results of the three hour treatment.  Acetylation in the NaCl treated cells rose slightly 
to 47%.  Acetylation in the other treatments remained stable; 63% for the L-lactate 
treatment, 68% for the D-lactate treatment and 72% for the TSA treatment.  The standard 
deviations from these values were all below 6% (D-lactate treatment), again giving good 
confidence in the results.  The results are summarised in Figure 4.7 below. 
 
Figure 4.7:  Graph showing the combined results of all treatments over the three time periods for 
cells supplemented with 5 units HDAC 1; 30 minutes (white), 3 hours (light grey) and 6 hours (dark 
grey). 
 
The NaCl control treatment exhibited consistently lower acetylation than all other 
treatments after each time period.  The other treatments each displayed a similar pattern 
in acetylation, specifically that acetylation would reach a maximum value after thirty 






The following spectra show the results of treatment with the four compounds over similar 
time periods, however, in this case cells were supplemented with 10 units HDAC 1 
instead of 5 units.  Figure 4.8 below displays the results of the thirty minute treatment. 
 
 
Figure 4.8:  LC-MS spectra for the 9
+
 charge state of histone H4 after 30 minutes treatment with L- 
or D-lactate (blue and green respectively).  NaCl (black) and TSA (red) were included as negative 
and positive controls respectively.  The di-methylated peaks are labelled and numbered in order of 
acetylation state where (N-Ac) means N-terminally acetylated and (2 Ac) means two acetyl groups 
are present etc. 
 
 
As found in the earlier experiments involving supplementation with 5 units of HDAC 1, 
acetylation of the NaCl treated cells was low at 38%.  Acetylation after all other 
treatments was higher; 74% (L-lactate), 78% (D-lactate) and 61% (TSA).  Standard 
deviations were all below 8% (NaCl) with the other values typically around 4%.  While 
the effect of the lactate treatments still show that L- and D-lactate are inhibitors of 
histone de-acetylation, the effect of the TSA treatment is reduced when compared to the 









result of the increased amount of HDAC1 supplemented to the cells. However, it is also 
possible that this result is partly due to the charge states chosen for the calculation 
performed.  The similarity in the increased levels of acetylation of the lactate treated 
samples when compared to the data for supplementation with 5 units of HDAC 1 suggest 
this may be the case. 
 
Figure 4.9 below shows the results of the three hour treatment. 
 
Figure 4.9:  LC-MS spectra for the 9
+
 charge state of histone H4 after 3 hours treatment with L- or 
D-lactate (blue and green respectively).  NaCl (black) and TSA (red) were included as negative and 
positive controls respectively.  The di-methylated peaks are labelled and numbered in order of 
acetylation state where (N-Ac) means N-terminally acetylated and (2 Ac) means two acetyl groups 
are present etc. 
 
 
Acetylation in the NaCl treated cells rose slightly to 43%, similar to the results seen for 
the same time course following supplementation with 5 units of HDAC 1.  Acetylation in 
the lactate treated cells dropped to 66% (L-lactate) and 69% (D-lactate), while this value 









treated cells were simiar to those observed earlier for the same time course, again 
indicating that after three hours treatment the inhibitory effect of the lactate was reduced 
potentially due to metabolism of the treatment.  The increase in value calculated for the 
TSA treatment is likely a better indication of the true level of acetylation when compared 
to the thirty minute time course.  This can be confirmed to an extent by the low standard 
deviations from the calculated values, all of which were under 4% (TSA). 
 
Figure 4.10 below displays the results of the six hour treatments.   
 
Figure 4.10:  LC-MS spectra for the 9
+
 charge state of histone H4 after 6 hours treatment with L- or 
D-lactate (blue and green respectively).  NaCl (black) and TSA (red) were included as negative and 
positive controls respectively.  The di-methylated peaks are labelled and numbered in order of 
acetylation state where (N-Ac) means N-terminally acetylated and (2 Ac) means two acetyl groups 
are present etc. 
 
 
Differences were apparent when compared to previous spectra.  Acetylation in the NaCl 
treatment remained fairly stable at a value of 40%.  A drop in acetylation for the L-lactate 









in the N-terminally acetylated di-methylated form of H4.  The level of acetylation for the 
L-lactate treatment was calculated as 60%.  Acetylation after six hours with the other 
treatments (D-lactate and TSA) remained elevated with values of 76% and 81% 
respectively.  All standard deviations were low with a maximum value of 5% (NaCl) 
giving good confidence with the results.  Similar to the data for supplementation with 5 
units of HDAC 1, acetylation levels fell after three hours for the L-lactate treatment, 
however, in this case the level of acetylation continued to fall after six hours.  These 
results are summarised in Figure 4.11 below. 
 
Figure 4.11:  Graph showing the combined results of all treatments over the three time periods for 
cells supplemented with 10 units of HDAC 1; 30 minutes (white), 3 hours (light grey) and 6 hours 
(dark grey). 
 
With the exception of the anomalous thirty minute TSA treatment, the following trends 
were observed in the data above; the treatments had their maximum inhibitory effect after 
thirty minutes.  After three hours and six hours, acetylation after TSA treatment was high 




of HDAC 1 activity than L-lactate, however L-lactate did inhibit HDAC 1 activity when 
compared to the NaCl control treatment.  The similarity and lack of variation in 
acetylation after NaCl treatment gave an indication of the base level of acetylation 
expected in untreated cells, which was visible in all LC-MS spectra as the base peak at ~ 
1257 m/z.  As shown through fragmentation work in the previous chapter, this peak 
represents H4 which carries an N-terminal acetylation and di-methylation at lysine 20. 
 
 
4.3.2 HDAC 2 Treatment 
The following data were acquired as described previously, with the exception that instead 
of supplementing cells with HDAC 1, HDAC 2 was used.  Any difference in results 
could then be attributed to a change in the inhibitory effect of the treatments with respect 
to the de-acetylase enzyme chosen.  Figure 4.12 below shows the results of the various 
treatments after thirty minutes exposure to each of the compounds after cells were 





Figure 4.12:  LC-MS spectra for the 9
+
 charge state of histone H4 after 30 minutes treatment with L- 
or D-lactate (blue and green respectively) after cells were supplemented with 5 units of HDAC 2.  
NaCl (black) and TSA (red) were included as negative and positive controls respectively.  The di-
methylated peaks are labelled and numbered in order of acetylation state where (N-Ac) means N-
terminally acetylated and (2 Ac) means two acetyl groups are present etc. 
 
 
NaCl treatment had little effect in acetylation level with a value of 31%.  L- and D-lactate, 
and TSA treatment resulted in an increase in acetylation of H4 with values of 60%, 80% 
and 82% respectively.  The standard deviations from these values were all consistently 
low with a maximum value of 4% (NaCl).  These results compare well with the data from 
the earlier experiments using supplementation with 5 units of HDAC 1, which gave 
similar results after thirty minutes.  Figure 4.13 below shows the levels of acetylation 










Figure 4.13:  LC-MS spectra for the 9
+
 charge state of histone H4 after 3 hours treatment with L- or 
D-lactate (blue and green respectively) after cells were supplemented with 5 units of HDAC 2.  NaCl 
(black) and TSA (red) were included as negative and positive controls respectively.  The di-
methylated peaks are labelled and numbered in order of acetylation state where (N-Ac) means N-
terminally acetylated and (2 Ac) means two acetyl groups are present etc. 
 
 
After three hours a more significant change in acetylation was observed in all treatments, 
except for NaCl which rose slightly to 38%.  Acetylation in the L-lactate treated cells 
dropped to 55%, with the D-lactate and TSA treatments also showing a drop in 
acetylation with values of 66% and 72% respectively.  Standard deviations from these 
values were all low with a maximum of 5% (NaCl) giving good confidence in the results.  
Such a significant drop in acetylation was most likely a result of metabolism of each of 
the treatments.  Figure 4.14 below displays the results of the six hour treatment with each 











Figure 4.14:  LC-MS spectra for the 9
+
 charge state of histone H4 after 6 hours treatment with L- or 
D-lactate (blue and green respectively) after cells were supplemented with 5 units of HDAC 2.  NaCl 
(black) and TSA (red) were included as negative and positive controls respectively.  The di-
methylated peaks are labelled and numbered in order of acetylation state where (N-Ac) means N-
terminally acetylated and (2 Ac) means two acetyl groups are present etc. 
 
After six hours treatment, acetylation in the NaCl treated cells remained stable at 39%.  
Acetylation in all other treatments dropped.  Acetylation in the L-lactate treated cells fell 
to 45%, in the D-lactate treated cells this value was 59% and only a slight drop was 
observed in the TSA treated cells with a final value of 69%.  There was greater variation 
in the standard deviation for these values in the six hour treatment, with the largest from 
the NaCl treated cells (8%).  All others were below 6% giving good confidence in the 
results.  The larger standard deviation in the NaCl treatment was most likely a result of 
the charge states chosen for the calculation used to quantify the level of acetylation.  
Figure 4.15 below summarises the results of the experiments following supplementation 










Figure 4.15:  Graph showing the combined results of all treatments over the three time periods for 
cells supplemented with 5 units of HDAC 2; 30 minutes (white), 3 hours (light grey) and 6 hours 
(dark grey). 
 
Comparing this data with that shown in Figure 4.7 (supplementation with 5 units of 
HDAC 1), the following observations can be made:  L-lactate is a more potent inhibitor 
of HDAC 1 than HDAC 2.  This was true for all three treatment times.  At three hours 
and six hours the level of acetylation in the L-lactate treated cells continued to drop in the 
HDAC 2 treated cells, while it remained stable in the HDAC 1 treated cells.  D-lactate 
and TSA are more potent inhibitors of the two HDAC enzymes used than L-lactate, with 
H4 hyper-acetylation evident at all time periods.  NaCl has little effect as a histone de-
acetylase inhibitor with acetylation values consistent across all time periods, which were 
slightly elevated when compared to the results presented in Chapter 3. 
The following LC-MS spectra display the 9
+
 charge state of histone H4 from cells treated 
with the same four compounds, the only change being that cells were supplemented with 





Figure 4.16:  LC-MS spectra for the 9
+
 charge state of histone H4 after 30 minutes treatment with L- 
or D-lactate (blue and green respectively) after cells were supplemented with 10 units of HDAC 2.  
NaCl (black) and TSA (red) were included as negative and positive controls respectively.  The di-
methylated peaks are labelled and numbered in order of acetylation state where (N-Ac) means N-
terminally acetylated and (2 Ac) means two acetyl groups are present etc. 
 
 
As with all previous HDAC treatments, the level of acetylation in the NaCl treated cells 
was low at 41%.  Acetylation was elevated in the remaining three samples; 58% in the L-
lactate treated cells, 64% in the D-lactate treated cells and 71% in the TSA treated cells.  
The standard deviations for these values were higher than in other treatments, but also 
consistent with each other, with values in the range of 7% to 9%.  This variation could 
potentially be accounted for by the charge states chosen for the calculation.  
 












Figure 4.17:  LC-MS spectra for the 9
+
 charge state of histone H4 after 3 hours treatment with L- or 
D-lactate (blue and green respectively) after cells were supplemented with 10 units of HDAC 2.  NaCl 
(black) and TSA (red) were included as negative and positive controls respectively.  The di-
methylated peaks are labelled and numbered in order of acetylation state where (N-Ac) means N-
terminally acetylated and (2 Ac) means two acetyl groups are present etc. 
 
Acetylation was low in the NaCl treated cells with a value of 42%.  When compared to 
Figure 4.16 (30 minute treatment), acetylation was reduced in the other three samples.  
The L-lactate treated cells were acetylated to 49%, the D-lactate treated cells to 60% and 
the TSA treated cells to 61%.  Standard deviations were low with a maximum of 7% 
(TSA treatment) giving good confidence in the results.   
 
The final samples investigated were as above, but given a six hour treatment with each of 










Figure 4.18:  LC-MS spectra for the 9
+
 charge state of histone H4 after 6 hours treatment with L- or 
D-lactate (blue and green respectively) after cells were supplemented with 10 units of HDAC 2.  NaCl 
(black) and TSA (red) were included as negative and positive controls respectively.  The di-
methylated peaks are labelled and numbered in order of acetylation state where (N-Ac) means N-
terminally acetylated and (2 Ac) means two acetyl groups are present etc. 
 
 
With the exception of the TSA treated cells, acetylation fell in each of the samples after 
six hours treatment.  Acetylation dropped slightly to 38% in the NaCl treated cells, this 
value fell by a greater amount in cells treated with L-lactate to 43% and acetylation again 
dropped slightly in the D-lactate treated cells to 58%.  In the TSA treated cells, 
acetylation rose to 65%, an increase of over 4%.  Standard deviations from these values 
ranged from 5% (L-lactate) to 8% (NaCl).  This variation could be a result of the charge 









Figure 4.19 below summarises the results of these experiments following 
supplementation with 10 units of HDAC 2. 
 
Figure 4.19:  Graph showing the combined results of all treatments over the three time periods for 
cells supplemented with 10 units of HDAC 2; 30 minutes (white), 3 hours (light grey) and 6 hours 
(dark grey). 
 
The following observations can be made regarding this data.  Since there is little change 
in the acetylation level of NaCl treated cells across all time periods, NaCl served as a 
good negative control, providing confidence in the changes in acetylation seen in the 
lactate treated samples.  The change in acetylation due to the addition of L-lactate is 
consistent with the hypothesis that L-lactate is an inhibitor of histone de-acetylase 2, and 
that its inhibitory effect reached its maximum shortly after administration to the cells.  
This inhibitory effect then decreases with prolonged treatment time.  D-lactate is also an 
inhibitor of histone de-acetylase 2 activity, and similar to L-lactate its maximum effect is 
seen shortly after administration.  In contrast to L-lactate, the inhibitory effect of D-




of hyper-acetylation.  TSA, as expected, is an effective inhibitor of histone de-acetylase 2 
activity with a maximum effect seen after thirty minutes treatment.  Similar to D-lactate, 
the inhibitory effect of TSA decreased by a lesser extent with increasing time. 
 
4.4 Conclusions   
 
The combined results from these experiments demonstrate that when supplemented with 
either HDAC 1 or HDAC 2, the base level of acetylation in HCT-116 cells is roughly 
37%.  This is evident in all NaCl treated cells over all time periods tested.  NaCl is not 
known to inhibit histone de-acetylase activity giving confidence that this is the base 
acetylation level.  However, it is noteworthy that this base level of acetylation is higher 
than seen in completely untreated cells (data presented in Section 3.3.1). 
 
L-lactate is observed to be an inhibitor of both HDAC 1 and HDAC 2 activity.  The effect 
of L-lactate reaches its maximum soon after administration, and decreases thereafter.  L-
lactate is a more potent inhibitor of HDAC 1 than HDAC 2, with lower levels of 
acetylation observed when cells are supplemented with HDAC 1 compared to HDAC 2. 
 
D-lactate is also observed to be an inhibitor of HDAC 1 and HDAC 2 activity.  The 
inhibitory effect of D-lactate is greater than that of L-lactate.  This is observed to be the 
case for cells supplemented with either HDAC 1 or HDAC 2.  The inhibitory effect also 
diminishes over time, similar to L-lactate treated cells.   
 
To test that a statistical difference exists in the data presented above, analysis of variance 
(ANOVA) was performed on the results used to generate Figures 4.7, 4.11, 4.15 and 4.19 
(the graphs which summarise the data presented in the spectra).  ANOVA was performed 
on each of the treatments against the mean acetylation value (with the standard deviation).  
In each case tested the p- value generated was 0.001 or lower indicating a difference in 
the results of each of the treatments.  When ANOVA was performed by comparing 
treatment time with acetylation level the p- value generated was p = 0.525, indicating that 





The data presented above demonstrate that lactic acid is able to affect the acetylation 
profile of histone H4.  The established links between histone post-translational 
modification and gene expression lend credence to the hypothesis that histone PTMs 
could potentially account for the increase in expression of genes associated with 
glycolysis
176-178
.  This is of interest when considering the Warburg effect and its links to 
the metabolism of cancerous cells.  Malignant cells are known to generate most of their 
energy through glycolysis, and fail to utilise the citric acid cycle and oxidative 
phosphorylation.  It has been hypothesised that this is a result of malignant cells shutting 
down mitochondria (where the citric acid cycle takes place) through various mechanisms 
including a lack of essential intermediates
179
.  The increase in glycolysis and resulting 
increase in pyruvic acid would lead to an increase in intra-cellular lactic acid 
concentration.  The data presented in this chapter has demonstrated that lactate has an 
inhibitory effect on histone de-acetylase enzymes; this inhibitory effect is not likely due 
to any pH changes associated with increased lactic acid concentration since the data show 
that D-lactate (which would cause a similar change in pH to L-lactate) is a more potent 
inhibitor of histone de-acetylase enzymes than L-lactate.  In the examples presented 
above the inhibitory effect is temporary since the cell line chosen is not known to have 
reduced mitochondrial activity.  As such, mechanisms exist for the metabolism of the 
supplemented L-lactate which resulted in a brief increase in acetylated forms of histone 
H4.  In vivo , where mitochondrial function may be impaired the effect would last longer. 
In contrast, D-lactate is not easily metabolised by the cells which is visible as the longer 
lasting effects of the D-lactate treatment.   
 
This inhibition would manifest as an increase in acetylated forms of histone H4 with the 
associated DNA more accessible to transcription factors.  The steps described above 
suggest a self perpetuating cycle where the altered histone PTM profile increases gene 
expression and cell proliferation.  This hypothesis is in agreement with the data presented 
here which shows that lactic acid can inhibit histone de-acetylase enzymes, leading to a 







4.5 Future work 
 
Future work could expand on this study, beginning with testing the inhibitory effect of L-
lactate on other histone de-acetylase enzymes.  Of the 18 known histone de-acetylases, 
HDAC 1 and HDAC 2 are hydrolase enzymes which do not depend on the presence of 
NAD
+
/NADH to exert their action
137
.  A similar experimental procedure to that described 
above could be performed, substituting other HDAC enzymes and determining if any 
changes to acetylation occur.  This would help determine how broad the inhibitory effect 



























The Post-translational Modification of Histone H4 as a 
Result of Rett Syndrome 
 
This chapter deals with the subject of histone post translational modifications when 
looking at a specific biological condition, in this case Rett syndrome.  An introduction is 
given which contains a detailed description of Rett syndrome and provides a background 
to the work undertaken.  The methods used are described, and the results of the work 




Rett syndrome is a neurological condition affecting ~ 1 in 15,000 births
181
.  The condition 
is more prevalent in females, a consequence of the many mutations known to cause the 
syndrome being located on the X chromosome
182
.  Since females have two X 
chromosomes, a level of redundancy exists in the genetic information carried within each, 
resulting in the majority of sufferers being female in gender
183
.  Mutations occurring in 
the X chromosome in males typically result in early termination of the fetus
184
.  The 
condition was first described by Andreas Rett in 1966
185,186
, a medical doctor who noted 
patterns in the behaviour of several of his patients.  The characteristic behaviours he 
noted included reduced speech and motor abilities, coupled with hand-wringing 
movements, now a well recognized symptom of the condition
187
.  Interestingly, he found 
little correlation between those who suffered from the condition and a genetic family link, 
suggesting that transmission of the condition did not follow classic Mendelian laws.  It is 
now known that most cases of Rett syndrome occur sporadically, making prediction of 
the occurrence of cases extremely difficult
188
.  To date there is no screening method for 
Rett syndrome, so potential sufferers can not be identified early.  Diagnosis is made 




months (typically six to twelve months) before cases are confirmed
189
.  While there is no 
suitable early detection method, there is some level of treatment available to patients with 
Rett syndrome
190
.   
 
In 1999 the cause of Rett syndrome was identified; a mutation localized to a specific gene 
on the X chromosome
184
.  The gene encoded a protein which was found to bind 
methylated DNA
191
.  Methyl DNA binding proteins are divided into four groups; the 
mutation specific to Rett syndrome effecting methyl CpG binding protein-2 (MeCP2)
192
.  
MeCP2 has been ascribed several molecular functions, one of which is a role in 
remodelling chromatin complexes.  However, the mechanisms underlying this function 
are not well understood.  One theory suggests that the specificity of MeCP2 for binding 
methylated DNA allows it to serve as a marker for other chromatin remodelling 
enzymes
193-195
.  Studies on genetically engineered mice have provided important clues to 
the function of MeCP2.  Deletion of the MeCP2 gene has resulted in a Rett-like condition, 
while tissue wide neuronal expression of MeCP2 can resurrect some of the lost 
functions
196,197
.  These studies strengthen the belief that Rett syndrome is a neural 
condition.  However, there is still debate over whether it is a neuro-degenerative or a 
neuro-developmental disorder
198
.  While many who suffer from the illness do not carry 
deletions of the MeCP2 gene, numerous studies have shown that mutations of the gene 
can result in Rett syndrome.   
 
The MeCP2 protein contains three major domains which are responsible for its activity; a 
methyl binding domain, a transcriptional repression domain and a C-terminal 
domain
199,200
.  The functions of the C-terminal region are not well understood, but 
mapping of MeCP2 mutations has shown that the majority occur at or close to either of 
the first domains.  Figure 5.1 below displays the three domains along with the locations 
of the most commonly seen mutations and their frequency. 
 
While MeCP2 is thought to have several functions, it is of interest from an epigenetic 
perspective as it serves as a bridge between the two main avenues of epigenetic control; 
DNA methylation and chromatin structure
201




if alteration of MeCP2 (whether by deletion or mutation) can result in changes to histone 
post-translational modification.  While changes were found, results were often in  
 
 





contradiction to other studies leading to some confusion over how MeCP2 can affect 
histone PTMs
203-206
.  With this as a starting point, the aims of the work described in this 
chapter were as follows:   
 
to identify if MeCP2 deletion can result in changes to the PTM profile of histone H4; 
to characterise any observed changes in histone H4 PTM profile, and to investigate the 









5.2.1 Tissue Sampling and Protein Extraction 
The experiments described in this chapter did not require cell culture as a source of 
histone proteins; instead the protein extraction was carried out on primary animal tissue, 
specifically whole mouse brain.   The differences in procedure for histone extraction from 
cell cultures compared to using a tissue composed of multiple cell types presented several 
challenges which were addressed by modifying the acid extraction technique as described 
below.  The pooled mouse brain samples were supplied by the research group of 
professor Adrian Bird of the Wellcome Trust Centre for Cell Biology (at the University 
of Edinburgh) and were the combined histone extracts of six mouse brains in each sample, 
with mice varying in age from six weeks to eighteen weeks.  The single mouse brains 
used in the latter part of this work were donated by the Bird research group, however the 
histone extraction procedure was performed at the Scottish Instrumentation and Resource 
Centre for Advanced Measurement Science.  All animals were reared and sacrificed at 
the University of Edinburgh  
 
Whole mouse brain was kept frozen until homogenization.  At the start of the procedure 
the brains were allowed to defrost completely at room temperature before 
homogenization in specially prepared buffer (PBS with 0.2 M H2SO4 in H2O, 100 % 
TCA with 50 mM HCl in H2O and added spermidine).  Brains were placed in individual 
test tubes with 3 ml buffer and homogenized on a Potter S homogenizer at 1100 rpm for 7 
strokes.  The homogenate was transferred onto a 1 ml cushion of buffer in an SW-60 
centrifuge tube and was then ultra-centrifuged at 27,600 rpm for 40 minutes at 4 °C.  A 
spatula was used to remove the fatty plug and the lysate was decanted, the tubes were 
then inverted and allowed to drip dry on ice.  The nuclei were resuspended in 1 ml PBS 
with sodium butyrate and centrifuged at 400 g for 5 minutes at 4 °C.  The supernatant 
was removed, the pellet washed in 0.5 ml PBS with sodium butyrate and centrifuged 
again at 400 g for 5 minutes at 4 °C.  The supernatant was again removed and the pellet 




tube.  After incubation with H2SO4, the Eppendorf tubes were centrifuged at 13,000 rpm 
for 30 minutes at 4°C.  The supernatant was transferred to a clean eppendorf and TCA 
was added to 20 % volume (250 μl), this was mixed and incubated on ice for 30 minutes.  
After incubation the Eppendorf tubes were centrifuged at 13,000 rpm for 30 minutes at 
4°C.  The supernatant was discarded and the pellet washed with 1 ml 50 mM HCl in 
acetone for 90 minutes and rotated at 4 °C.  They were then centrifuged at 13,000 rpm for 
20 minutes at 4°C, the supernatant discarded and the pellet washed in pure acetone 
overnight at 4°C.   
 
The following day the Eppendorf tubes were spun at 13,000 rpm for 30 minutes at 4°C, 
the supernatant discarded and pellets allowed to air dry at room temperature.  Pellets 
were then resuspended in 100 μl H2O ready for LC-MS analysis. 
 
5.2.2 Liquid Chromatography and Mass Spectrometry 
LC-MS was performed as described previously under the following conditions.  A Vydac 
C18 column was used for sample separation, operated at 30°C with a flow rate of 50 μl 
min
-1
 using the following gradient.  Solvent A was 98% H2O with 0.03% TFA and 2% 
acetone, and solvent B was 80% acetone and 20% H2O with 0.03% TFA.  10 μl of 
sample was loaded onto the column for each run and separated over a 37 minute linear 
gradient.  The gradient rose to 44% B over 5minutes, from 5 to 22 minutes to 49% B, and 
held at 49% for a further 5 minutes.  At 27 minutes Buffer B was increased to 100% and 
held for 5 minutes, before Buffer A was increased to 100% and held for 5 minutes.  
Histone fractions were collected manually from each run and stored on ice for subsequent 
fragmentation work.   
 
CID and ECD were performed on each fraction collected.  For fragmentation work, 
samples were directly infused into the mass spectrometer using a Tri-Versa Nanomate.  
Precursor ions were isolated and ion accumulation times for CID were 1 second.  The 
collision voltage was set to ~ 18 V and each spectrum was the sum of 500 mass analyses.  
ECD was performed with extended ion accumulation times, typically 20 seconds.  The 




~0.06 seconds.  Similar to the CID experiments, each spectrum was the sum of 500 mass 
analyses whenever possible.  The instrument used for mass analysis was a Bruker 
Daltonics solariX FT-ICR equipped with a 12 Tesla superconducting magnet.  
 
5.2.3 Data Analysis 
Data were acquired in broadband mode with a mass range of 500-3000 m/z, and data was 
analyzed using DataAnalysis software (Bruker Daltonics), before being exported and 
plotted in Microcal Origin (v 6.0).  Fragmentation spectra were analysed by searching 



























5.3.1 Top-Down Mass Spectrometry 
5.3.1.1 Pooled Mouse Brain Samples 
The initial study of the effects of MeCP2 deletion on histone PTM profile were 
conducted on pooled mouse brain samples.  Figure 5.2 below displays the mass spectra 
acquired for the 15
+






Figure 5.2: Mass spectra for the 15
+
 charge state of histone H4 from WT (black) and MeCP2 
knockout (blue) samples.  The mono-isotopic intact masses of the four most abundant peaks are 
given. 
 
The mass spectra display a clear difference in PTM profile between the two samples.  To 










CID and ECD.  The results of the fragmentation of the WT sample are shown in the 
following figures.  Figure 5.3 below shows the mass spectrum for the 15
+
 charge state of 





Figure 5.3:  Mass spectrum for the 15
+ 
charge state of histone H4 from pooled brain samples of wild 
type mice, along with ion species (indicated in blue and green) selected for fragmentation. 
 
CID and ECD fragmentation was performed on both ion species.  The CID fragmentation 






              
               
 
Figure 5.4: CID mass spectrum of ion at 754 m/z from WT pooled mouse brain samples.  A complete 
list of the assigned fragment ions is attached as Appendix A22. 
 
The ECD fragmentation spectrum for this ion at 754 m/z is shown in Figure 5.5 below, 
along with a combined fragment ion map for this species of histone H4 generated from 

























































































































































             
 
              
Figure 5.5: ECD fragmentation spectrum of ion at 754 m/z.   A complete list of the assigned fragment 
ions is attached as Appendix A23. 












































































































































































































































































































































Figure 5.6: Fragment ion map of combined CID and ECD spectra for the ion at 754 m/z.    
 
As can be seen from the CID and ECD spectra, extensive fragmentation was achieved on 
the ion at 754 m/z.  CID and ECD fragmentation both confirmed that this ion 
corresponded to histone H4 carrying an N-terminal acetylation and di-methylation at 
lysine 20.   
 
The most pronounced difference in ion abundances between the WT and MeCP2 
knockout samples was visible for the next ion species investigated, at 756 m/z (green).  
Figure 5.7 below displays the CID spectrum obtained from fragmentation of this ion. 






              
 
Figure 5.7: CID fragmentation spectrum of ion at 756 m/z from pooled WT brain sample.   A 













































































Figure 5.8 below shows the ECD spectrum for this ion at 756 m/z along with a combined 
fragment ion map for this species of histone H4 generated from both the CID and ECD 
data (Figure 5.9). 
              
              
Figure 5.8: ECD spectrum of ion at 756 m/z from pooled WT mouse brain samples.   A complete list 


















































































































































































Figure 5.9: Fragment ion map of combined CID and ECD spectra of the ion at 756 m/z.    
 
The CID and ECD fragmentation data for this ion at 756 m/z confirmed that the observed 
increase in mass from that of the the ion at 754 m/z was due to tri-methylation at lysine 
20.  The level of fragmentation achieved, as displayed in the fragment ion map, provides 
strong evidence that this ion species at 756 m/z was not a heterogeneous mixture of 
modified forms of H4; i.e.  H4 with the addition of a single methyl group at one of the N-
terminal lysines, nor was it acetylated at lysine 20 which could have potentially 
accounted for the observed increase in mass. 
 
Since there was a clear difference in the ion abundance for these ions at 754 m/z and 756 
m/z between the wild type and MeCP2 knockout samples (see Figure 5.2), these ions 
were selected for isolation and fragmentation in the MeCP2 knockout samples.  Figure 
5.10 below shows the mass spectrum for the 15
+
 charge state from the knockout samples 










Figure 5.10: Mass spectrum for the 15
+
 charge state of histone H4 from pooled brain samples of 
MeCP2 knockout mice along with ion species (indicated in blue and green) isolated for fragmentation. 
 
CID and ECD were performed on both ions selected; Figure 5.11 below shows the CID 







            
            
 
Figure 5.11: CID spectrum of ion at 754 m/z from pooled MeCP2 mouse brain samples.  A complete 
list of the assigned fragment ions is attached as Appendix A26. 
 
Figure 5.12 below shows the ECD spectrum acquired for the same ion, along with a 
combined fragment ion map for this species of histone H4 generated from both the CID 









































































           
 
Figure 5.12: ECD spectrum of ion at 754 m/z from pooled MeCP2 knockout mouse brain samples.   A 








































Figure 5.13: Fragment ion map of combined CID and ECD spectra for the ion at 754 m/z 
 
While CID and ECD of the ion at 754 m/z from the MeCP2 knockout mice did not 
provide extensive sequence coverage, enough N-terminal fragments were generated to 
conclude that in the MeCP2 knockout mice, this ion species corresponded to the 
‘unmodified’ form of histone H4, identical to that seen in the wild type mice. 
 
CID and ECD experiments were then performed on the ion at 756 m/z (green) from the 




           
 
            
 
Figure 5.14:  CID spectrum of ion at 756 m/z from pooled MeCP2 knockout mice brain samples.   A 


















































Figure 5.15 below shows the ECD spectrum obtained from the same ion along with a 
combined fragment ion map for this species of histone H4 generated from both the CID 
and ECD data (Figure 5.16). 
            
            
Figure 5.15: ECD spectrum of ion at 756 m/z from pooled MeCP2 knockout mice brain samples.   A 




















































Figure 5.16: Fragment ion map of combined CID and ECD spectra for the ion at 756 m/z.    
 
Similar to the fragmentation experiments on the ion at 754 m/z, little fragmentation was 
achieved.  However, enough N-terminal fragments were generated to conclude that the 
ion at 756 m/z from the MeCP2 knockout mice was the same as that from the wild type 
mice, i.e. that it was N-terminally acetylated histone H4 with a tri-methyl group at lysine 
20. 
 
5.3.1.2 Single Mouse Brain Samples 
The results of the initial fragmentation studies on the pooled brain samples presented 
above suggested that MeCP2 mutation could possibly be linked to an altered PTM profile 
of histone H4, and more specifically correlated to an increase in tri-methylation at lysine 
20.  To investigate this possibility further, and to try and refine the hypothesis that 
MeCP2 mutation could result in altered histone post-translational modification,  histone 
samples were harvested from the brains of single mice and analyzed individually.  The 
symptoms of Rett syndrome are known to become apparent in affected mice weeks after 
birth, so two mice at an age of six weeks (one wild type and one MeCP2 knockout) were 
sacrificed for this investigation.  While a potential obstacle to this study was the reduced 




were confounded by the mixed ages of the mice used in the pooled brain samples was 
considered an acceptable justification for the additional animal sacrifice. 
 
Figure 5.17 below shows the mass spectrum for the 13
+
 charge state of histone H4 from 
the wild type mouse brain sample, along with the ions chosen for isolation and 
fragmentation.  CID and ECD experiments were performed on each ion species. 
 
Figure 5.17:  Mass spectrum for the 13
+
 charge state of histone H4 from wild type whole mouse brain.  
The ion species chosen for subsequent fragmentation (indicated in blue, green, red and yellow) are 
shown in the layers underneath. 
 
The mass spectrum for the 13
+
 charge state of histone H4 from this wild type whole 
mouse brain sample had a similar PTM distribution to that of the pooled wild type mouse 
brain samples (Figure 5.3).  In this case, sufficient amounts of H4 were extracted to allow 
fragmentation of four isolated ion species, and the isolation of each of these ions was 
superior to that achieved from the pooled brain samples.  The CID spectrum of the ion at 




            
 
            
 
Figure 5.18: CID fragmentation spectrum of ion at 870.6 m/z from single wild type mouse brain 































































































































The ECD spectrum for this same ion species at 870.6 m/z is shown in Figure 5.19 below, 
along with a combined fragment ion map for this species of histone H4 generated from 
both the CID and ECD data (Figure 5.20). 










































































































































            
Figure 5.19:  ECD fragmentation spectrum of ion at 870.6 m/z from wild type single mouse brain 

























































































































































































































As can be seen from the combined fragment ion map, near complete sequence coverage 
was achieved after combining the results of the CID and ECD data.  The identity of the 
ion at 870.6 m/z was confirmed as the ‘unmodified’ form of histone H4.   
 
The next ion selected for fragmentation (green) had a mass-to-charge ratio of 871.8, 
which corresponded to an intact mass of 11,313 Da.  The CID spectrum acquired from 
this ion is shown in Figure 5.21 below. 
 
 












































            
 
Figure 5.21:  CID fragmentation spectrum of ion at 871.8 m/z from wild type single mouse brain 
sample.   A complete list of the assigned fragment ions is attached as Appendix A32. 
 
Figure 5.22 below, shows the ECD spectrum acquired from the same ion with a 
combined fragment ion map for this species of histone H4 generated from both the CID 














































            
 
             
Figure 5.22:  ECD fragmentation spectrum of ion at 871.8 m/z from wild type single mouse brain.   A 
























































































































































































































































































Figure 5.23:  Fragment ion map of combined CID and ECD data for the ion at 871.8 m/z.    
 
 
Similar to the fragment ion map shown in Figure 5.20, the combined fragment ion map 
above demonstrates that almost complete sequence coverage was achieved on the 
selected ion.  The precursor ion had a mass increase of 14 Da compared to the 
unmodified form of histone H4.  This mass increase was identified as being due to a tri-
methylation at lysine 20 instead of the di-methylation more typically seen.  Mass 
accuracy of each of the fragment ions was below 10 ppm, confirming that the mass 
increase was not due to acetylation of Lysine 20. 
 
The next ion species selected for fragmentation was at 873.8 m/z (red).  Figure 5.24 




            
            
 
Figure 5.24:  CID fragmentation spectrum of ion at 873.8 m/z from wild type single mouse brain 



















































































































Figure 5.25 below shows the ECD spectrum gathered from the same ion with a combined 
fragment ion map for this species of histone H4 generated from both the CID and ECD 
data (Figure 5.26). 

































































































            
Figure 5.25:  ECD spectrum of ion at 873.8 m/z from wild type single mouse brain.   A complete list of 

















Figure 5.26:  Fragment ion map of combined CID and ECD data for the ion at 873.8 m/z.    
 
 
The fragmentation data for this ion species at 873.8 m/z revealed that the mass increase of 





































































































































































of an acetyl group at lysine 16.  No fragments corresponding to the acetylation of a 
different residue were found.  This is in good agreement with the data presented in 
Chapter 3, in which the order of lysine acetylation in histone H4 was established. 
 
The final ion selected for fragmentation was at 875.0 m/z (yellow).  Figure 5.27 below 

































































            
Figure 5.27:  CID fragmentation spectrum of ion at 875.0 m/z from wild type single mouse brain 
sample.   A complete list of the assigned fragment ions is attached as Appendix A36. 
 
 
Figure 5.28 below shows the ECD spectrum acquired from the same ion along with a 
combined fragment ion map for this species of histone H4 generated from both the CID 



































            
            
Figure 5.28:  ECD spectrum of ion at 875.0 m/z from wild type single mouse brain.   A complete list of 




























































































































































Figure 5.29:  Fragment ion map of combined CID and ECD data for the ion at 875.0 m/z.    
 
While less sequence coverage was achieved in fragmenting this ion, specifically in the N-
terminal region, when the CID and ECD data were combined, the fragment ion map 
revealed that this ion was tri-methylated at lysine 20 and carried an acetyl group at lysine 
16.  Neither the CID or ECD data revealed the presence of ion species which would 
correspond to acetylation of a different lysine residue.  In addition, the mass 
measurement error of all ions shown was below 10 ppm, giving confidence in the results. 
 
The data presented above enabled the identification of four of the most abundant histone 
H4 isoforms from wild type whole mouse brain.  Since the greatest change in PTM 
profile was seen among these modified forms of histone H4, the same series of 
experiments was carried out on whole mouse brain from MeCP2 knockout mice.  A 
single mouse was sacrificed, its brain harvested and the histone extraction procedure was 
performed.  In order to maximize the probability of observing an altered PTM profile, the 
mouse selected for sacrifice was six weeks of age, typically the latest age at which the 
effects of MeCP2 mutation are visible.  Figure 5.30 below shows the mass spectrum for 
the 13
+
 charge state of histone H4 from the MeCP2 knockout mouse along with the ion 





Figure 5.30:  13
+
 charge state of histone H4 from MeCP2 knockout whole mouse brain (black) with 
ions selected for subsequent fragmentation (indicated in blue, green, red and yellow). 
 
Figure 5.31 below shows the spectrum generated from CID fragmentation of the ion at 




            
            
Figure 5.31:  CID spectrum of ion at 870.6 m/z from MeCP2 knockout whole mouse brain.   A 













































































































































Figure 5.32 below shows the spectrum generated after ECD fragmentation of the same 
ion with a combined fragment ion map for this species of histone H4 generated from both 
the CID and ECD data (Figure 5.33). 
            
            
Figure 5.32:  ECD spectrum of ion at 870.6 m/z from MeCP2 knockout whole mouse brain.   A 




























































































































































































































































Figure 5.33:  Fragment ion map of combined CID and ECD data for the ion at 870.6 m/z.    
 
The extensive sequence coverage confirmed that the ion at 870.6 m/z from the MeCP2 
knockout mouse brain was the N-terminally acetylated histone H4, di-methylated at 
Lysine 20.  The next ion selected for fragmentation was at 871.8 m/z (green)  The CID 




            
 
            
Figure 5.34:  CID spectrum of ion at 871.8 m/z from MeCP2 knockout whole mouse brain.   A 












































































































Figure 5.35 below shows the ECD spectrum generated from the same ion with a 
combined fragment ion map for this species of histone H4 generated from both the CID 
and ECD data (Figure 5.36). 
            
            
Figure 5.35:  ECD spectrum of ion at 871.8 m/z from MeCP2 knockout whole mouse brain.   A 























































































































Figure 5.36:  Fragment ion map of combined CID and ECD data for the ion at 871.8 m/z.    
 
 
The fragmentation data for this ion at 871.8 m/z confirmed that this ion species was N-
terminally acetylated histone H4 tri-methylated at lysine 20.  These PTMs were identical 
to those observed in the fragmentation spectra for the ion species at 871.8 m/z from the 
wild type mice sample. 
 
The ion at 873.8 m/z (red) was next chosen for fragmentation.  Figure 5.37 below shows 




            
 
            
Figure 5.37:  CID spectrum of ion at 873.8 m/z from MeCP2 knockout whole mouse brain.   A 













































































































































The ECD spectrum acquired is shown in Figure 5.38 below, along with a combined 
fragment ion map for this species of histone H4 generated from both the CID and ECD 
data (Figure 5.39). 
            
            
Figure 5.38:  ECD fragmentation spectrum of ion at 873.8 m/z from MeCP2 knockout whole mouse 

























































































































































Figure 5.39:  Fragment ion map of combined CID and ECD data for the ion at 873.8 m/z.    
 
 
Examination of the fragmentation data revealed that this ion species corresponded to 
histone H4 with an acetyl group at lysine 16.  The fragmentation data for the ion at 873.8 
m/z from the wild type mouse brain sample confirmed the presence of the same PTMs. 
 
The final ion selected for fragmentation was at 875.0 m/z (yellow).  The CID spectrum 





            
            
Figure 5.40:  CID spectrum of ion at 875.0 m/z from MeCP2 knockout whole mouse brain.   A 



























































































Figure 5.41 below shows the ECD spectrum acquired for the same ion along with a 
combined fragment ion map for this species of histone H4 generated from both the CID 





























Figure 5.41:  ECD spectrum of ion at 875.0 m/z from MeCP2 knockout whole mouse brain.   A 
complete list of the assigned fragment ions is attached as Appendix A45. 







































































Although ECD of this ion was not effective in fragmenting the N-terminal region, enough 
fragments were generated to confirm that this species was N-terminally acetylated 
histone H4 carrying a tri-methyl group at lysine 20 and an additional acetyl group at 
lysine 16, identical to the PTMs identified from the fragmentation data for ion species at 
875.0 m/z from the wild type mouse brain sample. 
 
 
5.3.2 Middle-Down Mass Spectrometry  
 
The data presented above confirmed that the modified histone forms seen in the two 
samples of single mouse brain, wild type and MeCP2 knockout, were identical in their 
post-translational modifications.  However, the relative abundance of these modified 
forms was different between the two samples.   
 
In the spectra for the precursor ions where the fragmentation data had confirmed the 
presence of a di-methyl group at lysine 20 there were no other fragment ions to suggest 
the presence of other modified forms in the sample.  However, the spectra for those 
precursor ions where the fragmentation data had confirmed the presence of a tri-
methylation at lysine 20 (i.e. ions at 871.8 m/z and 875.0 m/z) each revealed fragments 
corresponding to di-methylation at lysine 20.  The degree of mass isolation obtained for 
these precursor ions, shown in Figure 5.17 (WT) and Figure 5.30 (KO), suggested that 
only a single species was isolated.  In an attempt to account for the presence of fragments 
containing di-methylated lysine from the tri-methylated precursor ion, the fragmentation 
spectra were closely examined for the presence of mono-methylated lysine species.  The 
presence of a lysine bearing a single methyl group, in addition to the di-methyl group at 
lysine 20 would account for the mass difference of each ion.  However, in each case no 
fragments exhibiting a mass increase consistent with mono-methylated lysine were found.  
The fragment ion spectra presented above were all examined for the presence of ions 
which serve as markers for specific modified forms of histone H4, however none of the 
previously documented marker ions were found
207-209




In order to exclude the possibility that di-methylated precursor ions were present at low 
abundance within the mass isolation window of the tri-methylated ion species selected for 
fragmentation, the WT single mouse brain sample of histone H4 was analyzed by middle-
down mass spectrometry.  Endoproteinase Asp-N was selected to cleave histone H4 as it 
would provide an intact N-terminal region bearing all modifiable lysine residues.  Figure 









Figure 5.43:  Amino acids 1-30 of histone H4 (after removal of initial methionine).  The cleavage site 
of endoproteinase Asp-N is shown in red with resulting N-terminal fragment.  Lysines known to be 
post-translationally modified are highlighted. 
 
The broadband spectrum of histone H4 after digestion with Asp-N is shown in Figure 
5.44 below. 
Asp-N 





Figure 5.44:  Broadband spectrum of histone H4 after enzymatic digestion with endoproteinase   
Asp-N with 5+ and 6+ charge states of the tri-methylated peptide labelled. 
 
 




 charge states of the tri-methylated N-terminal fragment 
precursor ions were calculated and each was selected for CID and ECD fragmentation.  
Figure 5.45 below shows the mass spectrum for the 5
+
 charge state of this precursor ion 










Figure 5.45:  Mass spectrum for the 5
+
 charge state of tri-methylated N-terminal region of histone H4 
after digestion with Asp-N.  An isotope simulation is overlaid (blue squares).  The ion had an intact 
mass of 2,443 Da. 
 
The simulated isotope pattern and the isolation achieved suggested that the only species 
present was the tri-methylated form of the N-terminal region.  Figure 5.46 below shows 





            
                                                                     
              
Figure 5.46:  CID spectrum of 5
+
 charge state of tri-methylated N-terminal region of histone H4  at 
490 m/z after digestion with Asp-N.   Fragments corresponding to di-methylated species are shown in 
red.  A complete list of the assigned fragment ions is attached as Appendix A46.     
 
 
Figure 5.47 below shows the corresponding ECD spectrum acquired after fragmentation 
of the isolated tri-methylated histone H4 N-terminal precursor ion with a combined 







































































































































































































































Figure 5.47:  ECD spectrum of 5
+
 charge state of tri-methylated N-terminal region of histone H4 at 
490 m/z after digestion with Asp-N.    A combined fragment ion map is given at the bottom of the 
figure.   Fragments corresponding to di-methylated species are shown in red and fragments 
confirming the presence of di- and tri-methylated species in the fragment ion map are shown in black. 
A complete list of the assigned fragment ions is attached as Appendix A47.   
 
 
Fragments corresponding to the di-methylated form of the histone H4 N-terminal region 
were observed in the CID and ECD spectra of the 5
+
 charge state.  To determine if these 
fragments were the result of poor precursor isolation of the 5
+
 charge state, the 6
+
 charge 
state of the tri-methylated N-terminal region of histone H4 was also isolated as the 
precursor ion and subjected to fragmentation by CID and ECD.  Figure 5.48 below shows 
the mass spectrum for the 6
+
 charge state of this precursor ion following mass isolation, 






Figure 5.48:  6
+
 charge state of tri-methylated N-terminal region of histone H4 after digestion with 
Asp-N, with isotope simulation overlaid (blue squares). 
 
 
As was the case for the 5
+
 charge state, the excellent level of mass isolation achieved 
suggested that the only ions proceeding to fragmentation were tri-methylated H4 
precursors.  Figure 5.49 below shows the CID spectrum acquired from the 6
+
 charge state 





            
            
 
Figure 5.49:  CID spectrum of 6
+
 charge state of tri-methylated N-terminal region of histone H4 at 
408 m/z after digestion with Asp-N.  Fragments corresponding to di-methylated species are shown in 
red.   A complete list of the assigned fragment ions is attached as Appendix A48. 
 
Figure 5.50 below shows the spectrum acquired after ECD of the same ion with a 








































































            
 





































































Figure 5.50:  ECD spectrum of 6
+
 charge state of tri-methylated N-terminal region of histone H4 at 
408 m/z after digestion with Asp-N.  A combined fragment ion map is given at the bottom of the 
figure.   Fragments corresponding to di-methylated species are shown in red and fragments 
confirming the presence of di- and tri-methylated species in the fragment ion map are shown in black. 
A complete list of the assigned fragment ions is attached as Appendix A49.   
 
 
Fragmentation of the 6
+
 charge state of the tri-methylated N-terminal fragment revealed 
the presence of di-methylated fragments, with the di-methyl group located at lysine 20.  
Di-methylated fragments were observed in both CID and ECD spectra.   
 
To determine if the source of the di-methylated fragment ions was from a di-methylated 
precursor ion, isolated and fragment alongside the tri-methylated precursor, the 
abundance of the fragment ions was quantitatively compared to the abundance of the 
isolated precursor ions.  This quantitative comparison was based on the fragment ion 
relative ratios (FIRR), a technique in use to analyze the components of heterogeneous 
mixtures and which is particularly suitable for application to histone PTMs
210
.  As an 
example, if a tri-methylated precursor ion was isolated which consisted of a mixture of 
ions carrying a tri-methyl group at a single residue or a di-and mono-methyl group at two 
residues, although having the same intact mass, then the abundance of di- and mono-
methyl product ions should reflect the proportion of these ions present in the isolated 
precursor.  Figure 5.51 below shows the isolation that was achieved when selecting the 
ion at 756 m/z, corresponding to the 15
+
 charge state of histone H4 for fragmentation 





Figure 5.51:  Isolation of ion at 756 m/z corresponding to 15
+
 charge state of histone H4 from MeCP2 
knockout pooled mouse brain sample. 
 
Quantitation was carried out by integration of the area under the signal peaks and 
normalizing by this value to give a percentage abundance of each isoform in the isolation 
window.  In the above spectrum, mono-methylated histone H4 (756.6 m/z) accounted for 
roughly 20 % of the ions detected.  Di-methylated H4 (755.0 m/z and 757.4 m/z) 
accounted for roughly 17 % of the detected signal while tri-methylated H4 (755.7 m/z) 
accounted for over 60 % of the ions detected.  If the di-methylated precursor ions were 
the source of the di-methylated product ions observed in the CID and ECD spectra, their 
relative abundances should be similar to that of the precursor ions; in this case roughly 
4:1 (tri-methylated : di-methylated).  Figure 5.52 below shows an expanded region of the 
CID spectrum corresponding to the precursor isolation of the ion at 756 m/z as shown in 






Figure 5.52:  Expanded view of CID spectrum focusing on b53 product ions observed in MeCP2 
knockout pooled mouse brain sample.  Isotope simulations are overlaid for the tri-methylated 
product ion (red squares) and di-methylated product ion (blue squares). 
 
This region of the spectrum contains two fragment ions, both corresponding to modified 
forms of b53.  The red isotope simulation overlaid is that of a tri-methylated b53 ion while 
the blue simulation is that of the di-methylated ion, and the relative abundance of each is 
roughly 60 % : 40 % (di-methylated : tri-methylated).  This ratio does not match the 
results expected from the ratio of the precursor ions seen in Figure 5.51, suggesting that 
the di-methylated product ions could not all have originated from the di-methylated 
precursor ions. 
 
Further confirmation can be found by examination of Figure 5.48 above which showed 
the degree of mass isolation achieved for the 6
+
 charge state of the ion corresponding in 
mass to the tri-methylated N-terminal region of histone H4 after digestion with 








di-methylated product ion (z15) was present.  Figure 5.53 below shows an expanded view 
of the ECD fragmentation spectrum showing this z15 product ion together with the 






Figure 5.53:  Expanded view of ECD spectrum of 6
+
 charge state of tri-methylated N-terminal region 
of histone H4 from WT pooled mouse brain after digestion with   Asp-N focusing on z15 product ions.  
Isotope simulations are overlaid for tri-methylated product ions (red squares) and di-methylated 
product ions (blue squares). 
 
Although no other ions were detected in the isolation of the tri-methylated precursor, di-
methylated product ions were observed after fragmentation.  In each case where 
fragmentation was performed on a tri-methylated ion, di-methylated product ions were 









This observation can potentially shed some light on the contradicting results of previous 
work which focused on changes to histone H4 PTM profile due to MeCP2 mutation.   
 
5.4 Conclusions 
The results presented in Section 5.3 show that in a mouse model, MeCP2 mutation has an 
effect on the PTM profile of histone H4.  This was demonstrated in pooled and single 
mouse brain samples by top-down and middle-down mass spectrometry.  These changes 
can potentially be explained by the known function of MeCP2 as a protein which binds to 
methylated DNA.  Several DNA binding proteins are known to affect histone PTM 
profile through the recruitment of histone modifying enzymes, thus creating an altered 
PTM profile.  While an increase in the abundance of acetylated histone H4 was observed, 
hyper-acetylation was not seen in any of the samples investigated, suggesting a limit to 
the ability of MeCP2 mutation to result in increased acetylation of histone H4.   
 
In a mouse model, the PTM profile of histone H4 is similar to that observed in cells 
grown in culture (results shown in Chapter 3), and likely follow a similar order to the 
addition of post-translational modifications.  A difference is visible in the PTM profile of 
histone H4 for wild type mice when compared to MeCP2 knockout.  This difference has 
been characterized as an increase in the abundance of tri-methylated histone H4, with the 
tri-methyl group located at lysine 20.  This difference is evident in pooled brain samples 
and in samples generated from a single mouse brain.  Tri-methylation of histone H4, a 
modification known to accumulate in ageing tissues, serves as an indicator of 
transcriptional repression; an observation which is in agreement with earlier hypotheses 




Unlike cells grown in culture, the results presented above suggest that histone H4 
extracted from a primary tissue source exists as a heterogeneous mixture to a much lesser 
extent.  The fragmentation data did not suggest that modified species of H4 exist as a 
mixture with the modifications present at multiple lysine residues.  The interpretation of 




observation that di-methylated fragment ions can be present in the product ion spectra, 
even if they are absent during precursor isolation.  This leads to a hypothesis that the tri-
methylation at lysine 20 could be an inherently unstable modification, such that after the 
input of energy (during the fragmentation event), the loss of a methylene group occurs 
leading to the detection of a di-methylated product ion.  Di-methylated product ions were 
detected after CID and ECD fragmentation of wild type and MeCP2 knockout samples by 
top-down and middle-down mass spectrometry. 
 
5.5 Future Work 
While the results presented have revealed that MeCP2 mutation (in this case deletion) 
have resulted in an increase in tri-methylated histone H4, future work could focus on 
whether or not this effect is present in all neural cell types.  The work above was 
performed on whole brain samples, however neural tissue is known to be composed 
primarily of two cell types; neurons and glia.  In the brain, glia are present at roughly 
twice the number of neurons, so an extension to this work could begin by separation of 
each cell type from the whole brain (of wild type and MeCP2 knockout), followed by 
histone extraction and mass spectrometry.  This work could also confirm the results of a 




In addition, the present study has focused only on MeCP2 deletion (for the reason that 
deletion of the gene would most likely result in more severe symptoms).  As well as 
focusing on the analysis of histone H4 from single cell types, investigation into the 
effects of MeCP2 mutation, i.e. mutations leading to truncated forms of the protein could 
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Assigned fragment ions from CID of HCT-116 cells after treatment with 50 nM TSA 










y94 10613.9 10613.99 -0.0865 -8.15 
y63 7084.84 7084.868 -0.0283 -4 
  7084.84 7084.868 -0.0283 -4 
y49 5526.98 5527.006 -0.0257 -4.64 
  5526.98 5527.006 -0.0257 -4.64 
y42 4773.51 4773.52 -0.0096 -2 
y41 4626.45 4626.451 -0.0012 -0.25 
y40 4513.36 4513.367 -0.0071 -1.57 
y39 4384.31 4384.325 -0.0145 -3.31 
  4384.31 4384.325 -0.0145 -3.31 
y32 3616.89 3616.896 -0.0055 -1.53 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.68 3122.694 -0.0143 -4.57 
  3122.68 3122.694 -0.0143 -4.57 
y27 2985.62 2985.635 -0.0154 -5.14 
y26 2914.59 2914.598 -0.0082 -2.83 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.25 2401.26 -0.0095 -3.97 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.96 1784.971 -0.0105 -5.88 
  1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
  1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 























b100 11335.3 11335.37 -0.0716 -6.32 
b98 11131.2 11131.28 -0.0817 -7.34 
b88 9944.55 9944.588 -0.0383 -3.85 
b87 9781.48 9781.525 -0.0449 -4.59 
  9781.48 9781.525 -0.0449 -4.59 
b86 9682.41 9682.457 -0.0465 -4.81 
  9682.41 9682.457 -0.0465 -4.81 
b85 9583.35 9583.388 -0.0381 -3.98 
  9583.35 9583.388 -0.0381 -3.98 
b84 9468.32 9468.361 -0.0412 -4.35 
  9468.32 9468.361 -0.0412 -4.35 
b83 9337.28 9337.321 -0.0407 -4.36 
b81 9165.2 9165.236 -0.0359 -3.92 
b74 8344.71 8344.733 -0.0228 -2.73 
b71 7951.56 7951.579 -0.0192 -2.41 
b70 7850.5 7850.532 -0.0315 -4.01 
b63 7083.07 7083.103 -0.0325 -4.59 
  7083.07 7083.103 -0.0325 -4.59 
b55 6197.54 6197.57 -0.0301 -4.86 
b53 5940.4 5940.421 -0.0214 -3.6 
  5940.4 5940.421 -0.0214 -3.6 
b52 5811.35 5811.379 -0.0288 -4.95 
  5811.35 5811.379 -0.0288 -4.95 
b51 5682.3 5682.336 -0.0362 -6.37 
b45 5035.95 5035.967 -0.0172 -3.41 
b40 4538.64 4538.66 -0.0198 -4.36 
b39 4382.54 4382.559 -0.0187 -4.26 
b35 3886.22 3886.235 -0.0153 -3.93 
  3886.22 3886.235 -0.0153 -3.93 
b25 2808.56 2808.569 -0.0094 -3.36 
b24 2694.52 2694.527 -0.0065 -2.42 
b19 2055.11 2055.12 -0.0097 -4.72 
b10 1023.54 1023.546 -0.0061 -5.93 
b9 910.46 910.462 -0.002 -2.21 
  910.46 910.462 -0.002 -2.21 
b7 683.333 683.3351 -0.0021 -3 








Assigned fragment ions from ECD of HCT-116 cells after treatment with 50 nM TSA 










z101 11322.4 11322.36 0.0362 3.2 
z97 10882.2 10882.11 0.0858 7.88 
z96 10825.2 10825.09 0.1072 9.91 
z80 9028.07 9028.008 0.0621 6.88 
z79 8871.95 8871.907 0.0432 4.87 
z76 8529.81 8529.753 0.0571 6.7 
  8529.81 8529.753 0.0571 6.7 
z68 7721.32 7721.272 0.0478 6.19 
  7721.32 7721.272 0.0478 6.19 
z67 7565.21 7565.171 0.0389 5.14 
z64 7225 7224.949 0.0512 7.09 
z63 7068.86 7068.848 0.0123 1.74 
z62 6912.77 6912.747 0.0234 3.39 
z59 6699.67 6699.635 0.0347 5.19 
z58 6571.5 6571.54 -0.0403 -6.13 
z57 6415.42 6415.439 -0.0192 -2.99 
z56 6302.33 6302.355 -0.0251 -3.99 
z55 6215.32 6215.323 -0.0031 -0.5 
z54 6158.3 6158.302 -0.0016 -0.26 
z51 5769.05 5769.07 -0.0202 -3.5 
  5769.05 5769.07 -0.0202 -3.5 
z50 5640.05 5640.028 0.0224 3.97 
z49 5511.02 5510.985 0.035 6.35 
z48 5409.97 5409.937 0.0327 6.04 
z47 5253.83 5253.836 -0.0062 -1.18 
  5253.83 5253.836 -0.0062 -1.18 
z43 4856.57 4856.567 0.0027 0.55 
z42 4757.51 4757.499 0.0111 2.33 
z39 4368.33 4368.304 0.0261 5.99 
z32 3600.9 3600.875 0.0251 6.98 
z31 3499.84 3499.827 0.0128 3.66 
z15 1669.88 1669.881 -0.0014 -0.85 
























z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.51 1038.501 0.0091 8.81 
z9 910.45 910.4423 0.0077 8.49 
c100 11352.3 11352.4 -0.0979 -8.63 
c63 7100.18 7100.129 0.0511 7.2 
c60 6710.98 6710.934 0.0462 6.88 
c59 6611.87 6611.865 0.0046 0.7 
c55 6214.63 6214.597 0.0335 5.39 
c52 5828.42 5828.405 0.0149 2.55 
c48 5310.16 5310.131 0.0289 5.45 
c44 4896.9 4896.892 0.0076 1.55 
c41 4612.69 4612.708 -0.0176 -3.81 
c40 4555.67 4555.686 -0.0161 -3.54 
c38 4243.5 4243.484 0.0161 3.79 
c37 4172.46 4172.447 0.0132 3.16 
c36 4059.37 4059.363 0.0073 1.79 
c34 3747.19 3747.161 0.0295 7.87 
c24 2711.57 2711.553 0.0171 6.32 
c22 2440.43 2440.425 0.0052 2.13 
c21 2327.33 2327.341 -0.0107 -4.62 
c18 1916.06 1916.045 0.0151 7.87 
c17 1779 1778.986 0.014 7.86 
c14 1381.73 1381.742 -0.0123 -8.9 
c13 1324.71 1324.721 -0.0108 -8.18 













Assigned fragment ions from CID of HCT-116 cells after treatment with 100 nM TSA 










y63 7084.8 7084.868 -0.0683 -9.65 
y15 1685.89 1685.902 -0.0121 -7.17 
  1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
b99 11020.2 11020.26 -0.061 -5.54 
b88 9776.47 9776.546 -0.0761 -7.79 
b87 9613.41 9613.483 -0.0728 -7.57 
b86 9514.33 9514.414 -0.0844 -8.87 
  9514.33 9514.414 -0.0844 -8.87 
b85 9415.28 9415.346 -0.066 -7.01 
b84 9300.25 9300.319 -0.069 -7.42 
  9300.25 9300.319 -0.069 -7.42 
b83 9169.19 9169.279 -0.0885 -9.66 
b81 8997.11 8997.194 -0.0837 -9.31 
b71 7783.46 7783.537 -0.077 -9.89 
b63 6915.01 6915.06 -0.0504 -7.28 
b55 6029.5 6029.528 -0.028 -4.64 
b53 5772.34 5772.379 -0.0392 -6.79 
  5772.34 5772.379 -0.0392 -6.79 
b52 5643.3 5643.337 -0.0366 -6.49 
  5643.3 5643.337 -0.0366 -6.49 
b51 5514.27 5514.294 -0.024 -4.36 
b40 4370.61 4370.618 -0.0076 -1.74 
b39 4214.49 4214.517 -0.0265 -6.29 
b35 3718.18 3718.193 -0.0131 -3.53 
b19 1887.08 1887.078 0.0025 1.31 
b17 1593.91 1593.918 -0.0075 -4.71 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.55 996.5465 0.0035 3.56 























b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
























Assigned fragment ions from CID of HCT-116 cells after treatment with 500 nM TSA 










y94 10614 10613.99 0.0135 1.27 
y63 7084.86 7084.868 -0.0084 -1.18 
y49 5527 5527.006 -0.0057 -1.02 
  5527 5527.006 -0.0057 -1.02 
y42 4773.52 4773.52 0.0004 0.09 
y39 4384.31 4384.325 -0.0145 -3.31 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.74 3251.737 0.0031 0.97 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.04 1884.039 0.0011 0.58 
y16 1784.97 1784.971 -0.0005 -0.27 
y15 1685.9 1685.902 -0.0021 -1.23 
  1685.9 1685.902 -0.0021 -1.23 
y14 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
b100 11335.4 11335.37 0.0284 2.51 
b99 11188.3 11188.3 -0.0032 -0.29 
b94 10598 10597.99 0.0145 1.36 
b88 9944.58 9944.588 -0.0083 -0.83 
b87 9781.52 9781.525 -0.0049 -0.51 
  9781.52 9781.525 -0.0049 -0.51 
b86 9682.45 9682.457 -0.0065 -0.67 























b85 9583.38 9583.388 -0.0081 -0.85 
  9583.38 9583.388 -0.0081 -0.85 
b84 9468.35 9468.361 -0.0112 -1.18 
  9468.35 9468.361 -0.0112 -1.18 
b83 9337.31 9337.321 -0.0107 -1.14 
b82 9266.29 9266.284 0.0064 0.69 
b81 9165.23 9165.236 -0.0059 -0.64 
b71 7951.59 7951.579 0.0108 1.36 
b70 7850.52 7850.532 -0.0115 -1.46 
b63 7083.09 7083.103 -0.0125 -1.77 
  7083.09 7083.103 -0.0125 -1.77 
b55 6197.56 6197.57 -0.0101 -1.64 
b53 5940.42 5940.421 -0.0014 -0.23 
  5940.42 5940.421 -0.0014 -0.23 
b52 5811.37 5811.379 -0.0088 -1.51 
  5811.37 5811.379 -0.0088 -1.51 
b51 5682.33 5682.336 -0.0062 -1.09 
b45 5035.96 5035.967 -0.0072 -1.43 
b40 4538.65 4538.66 -0.0098 -2.15 
b39 4382.56 4382.559 0.0013 0.3 
b35 3886.23 3886.235 -0.0053 -1.36 
b25 2808.56 2808.569 -0.0094 -3.36 
b24 2694.52 2694.527 -0.0065 -2.42 
b19 2055.12 2055.12 0.0003 0.15 
b9 910.461 910.462 -0.001 -1.11 
  910.461 910.462 -0.001 -1.11 













Assigned fragment ions from CID of OCI-AML cells after treatment with 50 nM TSA 










y37 4171.19 4171.213 -0.0232 -5.55 
y29 3251.71 3251.737 -0.0269 -8.26 
y26 2914.57 2914.598 -0.0282 -9.69 
y19 2130.09 2130.106 -0.0163 -7.67 
y18 1999.05 1999.066 -0.0158 -7.92 
y16 1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
  1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y9 926.454 926.4629 -0.0089 -9.64 
y8 869.435 869.4415 -0.0065 -7.44 
y5 499.206 499.2086 -0.0026 -5.25 
b87 9613.42 9613.483 -0.0628 -6.53 
b86 9514.36 9514.414 -0.0544 -5.71 
b85 9415.27 9415.346 -0.076 -8.07 
b84 9300.29 9300.319 -0.029 -3.12 
b69 7583.37 7583.421 -0.0509 -6.71 
b68 7512.31 7512.384 -0.0738 -9.82 
b63 6915.01 6915.06 -0.0504 -7.28 
b59 6426.75 6426.797 -0.0469 -7.29 
b58 6298.65 6298.702 -0.0519 -8.24 
b53 5772.35 5772.379 -0.0292 -5.06 
b52 5643.3 5643.337 -0.0366 -6.49 
  5643.3 5643.337 -0.0366 -6.49 
b35 3718.17 3718.193 -0.0231 -6.22 
b31 3280.9 3280.918 -0.0181 -5.51 
b25 2640.52 2640.527 -0.0073 -2.76 
b24 2526.47 2526.484 -0.0144 -5.68 
b23 2411.45 2411.457 -0.0074 -3.07 























b19 1887.07 1887.078 -0.0075 -3.99 
b17 1593.91 1593.918 -0.0075 -4.71 
b16 1437.81 1437.816 -0.0064 -4.45 
b15 1309.72 1309.721 -0.0014 -1.1 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.541 996.5465 -0.0055 -5.47 
  996.541 996.5465 -0.0055 -5.47 
b10 939.521 939.525 -0.004 -4.25 
  939.521 939.525 -0.004 -4.25 
b9 826.438 826.4409 -0.0029 -3.55 
b8 769.416 769.4195 -0.0035 -4.51 
  769.416 769.4195 -0.0035 -4.51 
b7 641.323 641.3245 -0.0015 -2.35 
b5 527.28 527.2816 -0.0016 -3.02 


















Assigned fragment ions from ECD of OCI-AML cells after treatment with 50 nM TSA 










z100 11097.2 11097.3 -0.1001 -9.02 
  11097.2 11097.3 -0.1001 -9.02 
z99 10941.1 10941.2 -0.099 -9.05 
z98 10884.1 10884.18 -0.0776 -7.13 
  10884.1 10884.18 -0.0776 -7.13 
z96 10699 10699.06 -0.0612 -5.72 
z95 10642 10642.04 -0.0397 -3.73 
z93 10456.9 10456.92 -0.0233 -2.23 
  10456.9 10456.92 -0.0233 -2.23 
  10456.9 10456.92 -0.0233 -2.23 
z92 10343.8 10343.84 -0.0392 -3.79 
z90 10158.7 10158.72 -0.0228 -2.24 
z88 10044.6 10044.68 -0.0799 -7.95 
  10044.6 10044.68 -0.0799 -7.95 
z87 9973.58 9973.643 -0.0628 -6.29 
  9973.58 9973.643 -0.0628 -6.29 
z86 9845.49 9845.548 -0.0578 -5.87 
z85 9689.38 9689.447 -0.0667 -6.88 
z84 9552.34 9552.388 -0.0478 -5 
z80 9027.95 9028.008 -0.0579 -6.41 
z79 8871.87 8871.907 -0.0368 -4.15 
z78 8756.82 8756.88 -0.0599 -6.83 
z76 8529.7 8529.753 -0.0529 -6.2 
z73 8231.57 8231.589 -0.0188 -2.28 
z72 8130.52 8130.541 -0.0211 -2.59 
z70 7905.45 7905.393 0.0566 7.16 
z68 7721.27 7721.272 -0.0022 -0.28 
  7721.27 7721.272 -0.0022 -0.28 
z67 7565.23 7565.171 0.0589 7.79 
  7565.23 7565.171 0.0589 7.79 
  7565.23 7565.171 0.0589 7.79 
z66 7409.08 7409.07 0.01 1.35 























z64 7224.97 7224.949 0.0212 2.93 
  7224.97 7224.949 0.0212 2.93 
  7224.97 7224.949 0.0212 2.93 
z63 7068.83 7068.848 -0.0177 -2.5 
z62 6912.77 6912.747 0.0234 3.39 
  6912.77 6912.747 0.0234 3.39 
z59 6699.67 6699.635 0.0347 5.19 
  6699.67 6699.635 0.0347 5.19 
z58 6571.59 6571.54 0.0497 7.56 
z57 6415.46 6415.439 0.0208 3.25 
z56 6302.38 6302.355 0.0249 3.95 
z55 6215.33 6215.323 0.0069 1.11 
z54 6158.31 6158.302 0.0084 1.36 
z52 5932.12 5932.134 -0.0135 -2.28 
z51 5769.1 5769.07 0.0298 5.17 
  5769.1 5769.07 0.0298 5.17 
z50 5640 5640.028 -0.0276 -4.89 
z49 5510.95 5510.985 -0.035 -6.35 
z48 5409.91 5409.937 -0.0273 -5.05 
z47 5253.85 5253.836 0.0138 2.62 
  5253.85 5253.836 0.0138 2.62 
z43 4856.57 4856.567 0.0027 0.55 
z42 4757.49 4757.499 -0.0089 -1.87 
z39 4368.28 4368.304 -0.0239 -5.46 
z35 3886 3886.007 -0.0073 -1.89 
  3886 3886.007 -0.0073 -1.89 
z34 3770.99 3770.98 0.0096 2.55 
z32 3600.86 3600.875 -0.0149 -4.13 
z31 3499.82 3499.827 -0.0072 -2.06 
  3499.82 3499.827 -0.0072 -2.06 
z28 3106.66 3106.674 -0.0136 -4.38 
z21 2286.16 2286.171 -0.0105 -4.58 
z18 1983.03 1983.045 -0.0152 -7.66 
z15 1669.88 1669.881 -0.0014 -0.85 
z14 1506.83 1506.818 0.0119 7.9 
z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 
z9 910.439 910.4423 -0.0033 -3.59 
z8 853.419 853.4208 -0.0018 -2.12 













c101 11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
c93 10389.9 10389.95 -0.0483 -4.65 
c91 10105.7 10105.79 -0.0886 -8.77 
  10105.7 10105.79 -0.0886 -8.77 
c81 9014.15 9014.22 -0.0701 -7.78 
c71 7800.5 7800.563 -0.0633 -8.12 
c70 7699.46 7699.516 -0.0557 -7.23 
c63 6932.05 6932.087 -0.0367 -5.29 
  6932.05 6932.087 -0.0367 -5.29 
  6932.05 6932.087 -0.0367 -5.29 
c60 6542.86 6542.892 -0.0316 -4.84 
  6542.86 6542.892 -0.0316 -4.84 
c54 5890.44 5890.453 -0.0132 -2.25 
c53 5789.36 5789.406 -0.0455 -7.87 
c52 5660.35 5660.363 -0.013 -2.29 
  5660.35 5660.363 -0.013 -2.29 
c51 5531.31 5531.32 -0.0104 -1.87 
  5531.31 5531.32 -0.0104 -1.87 
c49 5255.2 5255.173 0.027 5.14 
c48 5142.1 5142.089 0.0111 2.15 
  5142.1 5142.089 0.0111 2.15 
  5142.1 5142.089 0.0111 2.15 
c47 5085.11 5085.068 0.0425 8.37 
c44 4728.88 4728.85 0.0297 6.29 
  4728.88 4728.85 0.0297 6.29 
  4728.88 4728.85 0.0297 6.29 
c43 4600.79 4600.755 0.0347 7.54 
  4600.79 4600.755 0.0347 7.54 
c42 4501.71 4501.687 0.0231 5.13 
c41 4444.67 4444.665 0.0046 1.03 
  4444.67 4444.665 0.0046 1.03 
c40 4387.68 4387.644 0.036 8.21 
c39 4231.57 4231.543 0.0271 6.41 
  4231.57 4231.543 0.0271 6.41 
c38 4075.48 4075.442 0.0383 9.39 













  4075.48 4075.442 0.0383 9.39 
c37 4004.44 4004.405 0.0354 8.83 
  4004.44 4004.405 0.0354 8.83 
c35 3735.25 3735.22 0.0305 8.17 
  3735.25 3735.22 0.0305 8.17 
  3735.25 3735.22 0.0305 8.17 
c34 3579.13 3579.118 0.0116 3.25 
  3579.13 3579.118 0.0116 3.25 
c27 2898.72 2898.696 0.0237 8.19 
c26 2770.66 2770.638 0.0223 8.05 
  2770.66 2770.638 0.0223 8.05 
c21 2159.32 2159.299 0.0214 9.92 
c19 1904.12 1904.104 0.0161 8.47 
  1904.12 1904.104 0.0161 8.47 


















Assigned fragment ions from CID of OCI-AML cells after treatment with 50 nM TSA 










y49 5527 5527.006 -0.0057 -1.02 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.51 4773.52 -0.0096 -2 
y39 4384.32 4384.325 -0.0045 -1.03 
y31 3515.84 3515.848 -0.0079 -2.24 
y30 3352.79 3352.785 0.0055 1.63 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y24 2630.4 2630.402 -0.0022 -0.82 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.459 926.4629 -0.0039 -4.24 
y8 869.438 869.4415 -0.0035 -3.99 
y5 499.207 499.2086 -0.0016 -3.25 
b70 7724.47 7724.5 -0.0299 -3.87 
b69 7625.43 7625.431 -0.0014 -0.19 
  7625.43 7625.431 -0.0014 -0.19 























b53 5814.37 5814.39 -0.0197 -3.4 
b52 5685.33 5685.347 -0.0172 -3.02 
  5685.33 5685.347 -0.0172 -3.02 
b51 5556.29 5556.305 -0.0146 -2.62 
b40 4412.61 4412.628 -0.0182 -4.12 
b39 4256.52 4256.527 -0.0071 -1.66 
b35 3760.19 3760.204 -0.0137 -3.63 
b34 3604.09 3604.103 -0.0126 -3.48 
b31 3322.92 3322.929 -0.0086 -2.59 
b25 2682.53 2682.538 -0.0078 -2.92 
b24 2568.49 2568.495 -0.0049 -1.9 
  2568.49 2568.495 -0.0049 -1.9 
b23 2453.46 2453.468 -0.008 -3.24 
  2453.46 2453.468 -0.008 -3.24 
b19 1929.08 1929.088 -0.0081 -4.18 
b18 1772.98 1772.987 -0.007 -3.93 
b17 1635.92 1635.928 -0.008 -4.92 
b16 1479.82 1479.827 -0.0069 -4.69 
b12 1166.65 1166.652 -0.002 -1.67 
b11 996.546 996.5465 -0.0005 -0.45 
  996.546 996.5465 -0.0005 -0.45 
b10 939.526 939.525 0.001 1.08 
  939.526 939.525 0.001 1.08 
b9 826.446 826.4409 0.0051 6.13 
b8 769.421 769.4195 0.0015 1.99 
  769.421 769.4195 0.0015 1.99 
b7 641.323 641.3245 -0.0015 -2.35 
b5 527.282 527.2816 0.0004 0.78 












Assigned fragment ions from ECD of OCI-AML cells after treatment with 50 nM TSA 










z95 10684 10684.05 -0.0502 -4.7 
z94 10555.9 10555.96 -0.0553 -5.24 
z90 10200.7 10200.73 -0.0333 -3.27 
z87 10015.6 10015.65 -0.0533 -5.32 
z85 9689.42 9689.447 -0.0267 -2.75 
z80 9027.99 9028.008 -0.0179 -1.98 
z79 8871.88 8871.907 -0.0268 -3.02 
z78 8756.85 8756.88 -0.0299 -3.41 
z76 8529.74 8529.753 -0.0129 -1.51 
z67 7565.12 7565.171 -0.0511 -6.75 
z66 7409.03 7409.07 -0.04 -5.39 
z64 7224.91 7224.949 -0.0388 -5.37 
z63 7068.82 7068.848 -0.0277 -3.92 
z62 6912.72 6912.747 -0.0266 -3.85 
z61 6855.69 6855.725 -0.0351 -5.12 
z59 6699.58 6699.635 -0.0553 -8.25 
z58 6571.49 6571.54 -0.0503 -7.65 
z57 6415.4 6415.439 -0.0392 -6.11 
z56 6302.32 6302.355 -0.0351 -5.57 
z55 6215.29 6215.323 -0.0331 -5.32 
z54 6158.27 6158.302 -0.0316 -5.14 
z52 5932.11 5932.134 -0.0235 -3.96 
z51 5769.05 5769.07 -0.0202 -3.5 
z49 5510.97 5510.985 -0.015 -2.72 
z48 5409.93 5409.937 -0.0073 -1.35 
z47 5253.8 5253.836 -0.0362 -6.89 
z43 4856.54 4856.567 -0.0273 -5.63 
z42 4757.48 4757.499 -0.0189 -3.97 
z39 4368.3 4368.304 -0.0039 -0.88 
z32 3600.87 3600.875 -0.0049 -1.36 
  3600.87 3600.875 -0.0049 -1.36 
z31 3499.82 3499.827 -0.0072 -2.06 























z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 
c101 11283.3 11283.39 -0.0878 -7.78 
  11283.3 11283.39 -0.0878 -7.78 
  11283.3 11283.39 -0.0878 -7.78 
c92 10303.9 10303.9 -0.0002 -0.02 
c81 9056.21 9056.231 -0.0206 -2.28 
c71 7842.56 7842.574 -0.0139 -1.77 
c70 7741.51 7741.526 -0.0162 -2.09 
c63 6974.09 6974.097 -0.0072 -1.04 
c59 6485.82 6485.834 -0.0138 -2.12 
c55 6088.55 6088.565 -0.0149 -2.44 
c54 5932.11 5932.07 0.0396 6.68 
c52 5702.36 5702.374 -0.0135 -2.37 
c51 5573.32 5573.331 -0.0109 -1.96 
c48 5184.08 5184.1 -0.0195 -3.75 
  5184.08 5184.1 -0.0195 -3.75 
c44 4770.84 4770.861 -0.0208 -4.36 
  4770.84 4770.861 -0.0208 -4.36 
c43 4642.76 4642.766 -0.0058 -1.26 
c41 4486.66 4486.676 -0.016 -3.56 
c40 4429.64 4429.655 -0.0145 -3.28 
c39 4273.55 4273.553 -0.0034 -0.8 
c37 4046.41 4046.415 -0.0052 -1.28 
c36 3933.31 3933.331 -0.0211 -5.37 
  3933.31 3933.331 -0.0211 -5.37 
c35 3777.22 3777.23 -0.01 -2.65 
c34 3621.12 3621.129 -0.0089 -2.46 
  3621.12 3621.129 -0.0089 -2.46 
c26 2812.64 2812.648 -0.0082 -2.93 
  2812.64 2812.648 -0.0082 -2.93 
c24 2585.5 2585.521 -0.0212 -8.21 
c23 2470.47 2470.494 -0.0243 -9.84 
c22 2314.39 2314.393 -0.0032 -1.38 
c21 2201.3 2201.309 -0.0091 -4.15 
c16 1496.85 1496.853 -0.0033 -2.2 
c15 1326.74 1326.748 -0.0078 -5.87 
c13 1198.68 1198.689 -0.0092 -7.69 







Assigned fragment ions from CID of OCI-AML cells after treatment with 50 nM TSA 










y26 2914.57 2914.598 -0.0282 -9.69 
y16 1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y8 869.434 869.4415 -0.0075 -8.59 
y5 499.206 499.2086 -0.0026 -5.25 
b63 6999.02 6999.081 -0.0614 -8.78 
  6999.02 6999.081 -0.0614 -8.78 
b53 5856.36 5856.4 -0.0403 -6.88 
  5856.36 5856.4 -0.0403 -6.88 
b52 5727.32 5727.358 -0.0377 -6.58 
  5727.32 5727.358 -0.0377 -6.58 
b51 5598.29 5598.315 -0.0251 -4.48 
b40 4454.62 4454.639 -0.0187 -4.2 
b39 4298.51 4298.538 -0.0276 -6.42 
b35 3802.2 3802.214 -0.0142 -3.73 
b25 2724.54 2724.548 -0.0084 -3.07 
b24 2610.5 2610.505 -0.0054 -2.08 
b23 2495.47 2495.479 -0.0085 -3.4 
  2495.47 2495.479 -0.0085 -3.4 
b17 1677.93 1677.939 -0.0086 -5.12 
b12 1166.65 1166.652 -0.002 -1.67 
b11 996.544 996.5465 -0.0025 -2.46 
b10 939.523 939.525 -0.002 -2.12 
b8 769.416 769.4195 -0.0035 -4.51 
  769.416 769.4195 -0.0035 -4.51 
b7 641.323 641.3245 -0.0015 -2.35 








Assigned fragment ions from CID of OCI-AML cells after treatment with 100 nM TSA 










y49 5527 5527.006 -0.0057 -1.02 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.53 4773.52 0.0104 2.18 
y39 4384.32 4384.325 -0.0045 -1.03 
y32 3616.9 3616.896 0.0045 1.23 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y24 2630.41 2630.402 0.0078 2.98 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.458 926.4629 -0.0049 -5.32 
y8 869.437 869.4415 -0.0045 -5.14 
y5 499.206 499.2086 -0.0026 -5.25 
b70 7724.47 7724.5 -0.0299 -3.87 
b69 7625.42 7625.431 -0.0114 -1.5 
  7625.42 7625.431 -0.0114 -1.5 























b53 5814.36 5814.39 -0.0297 -5.11 
b52 5685.32 5685.347 -0.0272 -4.78 
b39 4256.51 4256.527 -0.0171 -4.01 
b35 3760.19 3760.204 -0.0137 -3.63 
b31 3322.92 3322.929 -0.0086 -2.59 
b25 2682.53 2682.538 -0.0078 -2.92 
b24 2568.48 2568.495 -0.0149 -5.8 
  2568.48 2568.495 -0.0149 -5.8 
b23 2453.46 2453.468 -0.008 -3.24 
b19 1929.08 1929.088 -0.0081 -4.18 
b17 1635.92 1635.928 -0.008 -4.92 
b16 1479.82 1479.827 -0.0069 -4.69 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.545 996.5465 -0.0015 -1.46 
  996.545 996.5465 -0.0015 -1.46 
b10 939.524 939.525 -0.001 -1.05 
  939.524 939.525 -0.001 -1.05 
b9 826.44 826.4409 -0.0009 -1.13 
  826.44 826.4409 -0.0009 -1.13 
b8 769.419 769.4195 -0.0005 -0.61 
  769.419 769.4195 -0.0005 -0.61 
b7 641.322 641.3245 -0.0025 -3.91 
b5 527.281 527.2816 -0.0006 -1.12 














Assigned fragment ions from ECD of OCI-AML cells after treatment with 100 nM TSA 










z99 10983.3 10983.21 0.0904 8.23 
z98 10926.2 10926.19 0.0119 1.09 
z95 10684.1 10684.05 0.0498 4.66 
z94 10556 10555.96 0.0447 4.24 
z89 10143.8 10143.71 0.0881 8.69 
z87 10015.7 10015.65 0.0467 4.66 
z85 9689.49 9689.447 0.0433 4.47 
z80 9028.04 9028.008 0.0321 3.56 
z79 8871.95 8871.907 0.0432 4.87 
z78 8756.93 8756.88 0.0501 5.73 
z76 8529.8 8529.753 0.0471 5.53 
z68 7721.32 7721.272 0.0478 6.19 
z66 7409.14 7409.07 0.07 9.45 
z64 7225.01 7224.949 0.0612 8.47 
  7225.01 7224.949 0.0612 8.47 
z62 6912.79 6912.747 0.0434 6.28 
z54 6158.36 6158.302 0.0584 9.48 
z51 5769.11 5769.07 0.0398 6.9 
z49 5511.03 5510.985 0.045 8.17 
z43 4856.61 4856.567 0.0427 8.79 
z42 4757.54 4757.499 0.0411 8.64 
z39 4368.33 4368.304 0.0261 5.99 
z32 3600.9 3600.875 0.0251 6.98 
  3600.9 3600.875 0.0251 6.98 
z31 3499.85 3499.827 0.0228 6.51 
z11 1194.61 1194.602 0.008 6.73 
z10 1038.51 1038.501 0.0091 8.81 
c101 11283.4 11283.39 0.0122 1.08 
  11283.4 11283.39 0.0122 1.08 
  11283.4 11283.39 0.0122 1.08 
  11283.4 11283.39 0.0122 1.08 
c81 9056.28 9056.231 0.0494 5.45 























c70 7741.56 7741.526 0.0338 4.36 
c63 6974.14 6974.097 0.0428 6.13 
c52 5702.42 5702.374 0.0465 8.15 
c38 4117.49 4117.452 0.0377 9.16 
c34 3621.15 3621.129 0.0211 5.83 























Assigned fragment ions from CID of OCI-AML cells after treatment with 100 nM TSA 










y49 5527.02 5527.006 0.0143 2.59 
y42 4773.55 4773.52 0.0304 6.37 
y39 4384.34 4384.325 0.0155 3.53 
y32 3616.92 3616.896 0.0245 6.76 
y30 3352.8 3352.785 0.0155 4.61 
y29 3251.75 3251.737 0.0131 4.04 
y28 3122.7 3122.694 0.0057 1.84 
  3122.7 3122.694 0.0057 1.84 
y27 2985.64 2985.635 0.0046 1.56 
y26 2914.6 2914.598 0.0018 0.6 
y23 2502.32 2502.307 0.0128 5.11 
y22 2401.28 2401.26 0.0205 8.52 
y21 2302.2 2302.191 0.0089 3.86 
y20 2201.15 2201.143 0.0066 2.98 
y19 2130.11 2130.106 0.0037 1.72 
y18 1999.07 1999.066 0.0042 2.08 
y17 1884.04 1884.039 0.0011 0.58 
y16 1784.97 1784.971 -0.0005 -0.27 
y15 1685.9 1685.902 -0.0021 -1.23 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.46 926.4629 -0.0029 -3.16 
b53 5898.39 5898.411 -0.0208 -3.53 
b52 5769.35 5769.368 -0.0182 -3.16 
b39 4340.54 4340.548 -0.0081 -1.87 
b35 3844.21 3844.225 -0.0147 -3.83 
b29 3177.78 3177.807 -0.0271 -8.52 
b24 2652.5 2652.516 -0.016 -6.02 
b23 2537.48 2537.489 -0.009 -3.56 
























b12 1208.66 1208.663 -0.0025 -2.06 
b9 910.462 910.462 0 -0.01 
b8 853.439 853.4406 -0.0016 -1.82 
b5 569.29 569.2921 -0.0021 -3.74 






















Assigned fragment ions from ECD of OCI-AML cells after treatment with 100 nM TSA 










z78 8756.82 8756.88 -0.0599 -6.83 
z76 8529.74 8529.753 -0.0129 -1.51 
z39 4368.28 4368.304 -0.0239 -5.46 
c101 11367.3 11367.41 -0.1089 -9.58 
  11367.3 11367.41 -0.1089 -9.58 
  11367.3 11367.41 -0.1089 -9.58 




















Assigned fragment ions from CID of OCI-AML cells after treatment with 250 nM TSA 










y49 5526.98 5527.006 -0.0257 -4.64 
y39 4384.3 4384.325 -0.0245 -5.59 
y32 3616.88 3616.896 -0.0155 -4.3 
y30 3352.77 3352.785 -0.0145 -4.33 
y28 3122.68 3122.694 -0.0143 -4.57 
  3122.68 3122.694 -0.0143 -4.57 
y27 2985.62 2985.635 -0.0154 -5.14 
y26 2914.58 2914.598 -0.0182 -6.26 
y24 2630.39 2630.402 -0.0122 -4.63 
y22 2401.25 2401.26 -0.0095 -3.97 
y21 2302.18 2302.191 -0.0111 -4.83 
y20 2201.13 2201.143 -0.0134 -6.11 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.05 1999.066 -0.0158 -7.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.63 1210.623 0.0074 6.1 
y9 926.457 926.4629 -0.0059 -6.4 
y8 869.436 869.4415 -0.0055 -6.29 
y5 499.207 499.2086 -0.0016 -3.25 
b63 6957.04 6957.071 -0.0309 -4.44 
  6957.04 6957.071 -0.0309 -4.44 
b53 5814.36 5814.39 -0.0297 -5.11 
  5814.36 5814.39 -0.0297 -5.11 
b52 5685.32 5685.347 -0.0272 -4.78 
b39 4256.51 4256.527 -0.0171 -4.01 
b35 3760.19 3760.204 -0.0137 -3.63 

























b23 2453.46 2453.468 -0.008 -3.24 
b19 1929.08 1929.088 -0.0081 -4.18 
b17 1635.92 1635.928 -0.008 -4.92 
b16 1479.82 1479.827 -0.0069 -4.69 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.545 996.5465 -0.0015 -1.46 
  996.545 996.5465 -0.0015 -1.46 
b10 939.527 939.525 0.002 2.14 
b9 826.439 826.4409 -0.0019 -2.34 
  826.439 826.4409 -0.0019 -2.34 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.323 641.3245 -0.0015 -2.35 

















Assigned fragment ions from CID of OCI-AML cells after treatment with 500 nM TSA 










y49 5526.99 5527.006 -0.0157 -2.83 
y43 4872.58 4872.588 -0.008 -1.64 
y41 4626.46 4626.451 0.0088 1.91 
y39 4384.31 4384.325 -0.0145 -3.31 
y34 3786.99 3787.001 -0.0111 -2.92 
y32 3616.89 3616.896 -0.0055 -1.53 
y31 3515.83 3515.848 -0.0179 -5.08 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.68 3122.694 -0.0143 -4.57 
  3122.68 3122.694 -0.0143 -4.57 
y26 2914.58 2914.598 -0.0182 -6.26 
y24 2630.4 2630.402 -0.0022 -0.82 
y23 2502.3 2502.307 -0.0072 -2.88 
y22 2401.25 2401.26 -0.0095 -3.97 
y21 2302.18 2302.191 -0.0111 -4.83 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
  1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y9 926.458 926.4629 -0.0049 -5.32 
y8 869.437 869.4415 -0.0045 -5.14 
y5 499.205 499.2086 -0.0036 -7.25 
b70 7724.46 7724.5 -0.0399 -5.16 
b53 5814.36 5814.39 -0.0297 -5.11 























b25 2682.53 2682.538 -0.0078 -2.92 
b24 2568.49 2568.495 -0.0049 -1.9 
  2568.49 2568.495 -0.0049 -1.9 
b23 2453.46 2453.468 -0.008 -3.24 
b19 1929.08 1929.088 -0.0081 -4.18 
b17 1635.92 1635.928 -0.008 -4.92 
  1635.92 1635.928 -0.008 -4.92 
b16 1479.82 1479.827 -0.0069 -4.69 
  1479.82 1479.827 -0.0069 -4.69 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.543 996.5465 -0.0035 -3.46 
  996.543 996.5465 -0.0035 -3.46 
b10 939.521 939.525 -0.004 -4.25 
  939.521 939.525 -0.004 -4.25 
b9 826.439 826.4409 -0.0019 -2.34 
  826.439 826.4409 -0.0019 -2.34 
b8 769.417 769.4195 -0.0025 -3.21 
  769.417 769.4195 -0.0025 -3.21 
b7 641.322 641.3245 -0.0025 -3.91 
b5 527.28 527.2816 -0.0016 -3.02 















Assigned fragment ions from ECD of OCI-AML cells after treatment with 500 nM TSA 










z101 11196.4 11196.33 0.0679 6.06 
z95 10684.1 10684.05 0.0498 4.66 
z84 9552.41 9552.388 0.0222 2.33 
z73 8231.56 8231.589 -0.0288 -3.49 
z72 8130.47 8130.541 -0.0711 -8.74 
z64 7224.91 7224.949 -0.0388 -5.37 
  7224.91 7224.949 -0.0388 -5.37 
z63 7068.83 7068.848 -0.0177 -2.5 
  7068.83 7068.848 -0.0177 -2.5 
  7068.83 7068.848 -0.0177 -2.5 
z42 4757.51 4757.499 0.0111 2.33 
  4757.51 4757.499 0.0111 2.33 
z11 1194.61 1194.602 0.008 6.73 
c92 10303.9 10303.9 -0.0002 -0.02 
c91 10147.7 10147.8 -0.0991 -9.77 
  10147.7 10147.8 -0.0991 -9.77 
c67 7456.44 7456.394 0.0463 6.2 
c60 6584.86 6584.902 -0.0422 -6.41 
  6584.86 6584.902 -0.0422 -6.41 
c59 6485.89 6485.834 0.0562 8.67 
c52 5702.36 5702.374 -0.0135 -2.37 
c51 5573.38 5573.331 0.0491 8.81 
c44 4770.84 4770.861 -0.0208 -4.36 
c26 2812.66 2812.648 0.0118 4.18 
c13 1198.7 1198.689 0.0108 8.99 











Assigned fragment ions from CID of OCI-AML cells after treatment with 500 nM TSA 










y41 4626.41 4626.451 -0.0412 -8.9 
y30 3352.77 3352.785 -0.0145 -4.33 
  3352.77 3352.785 -0.0145 -4.33 
y26 2914.57 2914.598 -0.0282 -9.69 
y19 2130.09 2130.106 -0.0163 -7.67 
y18 1999.05 1999.066 -0.0158 -7.92 
y16 1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.79 1451.802 -0.0116 -8.02 
y12 1338.71 1338.718 -0.0076 -5.66 
  1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
y9 926.454 926.4629 -0.0089 -9.64 
y8 869.434 869.4415 -0.0075 -8.59 
y5 499.206 499.2086 -0.0026 -5.25 
b53 5856.35 5856.4 -0.0503 -8.59 
b52 5727.32 5727.358 -0.0377 -6.58 
b51 5598.27 5598.315 -0.0451 -8.06 
b35 3802.18 3802.214 -0.0342 -8.99 
b31 3364.93 3364.939 -0.0092 -2.72 
b27 2965.68 2965.691 -0.011 -3.71 
b25 2724.55 2724.548 0.0016 0.6 
b24 2610.49 2610.505 -0.0154 -5.91 
b23 2495.47 2495.479 -0.0085 -3.4 
  2495.47 2495.479 -0.0085 -3.4 
b19 1971.09 1971.099 -0.0086 -4.37 
b17 1677.93 1677.939 -0.0086 -5.12 
b12 1166.65 1166.652 -0.002 -1.67 
  1166.65 1166.652 -0.002 -1.67 
b11 996.539 996.5465 -0.0075 -7.48 
  996.539 996.5465 -0.0075 -7.48 























b9 826.439 826.4409 -0.0019 -2.34 
b8 769.416 769.4195 -0.0035 -4.51 
  769.416 769.4195 -0.0035 -4.51 
b7 641.323 641.3245 -0.0015 -2.35 
b5 527.28 527.2816 -0.0016 -3.02 























Assigned fragment ions from ECD of OCI-AML cells after treatment with 500 nM TSA 










z101 11238.3 11238.343 -0.0427 -3.8 
  11238.3 11238.343 -0.0427 -3.8 
  11238.3 11238.343 -0.0427 -3.8 
  11238.3 11238.343 -0.0427 -3.8 
z100 11181.3 11181.321 -0.0212 -1.9 
z98 10968.2 10968.199 0.0013 0.12 
z95 10726 10726.061 -0.0608 -5.67 
z90 10200.7 10200.733 -0.0333 -3.27 
z89 10143.7 10143.712 -0.0119 -1.17 
  10143.7 10143.712 -0.0119 -1.17 
z88 10086.7 10086.69 0.0096 0.95 
  10086.7 10086.69 0.0096 0.95 
z87 10015.6 10015.653 -0.0533 -5.32 
z85 9689.41 9689.4467 -0.0367 -3.79 
z83 9396.24 9396.2867 -0.0467 -4.97 
  9396.24 9396.2867 -0.0467 -4.97 
z80 9027.99 9028.0079 -0.0179 -1.98 
z79 8871.86 8871.9068 -0.0468 -5.27 
z78 8756.84 8756.8799 -0.0399 -4.55 
z76 8529.73 8529.7529 -0.0229 -2.68 
z75 8401.67 8401.6943 -0.0243 -2.89 
z72 8130.49 8130.5411 -0.0511 -6.28 
z68 7721.24 7721.2722 -0.0322 -4.17 
  7721.24 7721.2722 -0.0322 -4.17 
  7721.24 7721.2722 -0.0322 -4.17 
z66 7409 7409.07 -0.07 -9.44 
z65 7295.92 7295.9859 -0.0659 -9.03 
z64 7224.89 7224.9488 -0.0588 -8.14 
z63 7068.8 7068.8477 -0.0477 -6.75 
z62 6912.68 6912.7466 -0.0666 -9.63 
  6912.68 6912.7466 -0.0666 -9.63 
z55 6215.27 6215.3231 -0.0531 -8.54 
z52 5932.09 5932.1335 -0.0435 -7.33 























z49 5510.96 5510.985 -0.025 -4.54 
z48 5409.9 5409.9373 -0.0373 -6.9 
  5409.9 5409.9373 -0.0373 -6.9 
z47 5253.79 5253.8362 -0.0462 -8.8 
  5253.79 5253.8362 -0.0462 -8.8 
z43 4856.53 4856.5673 -0.0373 -7.68 
z42 4757.47 4757.4989 -0.0289 -6.08 
z39 4368.29 4368.3039 -0.0139 -3.17 
z35 3886.01 3886.0073 0.0027 0.68 
z34 3770.97 3770.9804 -0.0104 -2.76 
  3770.97 3770.9804 -0.0104 -2.76 
z32 3600.86 3600.8749 -0.0149 -4.13 
  3600.86 3600.8749 -0.0149 -4.13 
z29 3235.71 3235.7162 -0.0062 -1.91 
  3235.71 3235.7162 -0.0062 -1.91 
z21 2286.16 2286.1705 -0.0105 -4.58 
z20 2185.11 2185.1228 -0.0128 -5.85 
z15 1669.88 1669.8814 -0.0014 -0.85 
z14 1506.82 1506.8181 0.0019 1.27 
z10 1038.5 1038.5009 -0.0009 -0.82 
z9 910.443 910.4423 0.0007 0.8 
z8 853.421 853.4208 0.0002 0.22 
c101 11325.3 11325.398 -0.0983 -8.68 
  11325.3 11325.398 -0.0983 -8.68 
  11325.3 11325.398 -0.0983 -8.68 
  11325.3 11325.398 -0.0983 -8.68 
c100 11268.3 11268.377 -0.0769 -6.82 
c99 11121.2 11121.309 -0.1085 -9.75 
c91 10189.8 10189.81 -0.0097 -0.95 
  10189.8 10189.81 -0.0097 -0.95 
c71 7884.58 7884.5844 -0.0044 -0.56 
c70 7783.54 7783.5367 0.0033 0.42 
c67 7498.41 7498.4043 0.0057 0.76 
c63 7016.1 7016.1078 -0.0078 -1.11 
  7016.1 7016.1078 -0.0078 -1.11 
  7016.1 7016.1078 -0.0078 -1.11 
c60 6626.91 6626.9127 -0.0027 -0.41 
  6626.91 6626.9127 -0.0027 -0.41 
c59 6527.84 6527.8443 -0.0043 -0.66 













c55 6130.57 6130.5754 -0.0054 -0.88 
c54 5974.48 5974.4743 0.0057 0.95 
  5974.48 5974.4743 0.0057 0.95 
c53 5873.42 5873.4266 -0.0066 -1.13 
  5873.42 5873.4266 -0.0066 -1.13 
c52 5744.38 5744.384 -0.004 -0.7 
  5744.38 5744.384 -0.004 -0.7 
c51 5615.34 5615.3414 -0.0014 -0.26 
  5615.34 5615.3414 -0.0014 -0.26 
c50 5452.28 5452.2781 0.0019 0.34 
  5452.28 5452.2781 0.0019 0.34 
c48 5226.11 5226.11 0 0 
  5226.11 5226.11 0 0 
c47 5169.08 5169.0885 -0.0085 -1.65 
  5169.08 5169.0885 -0.0085 -1.65 
c46 5082.05 5082.0565 -0.0065 -1.28 
  5082.05 5082.0565 -0.0065 -1.28 
c45 4968.95 4968.9724 -0.0224 -4.52 
c44 4812.86 4812.8713 -0.0113 -2.36 
  4812.86 4812.8713 -0.0113 -2.36 
  4812.86 4812.8713 -0.0113 -2.36 
c43 4684.77 4684.7764 -0.0064 -1.36 
c41 4528.68 4528.6865 -0.0065 -1.44 
c40 4471.66 4471.665 -0.005 -1.13 
c39 4315.56 4315.5639 -0.0039 -0.91 
  4315.56 4315.5639 -0.0039 -0.91 
c38 4159.46 4159.4628 -0.0028 -0.68 
  4159.46 4159.4628 -0.0028 -0.68 
c37 4088.42 4088.4257 -0.0057 -1.4 
c36 3975.33 3975.3417 -0.0117 -2.93 
  3975.33 3975.3417 -0.0117 -2.93 
c35 3819.23 3819.2405 -0.0105 -2.76 
  3819.23 3819.2405 -0.0105 -2.76 
  3819.23 3819.2405 -0.0105 -2.76 
c34 3663.14 3663.1394 0.0006 0.15 
  3663.14 3663.1394 0.0006 0.15 
c32 3479.02 3479.0183 0.0017 0.5 
c30 3253.86 3253.8705 -0.0105 -3.24 
  3253.86 3253.8705 -0.0105 -3.24 













  3253.86 3253.8705 -0.0105 -3.24 
c29 3152.8 3152.8229 -0.0229 -7.25 
  3152.8 3152.8229 -0.0229 -7.25 
c27 2982.72 2982.7173 0.0027 0.89 
c26 2854.65 2854.6588 -0.0088 -3.07 
  2854.65 2854.6588 -0.0088 -3.07 
c24 2627.51 2627.5318 -0.0218 -8.29 
c23 2512.49 2512.5048 -0.0148 -5.91 
  2512.49 2512.5048 -0.0148 -5.91 
c22 2356.4 2356.4037 -0.0037 -1.58 
c21 2243.32 2243.3197 0.0003 0.15 
c19 1988.12 1988.125 -0.005 -2.49 
  1988.12 1988.125 -0.005 -2.49 
c18 1832.02 1832.0238 -0.0038 -2.1 
c17 1694.95 1694.9649 -0.0149 -8.81 
  1694.95 1694.9649 -0.0149 -8.81 
c16 1538.85 1538.8638 -0.0138 -8.99 
  1538.85 1538.8638 -0.0138 -8.99 
c15 1368.75 1368.7583 -0.0083 -6.09 
  1368.75 1368.7583 -0.0083 -6.09 
c14 1297.71 1297.7212 -0.0112 -8.65 
  1297.71 1297.7212 -0.0112 -8.65 
c13 1240.69 1240.6998 -0.0098 -7.87 
  1240.69 1240.6998 -0.0098 -7.87 
c12 1183.67 1183.6783 -0.0083 -7.01 
  1183.67 1183.6783 -0.0083 -7.01 
c8 828.457 828.4564 0.0006 0.77 












Assigned fragment ions from ECD of OCI-AML cells after treatment with 500 nM TSA 










z101 11280.4 11280.35 0.0468 4.15 
  11280.4 11280.35 0.0468 4.15 
  11280.4 11280.35 0.0468 4.15 
z99 11067.3 11067.23 0.0693 6.27 
z98 11010.2 11010.21 -0.0092 -0.83 
z94 10598 10597.97 0.0342 3.23 
  10598 10597.97 0.0342 3.23 
z93 10541 10540.94 0.0556 5.28 
z92 10427.9 10427.86 0.0397 3.81 
z90 10200.7 10200.73 -0.0333 -3.27 
z89 10143.8 10143.71 0.0881 8.69 
z88 10086.7 10086.69 0.0096 0.95 
z87 10015.7 10015.65 0.0467 4.66 
z85 9689.45 9689.447 0.0033 0.34 
  9689.45 9689.447 0.0033 0.34 
z83 9396.3 9396.287 0.0133 1.42 
  9396.3 9396.287 0.0133 1.42 
z80 9028.06 9028.008 0.0521 5.77 
z79 8871.89 8871.907 -0.0168 -1.89 
  8871.89 8871.907 -0.0168 -1.89 
z78 8756.9 8756.88 0.0201 2.3 
z76 8529.77 8529.753 0.0171 2.01 
  8529.77 8529.753 0.0171 2.01 
  8529.77 8529.753 0.0171 2.01 
z68 7721.29 7721.272 0.0178 2.31 
z67 7565.15 7565.171 -0.0211 -2.79 
  7565.15 7565.171 -0.0211 -2.79 
z66 7409 7409.07 -0.07 -9.44 
  7409 7409.07 -0.07 -9.44 
  7409 7409.07 -0.07 -9.44 
z65 7295.99 7295.986 0.0041 0.56 
  7295.99 7295.986 0.0041 0.56 























  7224.92 7224.949 -0.0288 -3.99 
  7224.92 7224.949 -0.0288 -3.99 
z63 7068.82 7068.848 -0.0277 -3.92 
  7068.82 7068.848 -0.0277 -3.92 
  7068.82 7068.848 -0.0277 -3.92 
z62 6912.74 6912.747 -0.0066 -0.95 
z61 6855.67 6855.725 -0.0551 -8.04 
  6855.67 6855.725 -0.0551 -8.04 
z59 6699.59 6699.635 -0.0453 -6.75 
  6699.59 6699.635 -0.0453 -6.75 
z58 6571.48 6571.54 -0.0603 -9.17 
  6571.48 6571.54 -0.0603 -9.17 
z57 6415.38 6415.439 -0.0592 -9.22 
z56 6302.3 6302.355 -0.0551 -8.75 
z55 6215.29 6215.323 -0.0331 -5.32 
z54 6158.27 6158.302 -0.0316 -5.14 
z53 6045.19 6045.218 -0.0276 -4.56 
z52 5932.12 5932.134 -0.0135 -2.28 
z50 5640.03 5640.028 0.0024 0.43 
z49 5511 5510.985 0.015 2.72 
z48 5409.96 5409.937 0.0227 4.19 
z47 5253.81 5253.836 -0.0262 -4.99 
  5253.81 5253.836 -0.0262 -4.99 
z45 5097.71 5097.746 -0.0363 -7.13 
z43 4856.55 4856.567 -0.0173 -3.57 
z42 4757.49 4757.499 -0.0089 -1.87 
z39 4368.32 4368.304 0.0161 3.7 
z35 3886.03 3886.007 0.0227 5.83 
z34 3771 3770.98 0.0196 5.2 
z32 3600.88 3600.875 0.0051 1.42 
  3600.88 3600.875 0.0051 1.42 
z31 3499.84 3499.827 0.0128 3.66 
  3499.84 3499.827 0.0128 3.66 
z28 3106.69 3106.674 0.0164 5.28 
z21 2286.17 2286.171 -0.0005 -0.2 
  2286.17 2286.171 -0.0005 -0.2 
z15 1669.89 1669.881 0.0086 5.14 
z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.51 1038.501 0.0091 8.81 













z9 910.448 910.4423 0.0057 6.29 
z8 853.425 853.4208 0.0042 4.91 
c101 11367.4 11367.41 -0.0089 -0.78 
  11367.4 11367.41 -0.0089 -0.78 
  11367.4 11367.41 -0.0089 -0.78 
  11367.4 11367.41 -0.0089 -0.78 
c93 10516 10515.98 0.0201 1.91 
c81 9140.3 9140.252 0.0483 5.28 
c71 7926.64 7926.595 0.045 5.68 
c70 7825.59 7825.547 0.0427 5.46 
c63 7058.16 7058.118 0.0417 5.91 
c60 6668.94 6668.923 0.0167 2.51 
c59 6569.88 6569.855 0.0252 3.83 
  6569.88 6569.855 0.0252 3.83 
c54 6016.51 6016.485 0.0252 4.18 
c52 5786.42 5786.395 0.0254 4.39 
  5786.42 5786.395 0.0254 4.39 
c51 5657.36 5657.352 0.008 1.42 
  5657.36 5657.352 0.008 1.42 
c50 5494.28 5494.289 -0.0087 -1.58 
c48 5268.12 5268.121 -0.0005 -0.1 
  5268.12 5268.121 -0.0005 -0.1 
c47 5211.07 5211.099 -0.0291 -5.58 
c45 5010.94 5010.983 -0.043 -8.58 
c44 4854.88 4854.882 -0.0019 -0.39 
  4854.88 4854.882 -0.0019 -0.39 
  4854.88 4854.882 -0.0019 -0.39 
c43 4726.78 4726.787 -0.0069 -1.46 
c40 4513.66 4513.676 -0.0156 -3.45 
c39 4357.57 4357.575 -0.0045 -1.03 
  4357.57 4357.575 -0.0045 -1.03 
c38 4201.47 4201.473 -0.0034 -0.8 
  4201.47 4201.473 -0.0034 -0.8 
c37 4130.45 4130.436 0.0137 3.33 
c36 4017.35 4017.352 -0.0022 -0.55 
c35 3861.24 3861.251 -0.0111 -2.87 
  3861.24 3861.251 -0.0111 -2.87 
  3861.24 3861.251 -0.0111 -2.87 
c34 3705.16 3705.15 0.01 2.7 













 3705.16 3705.15 0.01 2.7 
c30 3295.89 3295.881 0.0089 2.7 
c29 3194.84 3194.833 0.0066 2.06 
c27 3024.74 3024.728 0.0121 4 
c26 2896.67 2896.669 0.0007 0.24 
  2896.67 2896.669 0.0007 0.24 
c23 2554.49 2554.515 -0.0254 -9.94 
  2554.49 2554.515 -0.0254 -9.94 
c22 2398.42 2398.414 0.0057 2.39 
c18 1874.05 1874.034 0.0156 8.33 
c16 1580.87 1580.874 -0.0044 -2.76 
c9 885.483 885.4778 0.0052 5.85 



















Assigned fragment ions from CID of OCI-AML cells after treatment with 500 nM TSA 










y43 4872.54 4872.588 -0.048 -9.85 
y41 4626.41 4626.451 -0.0412 -8.9 
y30 3352.76 3352.785 -0.0245 -7.32 
y29 3251.71 3251.737 -0.0269 -8.26 
y28 3122.67 3122.694 -0.0243 -7.77 
  3122.67 3122.694 -0.0243 -7.77 
y27 2985.61 2985.635 -0.0253 -8.49 
y26 2914.57 2914.598 -0.0282 -9.69 
y19 2130.09 2130.106 -0.0163 -7.67 
y18 1999.05 1999.066 -0.0158 -7.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.96 1784.971 -0.0105 -5.88 
  1784.96 1784.971 -0.0105 -5.88 
y15 1685.89 1685.902 -0.0121 -7.17 
  1685.89 1685.902 -0.0121 -7.17 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
  1210.62 1210.623 -0.0026 -2.16 
y9 926.456 926.4629 -0.0069 -7.48 
y8 869.436 869.4415 -0.0055 -6.29 
y5 499.205 499.2086 -0.0036 -7.25 
b87 9781.48 9781.525 -0.0449 -4.59 
b86 9682.41 9682.457 -0.0465 -4.81 
b85 9583.33 9583.388 -0.0581 -6.06 
b70 7850.47 7850.532 -0.0615 -7.83 
  7850.47 7850.532 -0.0615 -7.83 
b69 7751.42 7751.463 -0.0431 -5.56 
  7751.42 7751.463 -0.0431 -5.56 
b68 7680.39 7680.426 -0.036 -4.68 
b63 7083.06 7083.103 -0.0425 -6 























b53 5940.39 5940.421 -0.0314 -5.28 
  5940.39 5940.421 -0.0314 -5.28 
b52 5811.35 5811.379 -0.0288 -4.95 
  5811.35 5811.379 -0.0288 -4.95 
b51 5682.32 5682.336 -0.0162 -2.85 
b39 4382.54 4382.559 -0.0187 -4.26 
b35 3886.22 3886.235 -0.0153 -3.93 
  3886.22 3886.235 -0.0153 -3.93 
b25 2808.56 2808.569 -0.0094 -3.36 
b24 2694.52 2694.527 -0.0065 -2.42 
b23 2579.49 2579.5 -0.0096 -3.71 
  2579.49 2579.5 -0.0096 -3.71 
b22 2423.39 2423.399 -0.0085 -3.49 
b17 1761.95 1761.96 -0.0097 -5.49 
b11 1080.56 1080.568 -0.0075 -6.97 
b10 1023.54 1023.546 -0.0061 -5.93 
b9 910.458 910.462 -0.004 -4.4 
  910.458 910.462 -0.004 -4.4 
b8 853.437 853.4406 -0.0036 -4.16 
  853.437 853.4406 -0.0036 -4.16 
b7 683.333 683.3351 -0.0021 -3 
b6 626.312 626.3136 -0.0016 -2.54 
b5 569.291 569.2921 -0.0011 -1.98 
b4 399.185 399.1866 -0.0016 -4.08 













Assigned fragment ions from ECD of OCI-AML cells after treatment with 500 nM TSA 










z101 11322.3 11322.36 -0.0638 -5.63 
  11322.3 11322.36 -0.0638 -5.63 
  11322.3 11322.36 -0.0638 -5.63 
z99 11109.2 11109.24 -0.0412 -3.71 
z97 10882.1 10882.11 -0.0142 -1.31 
  10882.1 10882.11 -0.0142 -1.31 
z96 10825 10825.09 -0.0928 -8.57 
  10825 10825.09 -0.0928 -8.57 
  10825 10825.09 -0.0928 -8.57 
z94 10597.9 10597.97 -0.0658 -6.21 
z93 10540.9 10540.94 -0.0444 -4.21 
  10540.9 10540.94 -0.0444 -4.21 
  10540.9 10540.94 -0.0444 -4.21 
z88 10086.6 10086.69 -0.0904 -8.96 
z87 10015.6 10015.65 -0.0533 -5.32 
z85 9689.38 9689.447 -0.0667 -6.88 
z84 9552.32 9552.388 -0.0678 -7.1 
  9552.32 9552.388 -0.0678 -7.1 
z83 9396.22 9396.287 -0.0667 -7.1 
  9396.22 9396.287 -0.0667 -7.1 
z81 9141.05 9141.092 -0.042 -4.59 
z80 9027.96 9028.008 -0.0479 -5.31 
z79 8871.85 8871.907 -0.0568 -6.4 
z78 8756.82 8756.88 -0.0599 -6.83 
z76 8529.7 8529.753 -0.0529 -6.2 
  8529.7 8529.753 -0.0529 -6.2 
  8529.7 8529.753 -0.0529 -6.2 
z75 8401.65 8401.694 -0.0443 -5.27 
z72 8130.49 8130.541 -0.0511 -6.28 
  8130.49 8130.541 -0.0511 -6.28 
z68 7721.23 7721.272 -0.0422 -5.46 
  7721.23 7721.272 -0.0422 -5.46 























z66 7409.02 7409.07 -0.05 -6.74 
  7409.02 7409.07 -0.05 -6.74 
z65 7295.94 7295.986 -0.0459 -6.29 
z64 7224.9 7224.949 -0.0488 -6.75 
  7224.9 7224.949 -0.0488 -6.75 
z63 7068.8 7068.848 -0.0477 -6.75 
  7068.8 7068.848 -0.0477 -6.75 
  7068.8 7068.848 -0.0477 -6.75 
z62 6912.69 6912.747 -0.0566 -8.19 
  6912.69 6912.747 -0.0566 -8.19 
z61 6855.67 6855.725 -0.0551 -8.04 
  6855.67 6855.725 -0.0551 -8.04 
z59 6699.59 6699.635 -0.0453 -6.75 
  6699.59 6699.635 -0.0453 -6.75 
z58 6571.49 6571.54 -0.0503 -7.65 
z57 6415.38 6415.439 -0.0592 -9.22 
z55 6215.28 6215.323 -0.0431 -6.93 
z54 6158.25 6158.302 -0.0516 -8.38 
z52 5932.09 5932.134 -0.0435 -7.33 
z51 5769.03 5769.07 -0.0402 -6.96 
z50 5639.99 5640.028 -0.0376 -6.67 
z49 5510.95 5510.985 -0.035 -6.35 
z48 5409.9 5409.937 -0.0373 -6.9 
z47 5253.8 5253.836 -0.0362 -6.89 
  5253.8 5253.836 -0.0362 -6.89 
z45 5097.7 5097.746 -0.0463 -9.09 
z43 4856.53 4856.567 -0.0373 -7.68 
z42 4757.47 4757.499 -0.0289 -6.08 
z39 4368.28 4368.304 -0.0239 -5.46 
z35 3885.99 3886.007 -0.0173 -4.46 
z34 3770.97 3770.98 -0.0104 -2.76 
z32 3600.86 3600.875 -0.0149 -4.13 
  3600.86 3600.875 -0.0149 -4.13 
z31 3499.82 3499.827 -0.0072 -2.06 
z29 3235.71 3235.716 -0.0062 -1.91 
  3235.71 3235.716 -0.0062 -1.91 
z21 2286.16 2286.171 -0.0105 -4.58 
  2286.16 2286.171 -0.0105 -4.58 
z18 1983.04 1983.045 -0.0052 -2.61 













z15 1669.88 1669.881 -0.0014 -0.85 
z14 1506.82 1506.818 0.0019 1.27 
z10 1038.5 1038.501 -0.0009 -0.82 
z9 910.439 910.4423 -0.0033 -3.59 
z8 853.42 853.4208 -0.0008 -0.95 
c93 10557.9 10557.99 -0.0904 -8.57 
c91 10273.8 10273.83 -0.0307 -2.99 
c81 9182.21 9182.262 -0.0522 -5.69 
c71 7968.57 7968.606 -0.0355 -4.46 
c70 7867.5 7867.558 -0.0578 -7.35 
c63 7100.1 7100.129 -0.0289 -4.06 
  7100.1 7100.129 -0.0289 -4.06 
  7100.1 7100.129 -0.0289 -4.06 
c60 6710.91 6710.934 -0.0238 -3.55 
  6710.91 6710.934 -0.0238 -3.55 
c59 6611.85 6611.865 -0.0154 -2.33 
  6611.85 6611.865 -0.0154 -2.33 
c57 6370.68 6370.686 -0.0064 -1 
c55 6214.59 6214.597 -0.0065 -1.05 
  6214.59 6214.597 -0.0065 -1.05 
c53 5957.43 5957.448 -0.0177 -2.97 
  5957.43 5957.448 -0.0177 -2.97 
c52 5828.39 5828.405 -0.0151 -2.59 
  5828.39 5828.405 -0.0151 -2.59 
c51 5699.34 5699.363 -0.0225 -3.95 
c48 5310.12 5310.131 -0.0111 -2.09 
  5310.12 5310.131 -0.0111 -2.09 
c47 5253.11 5253.11 0.0004 0.07 
  5253.11 5253.11 0.0004 0.07 
c46 5166.08 5166.078 0.0024 0.47 
  5166.08 5166.078 0.0024 0.47 
c45 5053 5052.994 0.0065 1.28 
c44 4896.89 4896.892 -0.0024 -0.49 
c43 4768.8 4768.798 0.0025 0.53 
c41 4612.71 4612.708 0.0024 0.52 
c40 4555.69 4555.686 0.0039 0.85 
  4555.69 4555.686 0.0039 0.85 
c39 4399.58 4399.585 -0.005 -1.14 
  4399.58 4399.585 -0.005 -1.14 













c38 4243.48 4243.484 -0.0039 -0.92 
c37 4172.44 4172.447 -0.0068 -1.63 
c36 4059.36 4059.363 -0.0027 -0.67 
c35 3903.26 3903.262 -0.0016 -0.42 
  3903.26 3903.262 -0.0016 -0.42 
c34 3747.15 3747.161 -0.0105 -2.81 
c32 3563.03 3563.039 -0.0093 -2.62 
c30 3337.89 3337.892 -0.0016 -0.49 
c29 3236.84 3236.844 -0.0039 -1.22 
c27 3066.72 3066.738 -0.0184 -6.01 
c26 2938.67 2938.68 -0.0098 -3.35 
  2938.67 2938.68 -0.0098 -3.35 
c25 2825.6 2825.596 0.0042 1.49 
c24 2711.55 2711.553 -0.0029 -1.05 
c23 2596.53 2596.526 0.0041 1.57 
  2596.53 2596.526 0.0041 1.57 
c22 2440.42 2440.425 -0.0048 -1.97 
c21 2327.34 2327.341 -0.0007 -0.32 
c19 2072.15 2072.146 0.004 1.91 
c18 1916.04 1916.045 -0.0049 -2.57 
c17 1778.98 1778.986 -0.006 -3.38 
c16 1622.87 1622.885 -0.0149 -9.19 
c15 1452.77 1452.779 -0.0094 -6.48 
c14 1381.73 1381.742 -0.0123 -8.9 
c13 1324.71 1324.721 -0.0108 -8.18 
c8 870.466 870.4669 -0.0009 -1.03 
c7 700.363 700.3614 0.0016 2.29 
c6 643.343 643.3399 0.0031 4.76 












Assigned fragment ions from CID of wild type pooled mouse brain sample (precursor ion 










y63 7084.85 7084.868 -0.0183 -2.59 
y50 5656.03 5656.048 -0.0183 -3.23 
y49 5526.99 5527.006 -0.0157 -2.83 
  5526.99 5527.006 -0.0157 -2.83 
y42 4773.5 4773.52 -0.0196 -4.1 
y41 4626.43 4626.451 -0.0212 -4.57 
y40 4513.35 4513.367 -0.0171 -3.79 
y39 4384.31 4384.325 -0.0145 -3.31 
y32 3616.88 3616.896 -0.0155 -4.3 
  3616.88 3616.896 -0.0155 -4.3 
y31 3515.83 3515.848 -0.0179 -5.08 
y30 3352.77 3352.785 -0.0145 -4.33 
y28 3122.68 3122.694 -0.0143 -4.57 
  3122.68 3122.694 -0.0143 -4.57 
  3122.68 3122.694 -0.0143 -4.57 
y27 2985.62 2985.635 -0.0154 -5.14 
y26 2914.58 2914.598 -0.0182 -6.26 
y23 2502.3 2502.307 -0.0072 -2.88 
y22 2401.24 2401.26 -0.0195 -8.13 
y21 2302.18 2302.191 -0.0111 -4.83 
y20 2201.13 2201.143 -0.0134 -6.11 
y19 2130.09 2130.106 -0.0163 -7.67 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
  1884.03 1884.039 -0.0089 -4.72 
y16 1784.96 1784.971 -0.0105 -5.88 
  1784.96 1784.971 -0.0105 -5.88 
y15 1685.9 1685.902 -0.0021 -1.23 
  1685.9 1685.902 -0.0021 -1.23 
y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.71 1338.718 -0.0076 -5.66 
y11 1210.62 1210.623 -0.0026 -2.16 
b101 11224.3 11224.35 -0.0509 -4.53 
b99 11020.2 11020.26 -0.061 -5.54 



































11020.2 11020.26 -0.061 -5.54 
b90 9960.62 9960.667 -0.0473 -4.75 
b88 9776.51 9776.546 -0.0361 -3.69 
b87 9613.45 9613.483 -0.0328 -3.41 
  9613.45 9613.483 -0.0328 -3.41 
b86 9514.38 9514.414 -0.0344 -3.61 
  9514.38 9514.414 -0.0344 -3.61 
  9514.38 9514.414 -0.0344 -3.61 
b85 9415.32 9415.346 -0.026 -2.76 
  9415.32 9415.346 -0.026 -2.76 
  9415.32 9415.346 -0.026 -2.76 
b84 9300.29 9300.319 -0.029 -3.12 
  9300.29 9300.319 -0.029 -3.12 
  9300.29 9300.319 -0.029 -3.12 
b82 9098.22 9098.241 -0.0214 -2.35 
b81 8997.16 8997.194 -0.0337 -3.75 
b71 7783.52 7783.537 -0.017 -2.18 
b70 7682.47 7682.489 -0.0193 -2.51 
  7682.47 7682.489 -0.0193 -2.51 
b69 7583.41 7583.421 -0.0109 -1.44 
  7583.41 7583.421 -0.0109 -1.44 
b63 6915.04 6915.06 -0.0204 -2.94 
b60 6525.84 6525.865 -0.0253 -3.88 
  6525.84 6525.865 -0.0253 -3.88 
  6525.84 6525.865 -0.0253 -3.88 
b59 6426.78 6426.797 -0.0169 -2.63 
  6426.78 6426.797 -0.0169 -2.63 
  6426.78 6426.797 -0.0169 -2.63 
b58 6298.69 6298.702 -0.0119 -1.89 
b57 6185.59 6185.618 -0.0279 -4.5 
b55 6029.51 6029.528 -0.018 -2.98 
b53 5772.36 5772.379 -0.0192 -3.33 
  5772.36 5772.379 -0.0192 -3.33 
  5772.36 5772.379 -0.0192 -3.33 
b52 5643.32 5643.337 -0.0166 -2.94 

























b51 5514.28 5514.294 -0.014 -2.54 
  5514.28 5514.294 -0.014 -2.54 
b50 5351.22 5351.231 -0.0107 -2 
  5351.22 5351.231 -0.0107 -2 
 
b40 4370.6 4370.618 -0.0176 -4.03 
b39 4214.5 4214.517 -0.0165 -3.92 
  4214.5 4214.517 -0.0165 -3.92 
b35 3718.18 3718.193 -0.0131 -3.53 
b24 2526.48 2526.484 -0.0044 -1.72 
  2526.48 2526.484 -0.0044 -1.72 
b19 1887.07 1887.078 -0.0075 -3.99 
  1887.07 1887.078 -0.0075 -3.99 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.543 996.5465 -0.0035 -3.46 
b10 939.522 939.525 -0.003 -3.18 
b8 769.417 769.4195 -0.0025 -3.21 






Assigned fragment ions from ECD of wild type pooled mouse brain sample (precursor 









z101 11154.3 11154.32 -0.0216 -1.94 
z95 10642 10642.04 -0.0397 -3.73 
z94 10513.9 10513.94 -0.0447 -4.25 
z93 10456.9 10456.92 -0.0233 -2.23 
  10456.9 10456.92 -0.0233 -2.23 
z90 10158.7 10158.72 -0.0228 -2.24 
z89 10101.7 10101.7 -0.0013 -0.13 
  10101.7 10101.7 -0.0013 -0.13 
z86 9845.54 9845.548 -0.0078 -0.79 
z85 9689.43 9689.447 -0.0167 -1.72 
  9689.43 9689.447 -0.0167 -1.72 
z80 9027.98 9028.008 -0.0279 -3.09 
z79 8871.9 8871.907 -0.0068 -0.77 
z78 8756.87 8756.88 -0.0099 -1.12 
  8756.87 8756.88 -0.0099 -1.12 
  8756.87 8756.88 -0.0099 -1.12 
z76 8529.74 8529.753 -0.0129 -1.51 
  8529.74 8529.753 -0.0129 -1.51 
  8529.74 8529.753 -0.0129 -1.51 
z68 7721.27 7721.272 -0.0022 -0.28 
  7721.27 7721.272 -0.0022 -0.28 
  7721.27 7721.272 -0.0022 -0.28 
z67 7565.16 7565.171 -0.0111 -1.46 
  7565.16 7565.171 -0.0111 -1.46 
z66 7409.07 7409.07 0 0 
  7409.07 7409.07 0 0 
z65 7295.98 7295.986 -0.0059 -0.81 
  7295.98 7295.986 -0.0059 -0.81 
z64 7224.94 7224.949 -0.0088 -1.22 
  7224.94 7224.949 -0.0088 -1.22 
  7224.94 7224.949 -0.0088 -1.22 
z63 7068.84 7068.848 -0.0077 -1.09 
  7068.84 7068.848 -0.0077 -1.09 
  7068.84 7068.848 -0.0077 -1.09 
     













z62 6912.74 6912.747 -0.0066 -0.95 
  6912.74 6912.747 -0.0066 -0.95 
z61 6855.72 6855.725 -0.0051 -0.75 
  6855.72 6855.725 -0.0051 -0.75 
  6855.72 6855.725 -0.0051 -0.75 
z59 6699.63 6699.635 -0.0053 -0.78 
z58 6571.54 6571.54 -0.0003 -0.04 
z57 6415.44 6415.439 0.0008 0.13 
  6415.44 6415.439 0.0008 0.13 
z56 6302.36 6302.355 0.0049 0.77 
  6302.36 6302.355 0.0049 0.77 
z55 6215.33 6215.323 0.0069 1.11 
z54 6158.3 6158.302 -0.0016 -0.26 
z52 5932.13 5932.134 -0.0035 -0.59 
z51 5769.07 5769.07 -0.0002 -0.03 
  5769.07 5769.07 -0.0002 -0.03 
  5769.07 5769.07 -0.0002 -0.03 
z50 5640.03 5640.028 0.0024 0.43 
  5640.03 5640.028 0.0024 0.43 
  5640.03 5640.028 0.0024 0.43 
z49 5510.98 5510.985 -0.005 -0.91 
  5510.98 5510.985 -0.005 -0.91 
z48 5409.94 5409.937 0.0027 0.5 
  5409.94 5409.937 0.0027 0.5 
  5409.94 5409.937 0.0027 0.5 
z47 5253.83 5253.836 -0.0062 -1.18 
z45 5097.75 5097.746 0.0037 0.72 
z43 4856.56 4856.567 -0.0073 -1.51 
  4856.56 4856.567 -0.0073 -1.51 
  4856.56 4856.567 -0.0073 -1.51 
  4856.56 4856.567 -0.0073 -1.51 
z42 4757.5 4757.499 0.0011 0.23 
  4757.5 4757.499 0.0011 0.23 
  4757.5 4757.499 0.0011 0.23 
z39 4368.3 4368.304 -0.0039 -0.88 
  4368.3 4368.304 -0.0039 -0.88 
z38 4254.26 4254.261 -0.0009 -0.22 
z35 3886 3886.007 -0.0073 -1.89 
z34 3770.97 3770.98 -0.0104 -2.76 













  3600.87 3600.875 -0.0049 -1.36 
z31 3499.82 3499.827 -0.0072 -2.06 
z29 3235.71 3235.716 -0.0062 -1.91 
z27 2969.61 2969.615 -0.0047 -1.58 
z24 2614.38 2614.382 -0.0015 -0.58 
z23 2486.28 2486.287 -0.0066 -2.63 
z21 2286.17 2286.171 -0.0005 -0.2 
  2286.17 2286.171 -0.0005 -0.2 
z20 2185.12 2185.123 -0.0028 -1.27 
  2185.12 2185.123 -0.0028 -1.27 
z19 2114.08 2114.086 -0.0057 -2.68 
z18 1983.04 1983.045 -0.0052 -2.61 
z15 1669.88 1669.881 -0.0014 -0.85 
z13 1435.78 1435.781 -0.001 -0.68 
z12 1322.7 1322.697 0.0031 2.33 
z11 1194.6 1194.602 -0.002 -1.64 
  1194.6 1194.602 -0.002 -1.64 
  1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 
  1038.5 1038.501 -0.0009 -0.82 
z9 910.442 910.4423 -0.0003 -0.3 
z8 853.422 853.4208 0.0012 1.39 
c101 11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
c92 10261.9 10261.89 0.0103 1 
c91 10105.8 10105.79 0.0114 1.13 
c88 9793.57 9793.573 -0.0025 -0.25 
c81 9014.21 9014.22 -0.0101 -1.12 
c76 8401.8 8401.813 -0.013 -1.54 
c74 8193.73 8193.717 0.0131 1.59 
c71 7800.55 7800.563 -0.0133 -1.71 
c63 6932.08 6932.087 -0.0067 -0.97 
c60 6542.89 6542.892 -0.0016 -0.25 
  6542.89 6542.892 -0.0016 -0.25 
c59 6443.82 6443.823 -0.0032 -0.5 
c55 6046.55 6046.554 -0.0043 -0.72 













c54 5890.45 5890.453 -0.0032 -0.55 
c53 5789.4 5789.406 -0.0055 -0.96 
c52 5660.36 5660.363 -0.003 -0.52 
  5660.36 5660.363 -0.003 -0.52 
  5660.36 5660.363 -0.003 -0.52 
c51 5531.32 5531.32 -0.0004 -0.07 
  5531.32 5531.32 -0.0004 -0.07 
  5531.32 5531.32 -0.0004 -0.07 
c50 5368.25 5368.257 -0.007 -1.31 
c49 5254.84 5254.79 0.0498 9.48 
c48 5142.09 5142.089 0.0011 0.21 
c47 5085.07 5085.068 0.0025 0.5 
c46 4998.03 4998.035 -0.0054 -1.09 
c45 4884.95 4884.951 -0.0014 -0.28 
c44 4728.85 4728.85 -0.0003 -0.05 
  4728.85 4728.85 -0.0003 -0.05 
  4728.85 4728.85 -0.0003 -0.05 
c43 4600.75 4600.755 -0.0053 -1.15 
c41 4444.66 4444.665 -0.0054 -1.22 
  4444.66 4444.665 -0.0054 -1.22 
c40 4387.64 4387.644 -0.004 -0.9 
  4387.64 4387.644 -0.004 -0.9 
c39 4231.54 4231.543 -0.0029 -0.68 
  4231.54 4231.543 -0.0029 -0.68 
c38 4075.44 4075.442 -0.0017 -0.43 
  4075.44 4075.442 -0.0017 -0.43 
  4075.44 4075.442 -0.0017 -0.43 
c37 4004.4 4004.405 -0.0046 -1.16 
c36 3891.32 3891.321 -0.0006 -0.15 
  3891.32 3891.321 -0.0006 -0.15 
c35 3735.22 3735.22 0.0005 0.14 
  3735.22 3735.22 0.0005 0.14 
c34 3579.12 3579.118 0.0016 0.46 
  3579.12 3579.118 0.0016 0.46 
  3579.12 3579.118 0.0016 0.46 
  3579.12 3579.118 0.0016 0.46 
c32 3394.99 3394.997 -0.0072 -2.12 
c29 3068.8 3068.802 -0.0018 -0.58 
c27 2898.7 2898.696 0.0037 1.29 













  2770.61 2770.638 -0.0277 -9.99 
  2770.61 2770.638 -0.0277 -9.99 
  2770.61 2770.638 -0.0277 -9.99 
c25 2657.55 2657.554 -0.0036 -1.37 
c24 2543.51 2543.511 -0.0007 -0.27 
  2543.51 2543.511 -0.0007 -0.27 
  2543.51 2543.511 -0.0007 -0.27 
c23 2428.49 2428.484 0.0062 2.57 
  2428.49 2428.484 0.0062 2.57 
  2428.49 2428.484 0.0062 2.57 
  2428.49 2428.484 0.0062 2.57 
c22 2272.38 2272.383 -0.0026 -1.17 
  2272.38 2272.383 -0.0026 -1.17 
c21 2159.3 2159.299 0.0014 0.65 
  2159.3 2159.299 0.0014 0.65 
c20 2060.23 2060.23 -0.0002 -0.09 
c19 1904.11 1904.104 0.0061 3.21 
  1904.11 1904.104 0.0061 3.21 
  1904.11 1904.104 0.0061 3.21 
c18 1748 1748.003 -0.0028 -1.58 
  1748 1748.003 -0.0028 -1.58 
  1748 1748.003 -0.0028 -1.58 
c17 1610.95 1610.944 0.0061 3.81 
c16 1454.84 1454.843 -0.0027 -1.89 
  1454.84 1454.843 -0.0027 -1.89 
c15 1326.75 1326.748 0.0022 1.67 
  1326.75 1326.748 0.0022 1.67 
  1326.75 1326.748 0.0022 1.67 
c14 1255.71 1255.711 -0.0007 -0.54 
  1255.71 1255.711 -0.0007 -0.54 
  1255.71 1255.711 -0.0007 -0.54 
c13 1198.69 1198.689 0.0008 0.65 
  1198.69 1198.689 0.0008 0.65 
  1198.69 1198.689 0.0008 0.65 
c12 1141.67 1141.668 0.0022 1.96 
  1141.67 1141.668 0.0022 1.96 
c11 1013.57 1013.573 -0.0028 -2.76 
  1013.57 1013.573 -0.0028 -2.76 
c9 843.469 843.4673 0.0017 2.04 













c8 786.448 786.4458 0.0022 2.77 
  786.448 786.4458 0.0022 2.77 
c7 658.351 658.3509 0.0001 0.21 
c6 601.33 601.3294 0.0006 1 
c5 544.309 544.3079 0.0011 1.95 























Assigned fragment ions from CID of wild type pooled mouse brain sample (precursor ion 










y68 7737.31 7737.293 0.0167 2.15 
y39 4384.362 4384.325 0.0373 8.5 
  4384.362 4384.325 0.0373 8.5 
y14 1522.832 1522.839 -0.0071 -4.68 
  1522.832 1522.839 -0.0071 -4.68 
y13 1451.799 1451.802 -0.0028 -1.9 
y12 1338.717 1338.718 -0.0005 -0.37 
y11 1210.624 1210.623 0.0017 1.44 
y5 499.2051 499.2086 -0.0035 -6.97 
b101 11238.27 11238.37 -0.0978 -8.71 
  11238.27 11238.37 -0.0978 -8.71 
b86 9528.36 9528.43 -0.07 -7.35 
  9528.36 9528.43 -0.07 -7.35 
  9528.36 9528.43 -0.07 -7.35 
b85 9429.283 9429.362 -0.0785 -8.32 
b83 9183.228 9183.294 -0.0659 -7.18 
  9183.228 9183.294 -0.0659 -7.18 
b60 6539.876 6539.881 -0.0051 -0.78 
b59 6440.785 6440.813 -0.0275 -4.27 
  6440.785 6440.813 -0.0275 -4.27 
b58 6312.717 6312.718 -0.0002 -0.04 
b55 6043.551 6043.544 0.0077 1.28 
b53 5786.374 5786.395 -0.0213 -3.67 
  5786.374 5786.395 -0.0213 -3.67 
  5786.374 5786.395 -0.0213 -3.67 
b52 5657.346 5657.352 -0.0062 -1.09 
  5657.346 5657.352 -0.0062 -1.09 
  5657.346 5657.352 -0.0062 -1.09 
b51 5528.314 5528.31 0.0045 0.81 
b50 5365.231 5365.246 -0.015 -2.79 
  5365.231 5365.246 -0.015 -2.79 
b39 4228.532 4228.532 -0.0002 -0.04 
  4228.532 4228.532 -0.0002 -0.04 
b25 2654.544 2654.543 0.001 0.37 


















     
b24 2540.496 2540.5 -0.0039 -1.55 
b19 1887.078 1887.078 0.0001 0.07 
  1887.078 1887.078 0.0001 0.07 
b17 1593.917 1593.918 -0.0002 -0.14 
b12 1124.645 1124.641 0.0035 3.09 
b11 996.5444 996.5465 -0.0021 -2.11 
b10 939.5188 939.525 -0.0062 -6.59 
b7 641.3262 641.3245 0.0017 2.65 





















Assigned fragment ions from ECD of wild type pooled mouse brain sample (precursor 










z95 10656.06 10656.06 0.0082 0.77 
z91 10300.8 10300.83 -0.0321 -3.12 
z76 8529.78 8529.753 0.0271 3.17 
z68 7721.272 7721.272 -0.0003 -0.04 
  7721.272 7721.272 -0.0003 -0.04 
z65 7295.984 7295.986 -0.0024 -0.33 
z64 7224.94 7224.949 -0.0091 -1.26 
z63 7068.846 7068.848 -0.002 -0.28 
z61 6855.721 6855.725 -0.0044 -0.64 
z57 6415.436 6415.439 -0.0027 -0.43 
z54 6158.299 6158.302 -0.0024 -0.4 
z51 5769.068 5769.07 -0.0021 -0.37 
z50 5640.027 5640.028 -0.0003 -0.06 
z49 5510.982 5510.985 -0.003 -0.54 
z48 5409.932 5409.937 -0.0057 -1.06 
z47 5253.835 5253.836 -0.0017 -0.32 
  5253.835 5253.836 -0.0017 -0.32 
z42 4757.496 4757.499 -0.003 -0.63 
  4757.496 4757.499 -0.003 -0.63 
z39 4368.303 4368.304 -0.0008 -0.19 
z34 3770.974 3770.98 -0.0064 -1.7 
  3770.974 3770.98 -0.0064 -1.7 
z32 3600.869 3600.875 -0.0058 -1.61 
z31 3499.823 3499.827 -0.0041 -1.17 
z28 3106.673 3106.674 -0.0008 -0.25 
z20 2185.118 2185.123 -0.0048 -2.21 
  2185.118 2185.123 -0.0048 -2.21 
z18 1983.043 1983.045 -0.0021 -1.03 
z15 1669.881 1669.881 -0.0003 -0.19 
z14 1506.822 1506.818 0.0041 2.73 
z12 1322.698 1322.697 0.0008 0.6 
z11 1194.599 1194.602 -0.0029 -2.4 



















     
z9 910.443 910.4423 0.0007 0.78 
c101 11255.32 11255.39 -0.0726 -6.45 
  11255.32 11255.39 -0.0726 -6.45 
  11255.32 11255.39 -0.0726 -6.45 
  11255.32 11255.39 -0.0726 -6.45 
c100 11198.33 11198.37 -0.0412 -3.68 
  11198.33 11198.37 -0.0412 -3.68 
c93 10403.94 10403.96 -0.0192 -1.85 
c91 10119.8 10119.8 -0.0078 -0.77 
c81 9028.228 9028.236 -0.0082 -0.91 
c71 7814.575 7814.579 -0.0043 -0.55 
c67 7428.395 7428.399 -0.0035 -0.47 
c63 6946.105 6946.102 0.0022 0.32 
c60 6556.903 6556.907 -0.0045 -0.69 
c59 6457.84 6457.839 0.0006 0.09 
  6457.84 6457.839 0.0006 0.09 
c55 6060.574 6060.57 0.0036 0.6 
c52 5674.382 5674.379 0.0035 0.61 
  5674.382 5674.379 0.0035 0.61 
c51 5545.343 5545.336 0.0068 1.23 
c40 4401.667 4401.66 0.0069 1.56 
c39 4245.554 4245.559 -0.005 -1.17 
  4245.554 4245.559 -0.005 -1.17 
c38 4089.46 4089.457 0.003 0.72 
  4089.46 4089.457 0.003 0.72 
c37 4018.423 4018.42 0.0022 0.56 
c36 3905.344 3905.336 0.0077 1.96 
c34 3593.138 3593.134 0.0037 1.02 
  3593.138 3593.134 0.0037 1.02 
c26 2784.656 2784.653 0.0028 1 
  2784.656 2784.653 0.0028 1 
c24 2557.529 2557.526 0.0026 1.01 
c23 2442.508 2442.499 0.0085 3.47 
  2442.508 2442.499 0.0085 3.47 
c21 2173.318 2173.314 0.0041 1.91 
  2173.318 2173.314 0.0041 1.91 
c19 1904.108 1904.104 0.0044 2.32 




















c18 1748.006 1748.003 0.0033 1.87 
  1748.006 1748.003 0.0033 1.87 
  1748.006 1748.003 0.0033 1.87 
c17 1610.95 1610.944 0.0064 3.95 
c16 1454.846 1454.843 0.0028 1.95 
  1454.846 1454.843 0.0028 1.95 
c15 1326.751 1326.748 0.003 2.24 
  1326.751 1326.748 0.003 2.24 
  1326.751 1326.748 0.003 2.24 
c14 1255.714 1255.711 0.0037 2.95 
  1255.714 1255.711 0.0037 2.95 
  1255.714 1255.711 0.0037 2.95 
c13 1198.693 1198.689 0.0035 2.89 
  1198.693 1198.689 0.0035 2.89 
  1198.693 1198.689 0.0035 2.89 
c12 1141.67 1141.668 0.0022 1.88 
  1141.67 1141.668 0.0022 1.88 
c11 1013.575 1013.573 0.0022 2.15 
  1013.575 1013.573 0.0022 2.15 
c10 956.5557 956.5514 0.0044 4.55 
  956.5557 956.5514 0.0044 4.55 
c9 843.4705 843.4673 0.0032 3.76 
  843.4705 843.4673 0.0032 3.76 
c8 786.4505 786.4458 0.0046 5.89 
  786.4505 786.4458 0.0046 5.89 
c7 658.3517 658.3509 0.0008 1.28 
c6 601.3309 601.3294 0.0015 2.5 
c5 544.3102 544.308 0.0022 4.01 












Assigned fragment ions from CID of MeCP2 Knockout pooled mouse brain sample 










y14 1522.83 1522.839 -0.0087 -5.75 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.72 1338.718 0.0024 1.81 
y11 1210.62 1210.623 -0.0026 -2.16 
b101 11224.3 11224.35 -0.0509 -4.53 
b87 9613.39 9613.483 -0.0928 -9.65 
  9613.39 9613.483 -0.0928 -9.65 
b86 9514.33 9514.414 -0.0844 -8.87 
  9514.33 9514.414 -0.0844 -8.87 
  9514.33 9514.414 -0.0844 -8.87 
b85 9415.27 9415.346 -0.076 -8.07 
  9415.27 9415.346 -0.076 -8.07 
  9415.27 9415.346 -0.076 -8.07 
b84 9300.27 9300.319 -0.049 -5.27 
  9300.27 9300.319 -0.049 -5.27 
  9300.27 9300.319 -0.049 -5.27 
b82 9098.19 9098.241 -0.0514 -5.65 
b59 6426.8 6426.797 0.0031 0.49 
b55 6029.54 6029.528 0.012 1.99 
b53 5772.35 5772.379 -0.0292 -5.06 
  5772.35 5772.379 -0.0292 -5.06 
b52 5643.31 5643.337 -0.0266 -4.72 
  5643.31 5643.337 -0.0266 -4.72 
b51 5514.26 5514.294 -0.034 -6.17 
b50 5351.22 5351.231 -0.0107 -2 
  5351.22 5351.231 -0.0107 -2 
b45 4867.93 4867.925 0.005 1.02 
b40 4370.63 4370.618 0.0124 2.83 
b39 4214.52 4214.517 0.0035 0.83 
  4214.52 4214.517 0.0035 0.83 
















































Assigned fragment ions from ECD of MeCP2 Knockout pooled mouse brain sample 










z47 5253.88 5253.836 0.0438 8.33 
c34 3579.09 3579.118 -0.0284 -7.92 
c26 2770.61 2770.638 -0.0277 -9.99 
c24 2543.49 2543.511 -0.0207 -8.14 
c23 2428.46 2428.484 -0.0238 -9.78 
c17 1610.93 1610.944 -0.0139 -8.6 
c15 1326.74 1326.748 -0.0078 -5.87 
c13 1198.68 1198.689 -0.0092 -7.69 



















Assigned fragment ions from CID of MeCP2 Knockout pooled mouse brain sample 










y49 5527.004 5527.006 -0.0018 -0.33 
y47 5269.952 5269.857 0.0948 18 
y19 2130.103 2130.106 -0.0038 -1.79 
y18 1999.077 1999.066 0.0114 5.71 
  1999.077 1999.066 0.0114 5.71 
y17 1884.037 1884.039 -0.0016 -0.86 
  1884.037 1884.039 -0.0016 -0.86 
y16 1784.969 1784.971 -0.0013 -0.71 
  1784.969 1784.971 -0.0013 -0.71 
y15 1685.91 1685.902 0.0081 4.82 
  1685.91 1685.902 0.0081 4.82 
y14 1522.839 1522.839 0.0003 0.16 
y13 1451.803 1451.802 0.0011 0.77 
y12 1338.716 1338.718 -0.0019 -1.45 
y11 1210.621 1210.623 -0.0021 -1.74 
b99 11020.25 11020.26 -0.0061 -0.55 
b70 7682.507 7682.489 0.0176 2.29 
b69 7583.423 7583.421 0.0016 0.21 
b59 6426.797 6426.797 -0.0003 -0.05 
b58 6298.707 6298.702 0.0055 0.88 
b53 5772.38 5772.379 0.0011 0.19 
  5772.38 5772.379 0.0011 0.19 
b52 5643.339 5643.337 0.0019 0.34 
  5643.339 5643.337 0.0019 0.34 
b50 5351.236 5351.231 0.0055 1.03 
b40 4370.615 4370.618 -0.0026 -0.59 
b39 4214.518 4214.517 0.0011 0.26 
  4214.518 4214.517 0.0011 0.26 
b24 2526.483 2526.484 -0.0013 -0.52 
b19 1887.078 1887.078 0.0005 0.24 
b12 1124.642 1124.641 0.0007 0.61 
b10 939.5247 939.525 -0.0003 -0.31 








Assigned fragment ions from ECD of MeCP2 Knockout pooled mouse brain sample 










z18 1983.043 1983.045 -0.0021 -1.03 
z15 1669.881 1669.881 0 -0.01 
z12 1322.697 1322.697 -0.0001 -0.08 
z11 1194.602 1194.602 -0.0004 -0.29 
z10 1038.502 1038.501 0.0007 0.63 
c38 4089.457 4089.457 -0.0005 -0.12 
c24 2557.524 2557.526 -0.0023 -0.9 
c23 2442.501 2442.499 0.0012 0.48 
c18 1748.002 1748.003 -0.0007 -0.39 
  1748.002 1748.003 -0.0007 -0.39 
c16 1454.842 1454.843 -0.0007 -0.51 
c15 1326.748 1326.748 -0.0001 -0.08 
c14 1255.711 1255.711 -0.0001 -0.06 
c13 1198.69 1198.689 0.0005 0.42 
c12 1141.669 1141.668 0.0012 1.05 
c10 956.5524 956.5514 0.001 1.06 
c9 843.4686 843.4673 0.0013 1.51 














Assigned fragment ions from CID of Wild Type single mouse brain sample (precursor 










y51 5785.05 5785.091 -0.0408 -7.06 
y50 5656.05 5656.048 0.0018 0.31 
y49 5527.01 5527.006 0.0043 0.79 
y47 5269.85 5269.857 -0.0069 -1.3 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.51 4773.52 -0.0096 -2 
y41 4626.45 4626.451 -0.0012 -0.25 
y39 4384.32 4384.325 -0.0045 -1.03 
y35 3902.01 3902.028 -0.018 -4.61 
y34 3786.99 3787.001 -0.0111 -2.92 
y32 3616.9 3616.896 0.0045 1.23 
y31 3515.84 3515.848 -0.0079 -2.24 
y30 3352.77 3352.785 -0.0145 -4.33 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y25 2786.5 2786.503 -0.0033 -1.18 
y24 2630.39 2630.402 -0.0122 -4.63 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.97 1784.971 -0.0005 -0.27 
  1784.97 1784.971 -0.0005 -0.27 
y15 1685.9 1685.902 -0.0021 -1.23 
  1685.9 1685.902 -0.0021 -1.23 
  1685.9 1685.902 -0.0021 -1.23 























 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.72 1338.718 0.0024 1.81 
y11 1210.63 1210.623 0.0074 6.1 
  1210.63 1210.623 0.0074 6.1 
  1210.63 1210.623 0.0074 6.1 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.46 926.4629 -0.0029 -3.16 
y8 869.439 869.4415 -0.0025 -2.84 
y5 499.207 499.2086 -0.0016 -3.25 
b69 7583.42 7583.421 -0.0009 -0.12 
  7583.42 7583.421 -0.0009 -0.12 
b68 7512.38 7512.384 -0.0038 -0.51 
  7512.38 7512.384 -0.0038 -0.51 
b63 6915.04 6915.06 -0.0204 -2.94 
b59 6426.79 6426.797 -0.0069 -1.07 
b58 6298.7 6298.702 -0.0019 -0.3 
  6298.7 6298.702 -0.0019 -0.3 
b53 5772.37 5772.379 -0.0092 -1.59 
  5772.37 5772.379 -0.0092 -1.59 
b52 5643.33 5643.337 -0.0066 -1.17 
b35 3718.19 3718.193 -0.0031 -0.84 
  3718.19 3718.193 -0.0031 -0.84 
b31 3280.92 3280.918 0.0019 0.59 
b25 2640.53 2640.527 0.0027 1.03 
b23 2411.46 2411.457 0.0026 1.07 
  2411.46 2411.457 0.0026 1.07 
b19 1887.08 1887.078 0.0025 1.31 
b17 1593.92 1593.918 0.0025 1.56 
  1593.92 1593.918 0.0025 1.56 
b16 1437.81 1437.816 -0.0064 -4.45 
  1437.81 1437.816 -0.0064 -4.45 
b13 1181.66 1181.663 -0.0029 -2.43 
b12 1124.64 1124.641 -0.0014 -1.25 
  1124.64 1124.641 -0.0014 -1.25 
b11 996.546 996.5465 -0.0005 -0.45 
  996.546 996.5465 -0.0005 -0.45 
b10 939.524 939.525 -0.001 -1.05 
  939.524 939.525 -0.001 -1.05 













b9 826.441 826.4409 0.0001 0.08 
  826.441 826.4409 0.0001 0.08 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.325 641.3245 0.0005 0.76 
b5 527.282 527.2816 0.0004 0.78 
b4 399.187 399.1866 0.0004 0.93 






















Assigned fragment ions from ECD of wild type single mouse brain sample (precursor ion 










z101 11154.3 11154.32 -0.0216 -1.94 
  11154.3 11154.32 -0.0216 -1.94 
  11154.3 11154.32 -0.0216 -1.94 
z100 11097.3 11097.3 -0.0001 -0.01 
  11097.3 11097.3 -0.0001 -0.01 
z95 10642 10642.04 -0.0397 -3.73 
  10642 10642.04 -0.0397 -3.73 
z94 10513.9 10513.94 -0.0447 -4.25 
  10513.9 10513.94 -0.0447 -4.25 
z93 10456.9 10456.92 -0.0233 -2.23 
z92 10343.8 10343.84 -0.0392 -3.79 
z90 10158.7 10158.72 -0.0228 -2.24 
z89 10101.7 10101.7 -0.0013 -0.13 
  10101.7 10101.7 -0.0013 -0.13 
  10101.7 10101.7 -0.0013 -0.13 
z88 10044.7 10044.68 0.0201 2 
  10044.7 10044.68 0.0201 2 
  10044.7 10044.68 0.0201 2 
z87 9973.64 9973.643 -0.0028 -0.28 
  9973.64 9973.643 -0.0028 -0.28 
z85 9689.44 9689.447 -0.0067 -0.69 
  9689.44 9689.447 -0.0067 -0.69 
z83 9396.29 9396.287 0.0033 0.35 
z80 9028 9028.008 -0.0079 -0.88 
  9028 9028.008 -0.0079 -0.88 
z79 8871.91 8871.907 0.0032 0.36 
  8871.91 8871.907 0.0032 0.36 
  8871.91 8871.907 0.0032 0.36 
z78 8756.88 8756.88 0.0001 0.02 
z76 8529.76 8529.753 0.0071 0.84 
  8529.76 8529.753 0.0071 0.84 
  8529.76 8529.753 0.0071 0.84 
























z73 8231.59 8231.589 0.0012 0.15 
  8231.59 8231.589 0.0012 0.15 
z72 8130.54 8130.541 -0.0011 -0.13 
z70 7905.39 7905.393 -0.0034 -0.43 
  7905.39 7905.393 -0.0034 -0.43 
z68 7721.27 7721.272 -0.0022 -0.28 
  7721.27 7721.272 -0.0022 -0.28 
z67 7565.17 7565.171 -0.0011 -0.14 
  7565.17 7565.171 -0.0011 -0.14 
  7565.17 7565.171 -0.0011 -0.14 
z66 7409.07 7409.07 0 0 
  7409.07 7409.07 0 0 
z65 7295.98 7295.986 -0.0059 -0.81 
z64 7224.95 7224.949 0.0012 0.17 
z63 7068.85 7068.848 0.0023 0.33 
  7068.85 7068.848 0.0023 0.33 
z62 6912.76 6912.747 0.0134 1.94 
z61 6855.73 6855.725 0.0049 0.71 
  6855.73 6855.725 0.0049 0.71 
z59 6699.64 6699.635 0.0047 0.71 
  6699.64 6699.635 0.0047 0.71 
  6699.64 6699.635 0.0047 0.71 
z58 6571.54 6571.54 -0.0003 -0.04 
z57 6415.44 6415.439 0.0008 0.13 
z56 6302.35 6302.355 -0.0051 -0.81 
z55 6215.32 6215.323 -0.0031 -0.5 
z54 6158.3 6158.302 -0.0016 -0.26 
z52 5932.14 5932.134 0.0065 1.09 
z51 5769.06 5769.07 -0.0102 -1.76 
  5769.06 5769.07 -0.0102 -1.76 
z50 5640.03 5640.028 0.0024 0.43 
  5640.03 5640.028 0.0024 0.43 
z49 5510.99 5510.985 0.005 0.91 
  5510.99 5510.985 0.005 0.91 
z48 5409.94 5409.937 0.0027 0.5 
  5409.94 5409.937 0.0027 0.5 
z47 5253.83 5253.836 -0.0062 -1.18 












  Mass (Da) 
 
Mass Error    
      (Da) 
 
Mass Error       
   (PPM) 
 
z42 4757.5 4757.499 0.0011 0.23 
  4757.5 4757.499 0.0011 0.23 
  4757.5 4757.499 0.0011 0.23 
z39 4368.31 4368.304 0.0061 1.41 
z35 3886.01 3886.007 0.0027 0.68 
  3886.01 3886.007 0.0027 0.68 
z34 3770.98 3770.98 -0.0004 -0.11 
  3770.98 3770.98 -0.0004 -0.11 
z32 3600.87 3600.875 -0.0049 -1.36 
  3600.87 3600.875 -0.0049 -1.36 
z31 3499.83 3499.827 0.0028 0.8 
  3499.83 3499.827 0.0028 0.8 
  3499.83 3499.827 0.0028 0.8 
z29 3235.72 3235.716 0.0038 1.18 
  3235.72 3235.716 0.0038 1.18 
z28 3106.68 3106.674 0.0064 2.06 
z24 2614.38 2614.382 -0.0015 -0.58 
  2614.38 2614.382 -0.0015 -0.58 
z21 2286.17 2286.171 -0.0005 -0.2 
  2286.17 2286.171 -0.0005 -0.2 
z20 2185.13 2185.123 0.0072 3.3 
z18 1983.04 1983.045 -0.0052 -2.61 
z15 1669.88 1669.881 -0.0014 -0.85 
z14 1506.82 1506.818 0.0019 1.27 
z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 
z9 910.443 910.4423 0.0007 0.8 
z8 853.421 853.4208 0.0002 0.22 
c101 11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
c94 10447 10446.97 0.0303 2.9 
c93 10389.9 10389.95 -0.0483 -4.65 
c91 10105.8 10105.79 0.0114 1.13 
  10105.8 10105.79 0.0114 1.13 
c88 9793.59 9793.573 0.0175 1.79 




















c77 8529.76 8529.908 -0.1479 -17.34 
  8529.76 8529.908 -0.1479 -17.34 
  8529.76 8529.908 -0.1479 -17.34 
c76 8401.69 8401.813 -0.123 -14.64 
c71 7800.56 7800.563 -0.0033 -0.43 
c70 7699.52 7699.516 0.0043 0.56 
c67 7414.38 7414.383 -0.0032 -0.43 
c63 6932.09 6932.087 0.0033 0.48 
  6932.09 6932.087 0.0033 0.48 
  6932.09 6932.087 0.0033 0.48 
c60 6542.89 6542.892 -0.0016 -0.25 
  6542.89 6542.892 -0.0016 -0.25 
  6542.89 6542.892 -0.0016 -0.25 
c59 6443.83 6443.823 0.0068 1.05 
c58 6315.73 6315.728 0.0017 0.27 
  6315.73 6315.728 0.0017 0.27 
c57 6202.65 6202.644 0.0058 0.93 
c55 6046.47 6046.554 -0.0843 -13.95 
  6046.47 6046.554 -0.0843 -13.95 
c54 5890.45 5890.453 -0.0032 -0.55 
  5890.45 5890.453 -0.0032 -0.55 
c53 5789.4 5789.406 -0.0055 -0.96 
  5789.4 5789.406 -0.0055 -0.96 
c52 5660.37 5660.363 0.007 1.24 
  5660.37 5660.363 0.007 1.24 
c51 5531.32 5531.32 -0.0004 -0.07 
  5531.32 5531.32 -0.0004 -0.07 
c48 5142.09 5142.089 0.0011 0.21 
  5142.09 5142.089 0.0011 0.21 
  5142.09 5142.089 0.0011 0.21 
c46 4998.03 4998.035 -0.0054 -1.09 
  4998.03 4998.035 -0.0054 -1.09 
c45 4884.95 4884.951 -0.0014 -0.28 
c44 4728.85 4728.85 -0.0003 -0.05 
  4728.85 4728.85 -0.0003 -0.05 
  4728.85 4728.85 -0.0003 -0.05 
c43 4600.75 4600.755 -0.0053 -1.15 




















c42 4501.69 4501.687 0.0031 0.69 
c41 4444.66 4444.665 -0.0054 -1.22 
  4444.66 4444.665 -0.0054 -1.22 
c40 4387.64 4387.644 -0.004 -0.9 
  4387.64 4387.644 -0.004 -0.9 
c39 4231.54 4231.543 -0.0029 -0.68 
  4231.54 4231.543 -0.0029 -0.68 
  4231.54 4231.543 -0.0029 -0.68 
c38 4075.44 4075.442 -0.0017 -0.43 
  4075.44 4075.442 -0.0017 -0.43 
  4075.44 4075.442 -0.0017 -0.43 
c37 4004.4 4004.405 -0.0046 -1.16 
  4004.4 4004.405 -0.0046 -1.16 
c36 3891.32 3891.321 -0.0006 -0.15 
  3891.32 3891.321 -0.0006 -0.15 
c35 3735.22 3735.22 0.0005 0.14 
  3735.22 3735.22 0.0005 0.14 
  3735.22 3735.22 0.0005 0.14 
c34 3579.12 3579.118 0.0016 0.46 
  3579.12 3579.118 0.0016 0.46 
c32 3395 3394.997 0.0028 0.83 
  3395 3394.997 0.0028 0.83 
c30 3169.85 3169.85 0.0005 0.17 
  3169.85 3169.85 0.0005 0.17 
c29 3068.8 3068.802 -0.0018 -0.58 
c27 2898.7 2898.696 0.0037 1.29 
  2898.7 2898.696 0.0037 1.29 
c26 2770.63 2770.638 -0.0077 -2.78 
  2770.63 2770.638 -0.0077 -2.78 
  2770.63 2770.638 -0.0077 -2.78 
c25 2657.55 2657.554 -0.0036 -1.37 
c24 2543.51 2543.511 -0.0007 -0.27 
  2543.51 2543.511 -0.0007 -0.27 
c23 2428.48 2428.484 -0.0038 -1.55 
  2428.48 2428.484 -0.0038 -1.55 
  2428.48 2428.484 -0.0038 -1.55 
c22 2272.38 2272.383 -0.0026 -1.17 




















c21 2159.3 2159.299 0.0014 0.65 
c19 1904.1 1904.104 -0.0039 -2.04 
  1904.1 1904.104 -0.0039 -2.04 
c18 1748 1748.003 -0.0028 -1.58 
  1748 1748.003 -0.0028 -1.58 
c17 1610.95 1610.944 0.0061 3.81 
  1610.95 1610.944 0.0061 3.81 
c16 1454.84 1454.843 -0.0027 -1.89 
  1454.84 1454.843 -0.0027 -1.89 
c15 1326.75 1326.748 0.0022 1.67 
  1326.75 1326.748 0.0022 1.67 
c14 1255.71 1255.711 -0.0007 -0.54 
  1255.71 1255.711 -0.0007 -0.54 
c13 1198.69 1198.689 0.0008 0.65 
  1198.69 1198.689 0.0008 0.65 
c12 1141.67 1141.668 0.0022 1.96 
  1141.67 1141.668 0.0022 1.96 
c11 1013.57 1013.573 -0.0028 -2.76 
  1013.57 1013.573 -0.0028 -2.76 
c10 956.552 956.5513 0.0007 0.69 
  956.552 956.5513 0.0007 0.69 
c9 843.468 843.4673 0.0007 0.85 
  843.468 843.4673 0.0007 0.85 
c8 786.446 786.4458 0.0002 0.23 
c7 658.351 658.3509 0.0001 0.21 
c6 601.33 601.3294 0.0006 1 
c5 544.309 544.3079 0.0011 1.95 
c4 416.214 416.213 0.001 2.45 










Assigned fragment ions from CID of wild type single mouse brain sample (precursor ion 










y49 5527.01 5527.006 0.0043 0.79 
  5527.01 5527.006 0.0043 0.79 
y42 4773.52 4773.52 0.0004 0.09 
y40 4513.37 4513.367 0.0029 0.64 
y39 4384.32 4384.325 -0.0045 -1.03 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y24 2630.41 2630.402 0.0078 2.98 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.04 1884.039 0.0011 0.58 
y16 1784.97 1784.971 -0.0005 -0.27 
  1784.97 1784.971 -0.0005 -0.27 
y15 1685.91 1685.902 0.0079 4.7 
  1685.91 1685.902 0.0079 4.7 
y14 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.72 1338.718 0.0024 1.81 
y11 1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.461 926.4629 -0.0019 -2.08 
y5 499.207 499.2086 -0.0016 -3.25 
b86 9528.43 9528.394 0.0364 3.82 
b85 9429.38 9429.325 0.0548 5.82 























b69 7597.44 7597.4 0.0399 5.25 
b68 7526.4 7526.363 0.037 4.92 
b53 5786.4 5786.358 0.0416 7.19 
b52 5657.35 5657.316 0.0342 6.04 
  5657.35 5657.316 0.0342 6.04 
b39 4228.53 4228.496 0.0343 8.11 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.546 996.5465 -0.0005 -0.45 
b10 939.525 939.525 0 0.01 
b9 826.441 826.4409 0.0001 0.08 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.324 641.3245 -0.0005 -0.8 
b5 527.282 527.2816 0.0004 0.78 
b4 399.187 399.1866 0.0004 0.93 


















Assigned fragment ions from ECD of wild type single mouse brain sample (precursor ion 










z101 11168.33 11168.34 -0.0106 -0.95 
  11168.33 11168.34 -0.0106 -0.95 
  11168.33 11168.34 -0.0106 -0.95 
z99 10955.2 10955.21 -0.0181 -1.65 
z98 10898.18 10898.19 -0.0166 -1.53 
z95 10656.04 10656.06 -0.0162 -1.52 
z92 10357.85 10357.85 -0.0096 -0.92 
z91 10300.82 10300.83 -0.015 -1.45 
z90 10172.73 10172.74 -0.0112 -1.1 
z88 10058.69 10058.7 -0.0011 -0.11 
  10058.69 10058.7 -0.0011 -0.11 
z87 9987.645 9987.658 -0.0138 -1.38 
z86 9859.551 9859.564 -0.0126 -1.28 
z85 9703.452 9703.462 -0.0101 -1.04 
z84 9566.396 9566.403 -0.0078 -0.82 
  9566.396 9566.403 -0.0078 -0.82 
  9566.396 9566.403 -0.0078 -0.82 
z83 9410.294 9410.302 -0.0083 -0.88 
  9410.294 9410.302 -0.0083 -0.88 
z79 8871.895 8871.907 -0.0117 -1.32 
z78 8756.869 8756.88 -0.0112 -1.28 
z77 8642.829 8642.837 -0.0085 -0.98 
z76 8529.744 8529.753 -0.0089 -1.05 
z75 8401.683 8401.694 -0.0118 -1.4 
z72 8130.523 8130.541 -0.0178 -2.19 
z68 7721.26 7721.272 -0.012 -1.55 
  7721.26 7721.272 -0.012 -1.55 
z67 7565.157 7565.171 -0.0144 -1.91 
  7565.157 7565.171 -0.0144 -1.91 
z66 7409.058 7409.07 -0.0116 -1.56 
z65 7295.978 7295.986 -0.0075 -1.03 
z64 7224.937 7224.949 -0.0119 -1.64 























z62 6912.741 6912.747 -0.006 -0.87 
z61 6855.704 6855.725 -0.0208 -3.03 
z59 6699.619 6699.635 -0.0166 -2.48 
z58 6571.529 6571.54 -0.011 -1.68 
z57 6415.427 6415.439 -0.0119 -1.86 
z54 6158.294 6158.302 -0.0076 -1.23 
z53 6045.207 6045.218 -0.0109 -1.81 
z52 5932.126 5932.134 -0.0074 -1.25 
z51 5769.064 5769.07 -0.006 -1.04 
z50 5640.016 5640.028 -0.0119 -2.11 
z49 5510.984 5510.985 -0.001 -0.18 
z48 5409.937 5409.937 -0.0003 -0.06 
z47 5253.829 5253.836 -0.0073 -1.38 
  5253.829 5253.836 -0.0073 -1.38 
z43 4856.561 4856.567 -0.0063 -1.31 
z42 4757.492 4757.499 -0.0065 -1.37 
z39 4368.302 4368.304 -0.0022 -0.5 
z35 3886.002 3886.007 -0.005 -1.28 
  3886.002 3886.007 -0.005 -1.28 
z32 3600.872 3600.875 -0.0033 -0.93 
  3600.872 3600.875 -0.0033 -0.93 
z31 3499.825 3499.827 -0.0027 -0.76 
  3499.825 3499.827 -0.0027 -0.76 
z18 1983.044 1983.045 -0.001 -0.5 
z15 1669.881 1669.881 -0.0009 -0.52 
z14 1506.818 1506.818 -0.0006 -0.38 
  1506.818 1506.818 -0.0006 -0.38 
z11 1194.602 1194.602 -0.0003 -0.23 
z9 910.4432 910.4423 0.0009 1.02 
z8 853.4201 853.4208 -0.0007 -0.83 
c100 11198.32 11198.37 -0.051 -4.55 
  11198.32 11198.37 -0.051 -4.55 
  11198.32 11198.37 -0.051 -4.55 
c92 10275.89 10275.91 -0.0124 -1.21 
c71 7814.573 7814.579 -0.0066 -0.84 
c70 7713.525 7713.531 -0.0065 -0.84 
c67 7428.394 7428.399 -0.0045 -0.6 
c63 6946.094 6946.102 -0.008 -1.15 
  6946.094 6946.102 -0.008 -1.15 













c60 6556.903 6556.907 -0.0049 -0.74 
  6556.903 6556.907 -0.0049 -0.74 
c59 6457.833 6457.839 -0.0064 -1 
  6457.833 6457.839 -0.0064 -1 
c55 6060.564 6060.57 -0.0064 -1.06 
  6060.564 6060.57 -0.0064 -1.06 
c54 5904.465 5904.469 -0.0043 -0.73 
c52 5674.373 5674.379 -0.0053 -0.93 
c51 5545.332 5545.336 -0.0041 -0.73 
  5545.332 5545.336 -0.0041 -0.73 
c50 5382.266 5382.273 -0.0065 -1.2 
c48 5156.099 5156.105 -0.0059 -1.14 
  5156.099 5156.105 -0.0059 -1.14 
c47 5099.073 5099.083 -0.0098 -1.93 
c46 5012.044 5012.051 -0.0073 -1.46 
c45 4898.956 4898.967 -0.0107 -2.19 
c44 4742.859 4742.866 -0.0067 -1.42 
  4742.859 4742.866 -0.0067 -1.42 
  4742.859 4742.866 -0.0067 -1.42 
c43 4614.763 4614.771 -0.008 -1.73 
  4614.763 4614.771 -0.008 -1.73 
  4614.763 4614.771 -0.008 -1.73 
c41 4458.674 4458.681 -0.0071 -1.6 
c40 4401.655 4401.66 -0.0049 -1.11 
c39 4245.552 4245.559 -0.0065 -1.53 
  4245.552 4245.559 -0.0065 -1.53 
c38 4089.449 4089.457 -0.0088 -2.15 
  4089.449 4089.457 -0.0088 -2.15 
c37 4018.416 4018.42 -0.0046 -1.16 
  4018.416 4018.42 -0.0046 -1.16 
c36 3905.328 3905.336 -0.0079 -2.02 
  3905.328 3905.336 -0.0079 -2.02 
c35 3749.229 3749.235 -0.0058 -1.54 
  3749.229 3749.235 -0.0058 -1.54 
  3749.229 3749.235 -0.0058 -1.54 
c34 3593.129 3593.134 -0.0047 -1.31 
  3593.129 3593.134 -0.0047 -1.31 
c32 3409.005 3409.013 -0.0079 -2.33 
c30 3183.862 3183.865 -0.0032 -1.01 













c29 3082.811 3082.818 -0.0062 -2.02 
  3082.811 3082.818 -0.0062 -2.02 
c27 2912.709 2912.712 -0.0027 -0.92 
c26 2784.649 2784.653 -0.0042 -1.49 
  2784.649 2784.653 -0.0042 -1.49 
c25 2671.564 2671.569 -0.0049 -1.82 
c24 2557.522 2557.526 -0.0044 -1.71 
  2557.522 2557.526 -0.0044 -1.71 
c23 2442.494 2442.499 -0.0054 -2.22 
  2442.494 2442.499 -0.0054 -2.22 
c21 2173.309 2173.314 -0.0057 -2.61 
  2173.309 2173.314 -0.0057 -2.61 
c20 2074.24 2074.246 -0.006 -2.88 
  2074.24 2074.246 -0.006 -2.88 
c19 1904.102 1904.104 -0.0015 -0.77 
  1904.102 1904.104 -0.0015 -0.77 
c18 1748.001 1748.003 -0.0016 -0.94 
  1748.001 1748.003 -0.0016 -0.94 
c17 1610.942 1610.944 -0.0021 -1.3 
  1610.942 1610.944 -0.0021 -1.3 
c16 1454.844 1454.843 0.0011 0.74 
c15 1326.746 1326.748 -0.0022 -1.64 
  1326.746 1326.748 -0.0022 -1.64 
c14 1255.708 1255.711 -0.003 -2.43 
c13 1198.687 1198.689 -0.0027 -2.29 
  1198.687 1198.689 -0.0027 -2.29 
c12 1141.664 1141.668 -0.0041 -3.63 
c10 956.5487 956.5514 -0.0026 -2.75 
  956.5487 956.5514 -0.0026 -2.75 
c9 843.467 843.4673 -0.0003 -0.41 
c8 786.4452 786.4458 -0.0006 -0.77 
c7 658.3497 658.3509 -0.0012 -1.78 
c6 601.3278 601.3294 -0.0016 -2.64 
c5 544.3058 544.308 -0.0021 -3.95 








Assigned fragment ions from CID of wild type single mouse brain sample (precursor ion 










y63 7084.85 7084.868 -0.0183 -2.59 
y49 5527 5527.006 -0.0057 -1.02 
y47 5269.85 5269.857 -0.0069 -1.3 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.51 4773.52 -0.0096 -2 
y41 4626.45 4626.451 -0.0012 -0.25 
y40 4513.35 4513.367 -0.0171 -3.79 
y39 4384.32 4384.325 -0.0045 -1.03 
y35 3902.02 3902.028 -0.008 -2.05 
y34 3787 3787.001 -0.0011 -0.28 
y32 3616.9 3616.896 0.0045 1.23 
y31 3515.84 3515.848 -0.0079 -2.24 
y30 3352.78 3352.785 -0.0045 -1.35 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y24 2630.4 2630.402 -0.0022 -0.82 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.97 1784.971 -0.0005 -0.27 
  1784.97 1784.971 -0.0005 -0.27 
y15 1685.91 1685.902 0.0079 4.7 
  1685.91 1685.902 0.0079 4.7 
y14 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.72 1338.718 0.0024 1.81 























  1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.463 926.4629 0.0001 0.08 
  926.463 926.4629 0.0001 0.08 
y8 869.44 869.4415 -0.0015 -1.69 
y5 499.207 499.2086 -0.0016 -3.25 
b68 7554.39 7554.394 -0.0043 -0.57 
  7554.39 7554.394 -0.0043 -0.57 
b63 6957.07 6957.071 -0.0009 -0.13 
b59 6468.83 6468.807 0.0226 3.49 
b53 5814.39 5814.39 0.0003 0.04 
b52 5685.35 5685.347 0.0028 0.5 
  5685.35 5685.347 0.0028 0.5 
  5685.35 5685.347 0.0028 0.5 
b51 5556.32 5556.305 0.0154 2.78 
b35 3760.21 3760.204 0.0063 1.69 
b27 2923.68 2923.681 -0.0005 -0.16 
b25 2682.54 2682.538 0.0022 0.81 
b24 2568.49 2568.495 -0.0049 -1.9 
  2568.49 2568.495 -0.0049 -1.9 
b23 2453.47 2453.468 0.002 0.84 
  2453.47 2453.468 0.002 0.84 
b19 1929.09 1929.088 0.0019 1 
b17 1635.93 1635.928 0.002 1.19 
  1635.93 1635.928 0.002 1.19 
  1635.93 1635.928 0.002 1.19 
b13 1181.66 1181.663 -0.0029 -2.43 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.546 996.5465 -0.0005 -0.45 
  996.546 996.5465 -0.0005 -0.45 
b10 939.525 939.525 0 0.01 
b9 826.441 826.4409 0.0001 0.08 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.325 641.3245 0.0005 0.76 
b6 584.303 584.303 0 -0.09 
b5 527.282 527.2816 0.0004 0.78 
b4 399.187 399.1866 0.0004 0.93 







Assigned fragment ions from ECD of wild type single mouse brain sample (precursor ion 










z101 11196.3 11196.33 -0.0321 -2.87 
  11196.3 11196.33 -0.0321 -2.87 
  11196.3 11196.33 -0.0321 -2.87 
z100 11139.3 11139.31 -0.0107 -0.96 
z99 10983.2 10983.21 -0.0096 -0.87 
z98 10926.2 10926.19 0.0119 1.09 
z96 10741.1 10741.07 0.0283 2.64 
z95 10684.1 10684.05 0.0498 4.66 
z94 10555.9 10555.96 -0.0553 -5.24 
  10555.9 10555.96 -0.0553 -5.24 
z90 10200.7 10200.73 -0.0333 -3.27 
z88 10086.7 10086.69 0.0096 0.95 
z87 10015.6 10015.65 -0.0533 -5.32 
z85 9689.44 9689.447 -0.0067 -0.69 
  9689.44 9689.447 -0.0067 -0.69 
z83 9396.28 9396.287 -0.0067 -0.71 
  9396.28 9396.287 -0.0067 -0.71 
z79 8871.9 8871.907 -0.0068 -0.77 
  8871.9 8871.907 -0.0068 -0.77 
z78 8756.87 8756.88 -0.0099 -1.12 
  8756.87 8756.88 -0.0099 -1.12 
z73 8231.59 8231.589 0.0012 0.15 
z68 7721.27 7721.272 -0.0022 -0.28 
  7721.27 7721.272 -0.0022 -0.28 
  7721.27 7721.272 -0.0022 -0.28 
z67 7565.17 7565.171 -0.0011 -0.14 
z66 7409.06 7409.07 -0.01 -1.35 
  7409.06 7409.07 -0.01 -1.35 
z64 7224.94 7224.949 -0.0088 -1.22 
  7224.94 7224.949 -0.0088 -1.22 
z63 7068.84 7068.848 -0.0077 -1.09 
z62 6912.74 6912.747 -0.0066 -0.95 
























z61 6855.71 6855.725 -0.0151 -2.21 
  6855.71 6855.725 -0.0151 -2.21 
z59 6699.63 6699.635 -0.0053 -0.78 
  6699.63 6699.635 -0.0053 -0.78 
z58 6571.53 6571.54 -0.0103 -1.57 
z57 6415.43 6415.439 -0.0092 -1.43 
z56 6302.36 6302.355 0.0049 0.77 
z55 6215.32 6215.323 -0.0031 -0.5 
z54 6158.29 6158.302 -0.0116 -1.89 
  6158.29 6158.302 -0.0116 -1.89 
z53 6045.19 6045.218 -0.0276 -4.56 
z51 5769.06 5769.07 -0.0102 -1.76 
  5769.06 5769.07 -0.0102 -1.76 
z50 5640.01 5640.028 -0.0176 -3.12 
  5640.01 5640.028 -0.0176 -3.12 
z49 5510.97 5510.985 -0.015 -2.72 
z48 5409.93 5409.937 -0.0073 -1.35 
z47 5253.83 5253.836 -0.0062 -1.18 
  5253.83 5253.836 -0.0062 -1.18 
z43 4856.56 4856.567 -0.0073 -1.51 
z42 4757.49 4757.499 -0.0089 -1.87 
  4757.49 4757.499 -0.0089 -1.87 
z39 4368.3 4368.304 -0.0039 -0.88 
z35 3886 3886.007 -0.0073 -1.89 
  3886 3886.007 -0.0073 -1.89 
z32 3600.87 3600.875 -0.0049 -1.36 
  3600.87 3600.875 -0.0049 -1.36 
z31 3499.82 3499.827 -0.0072 -2.06 
  3499.82 3499.827 -0.0072 -2.06 
z29 3235.71 3235.716 -0.0062 -1.91 
  3235.71 3235.716 -0.0062 -1.91 
z28 3106.68 3106.674 0.0064 2.06 
z21 2286.17 2286.171 -0.0005 -0.2 
z15 1669.88 1669.881 -0.0014 -0.85 
z14 1506.82 1506.818 0.0019 1.27 
z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 



















     
z8 853.42 853.4208 -0.0008 -0.95 
c67 7456.39 7456.394 -0.0037 -0.5 
c63 6974.09 6974.097 -0.0072 -1.04 
c60 6584.89 6584.902 -0.0122 -1.85 
  6584.89 6584.902 -0.0122 -1.85 
c59 6485.83 6485.834 -0.0038 -0.58 
c53 5831.41 5831.416 -0.0061 -1.04 
c52 5702.37 5702.374 -0.0035 -0.61 
  5702.37 5702.374 -0.0035 -0.61 
c51 5573.33 5573.331 -0.0009 -0.16 
  5573.33 5573.331 -0.0009 -0.16 
c48 5184.09 5184.1 -0.0095 -1.82 
  5184.09 5184.1 -0.0095 -1.82 
c46 5040.04 5040.046 -0.006 -1.18 
c44 4770.85 4770.861 -0.0108 -2.26 
  4770.85 4770.861 -0.0108 -2.26 
  4770.85 4770.861 -0.0108 -2.26 
c43 4642.77 4642.766 0.0042 0.9 
  4642.77 4642.766 0.0042 0.9 
c41 4486.67 4486.676 -0.006 -1.33 
c39 4273.55 4273.553 -0.0034 -0.8 
  4273.55 4273.553 -0.0034 -0.8 
c37 4046.41 4046.415 -0.0052 -1.28 
c36 3933.33 3933.331 -0.0011 -0.28 
  3933.33 3933.331 -0.0011 -0.28 
c35 3777.22 3777.23 -0.01 -2.65 
  3777.22 3777.23 -0.01 -2.65 
c34 3621.13 3621.129 0.0011 0.3 
  3621.13 3621.129 0.0011 0.3 
c32 3437 3437.008 -0.0077 -2.25 
c30 3211.85 3211.86 -0.01 -3.12 
c29 3110.81 3110.812 -0.0023 -0.75 
  3110.81 3110.812 -0.0023 -0.75 
c26 2812.64 2812.648 -0.0082 -2.93 
  2812.64 2812.648 -0.0082 -2.93 
c24 2585.52 2585.521 -0.0012 -0.48 
  2585.52 2585.521 -0.0012 -0.48 



















     
 
c22 2314.39 2314.393 -0.0032 -1.38 
  2314.39 2314.393 -0.0032 -1.38 
c21 2201.31 2201.309 0.0009 0.4 
c19 1946.11 1946.114 -0.0044 -2.27 
  1946.11 1946.114 -0.0044 -2.27 
c18 1790.01 1790.013 -0.0033 -1.85 
c17 1652.95 1652.954 -0.0044 -2.66 
  1652.95 1652.954 -0.0044 -2.66 
c16 1496.85 1496.853 -0.0033 -2.2 
c15 1326.75 1326.748 0.0022 1.67 
c14 1255.71 1255.711 -0.0007 -0.54 
  1255.71 1255.711 -0.0007 -0.54 
c13 1198.69 1198.689 0.0008 0.65 
  1198.69 1198.689 0.0008 0.65 
c12 1141.67 1141.668 0.0022 1.96 
  1141.67 1141.668 0.0022 1.96 
c10 956.549 956.5513 -0.0023 -2.45 
  956.549 956.5513 -0.0023 -2.45 
c9 843.467 843.4673 -0.0003 -0.33 
c8 786.445 786.4458 -0.0008 -1.04 
c7 658.35 658.3509 -0.0009 -1.3 
c6 601.328 601.3294 -0.0014 -2.33 
c5 544.306 544.3079 -0.0019 -3.56 












Assigned fragment ions from CID of wild type single mouse brain sample (precursor ion 










y49 5527.003 5527.006 -0.0026 -0.47 
y42 4773.533 4773.52 0.0132 2.76 
y39 4384.328 4384.325 0.0036 0.82 
y29 3251.732 3251.737 -0.0045 -1.37 
y28 3122.692 3122.694 -0.0025 -0.81 
  3122.692 3122.694 -0.0025 -0.81 
y27 2985.631 2985.635 -0.0039 -1.32 
y26 2914.595 2914.598 -0.0028 -0.96 
y22 2401.261 2401.26 0.0018 0.76 
y21 2302.189 2302.191 -0.002 -0.86 
y20 2201.143 2201.143 -0.0008 -0.37 
y19 2130.105 2130.106 -0.0018 -0.85 
y18 1999.064 1999.066 -0.0023 -1.18 
y17 1884.037 1884.039 -0.0018 -0.96 
y16 1784.973 1784.971 0.0029 1.6 
  1784.973 1784.971 0.0029 1.6 
y15 1685.901 1685.902 -0.001 -0.62 
y14 1522.839 1522.839 -0.0002 -0.15 
y13 1451.8 1451.802 -0.0012 -0.85 
y12 1338.715 1338.718 -0.003 -2.27 
y11 1210.621 1210.623 -0.0022 -1.78 
y10 1054.52 1054.522 -0.0019 -1.77 
y9 926.461 926.4629 -0.0019 -2.08 
y5 499.2067 499.2086 -0.0019 -3.85 
b68 7568.43 7568.41 0.0196 2.59 
b53 5828.407 5828.406 0.0017 0.28 
b52 5699.365 5699.363 0.0018 0.32 
b39 4270.536 4270.543 -0.0069 -1.61 
b35 3774.221 3774.219 0.0014 0.38 
b24 2582.511 2582.511 0.0001 0.03 
b23 2467.478 2467.484 -0.0057 -2.32 























b12 1124.641 1124.641 -0.0006 -0.51 
b11 996.5463 996.5465 -0.0002 -0.15 
b10 939.5248 939.525 -0.0003 -0.27 
b9 826.4412 826.441 0.0002 0.25 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.3245 641.3245 -0.0001 -0.09 
b6 584.3028 584.3031 -0.0003 -0.51 
b5 527.2815 527.2816 -0.0001 -0.25 
b4 399.1869 399.1867 0.0002 0.5 




















Assigned fragment ions from ECD of wild type single mouse brain sample (precursor ion 










z101 11210.34 11210.35 -0.0031 -0.28 
  11210.34 11210.35 -0.0031 -0.28 
z100 11153.33 11153.33 -0.0013 -0.12 
z99 10997.22 10997.23 -0.0041 -0.37 
z85 9703.462 9703.462 -0.0005 -0.05 
z84 9566.401 9566.403 -0.0022 -0.23 
z79 8871.903 8871.907 -0.0039 -0.44 
z78 8756.872 8756.88 -0.0074 -0.85 
z76 8529.749 8529.753 -0.0036 -0.42 
z75 8401.697 8401.694 0.0027 0.32 
z68 7721.274 7721.272 0.0021 0.27 
z67 7565.161 7565.171 -0.0098 -1.29 
z66 7409.057 7409.07 -0.0132 -1.78 
z64 7224.943 7224.949 -0.0063 -0.88 
z63 7068.837 7068.848 -0.0107 -1.51 
z62 6912.743 6912.747 -0.0041 -0.59 
z61 6855.723 6855.725 -0.0026 -0.38 
z59 6699.626 6699.635 -0.0095 -1.42 
  6699.626 6699.635 -0.0095 -1.42 
z58 6571.525 6571.54 -0.0157 -2.39 
z57 6415.428 6415.439 -0.0117 -1.82 
z54 6158.29 6158.302 -0.0119 -1.92 
  6158.29 6158.302 -0.0119 -1.92 
z51 5769.064 5769.07 -0.0067 -1.15 
  5769.064 5769.07 -0.0067 -1.15 
z47 5253.829 5253.836 -0.0069 -1.31 
  5253.829 5253.836 -0.0069 -1.31 
z43 4856.564 4856.567 -0.0035 -0.71 
z42 4757.493 4757.499 -0.0063 -1.33 
z39 4368.304 4368.304 0.0002 0.06 
z32 3600.873 3600.875 -0.0022 -0.61 
  3600.873 3600.875 -0.0022 -0.61 























z14 1506.818 1506.818 -0.0001 -0.09 
z11 1194.602 1194.602 -0.0002 -0.2 
z10 1038.501 1038.501 0.0006 0.56 
z9 910.442 910.4423 -0.0003 -0.32 
c101 11297.37 11297.4 -0.0376 -3.33 
  11297.37 11297.4 -0.0376 -3.33 
  11297.37 11297.4 -0.0376 -3.33 
  11297.37 11297.4 -0.0376 -3.33 
c71 7856.583 7856.59 -0.0071 -0.91 
c70 7755.545 7755.542 0.0026 0.33 
c67 7470.404 7470.41 -0.0057 -0.76 
c63 6988.109 6988.113 -0.0042 -0.6 
c60 6598.909 6598.918 -0.0086 -1.31 
c59 6499.846 6499.85 -0.004 -0.62 
c55 6102.58 6102.581 -0.0007 -0.12 
  6102.58 6102.581 -0.0007 -0.12 
c52 5716.388 5716.389 -0.0011 -0.19 
c51 5587.344 5587.347 -0.0031 -0.55 
c50 5424.281 5424.283 -0.0024 -0.45 
c45 4940.976 4940.978 -0.002 -0.41 
c44 4784.874 4784.877 -0.0026 -0.55 
  4784.874 4784.877 -0.0026 -0.55 
c43 4656.778 4656.782 -0.0039 -0.83 
  4656.778 4656.782 -0.0039 -0.83 
c41 4500.693 4500.692 0.0012 0.27 
c40 4443.666 4443.67 -0.0039 -0.89 
c39 4287.568 4287.569 -0.0014 -0.32 
  4287.568 4287.569 -0.0014 -0.32 
c38 4131.468 4131.468 -0.0003 -0.08 
c36 3947.342 3947.347 -0.0047 -1.19 
c35 3791.244 3791.246 -0.002 -0.52 
c34 3635.144 3635.145 -0.0012 -0.33 
  3635.144 3635.145 -0.0012 -0.33 
c26 2826.661 2826.664 -0.0026 -0.91 
c24 2599.533 2599.537 -0.0037 -1.43 
  2599.533 2599.537 -0.0037 -1.43 
c23 2484.507 2484.51 -0.0033 -1.34 
  2484.507 2484.51 -0.0033 -1.34 
c22 2328.41 2328.409 0.0006 0.28 













c21 2215.325 2215.325 0 0 
c19 1946.115 1946.115 0.0002 0.08 
c18 1790.014 1790.013 0.0004 0.24 
c17 1652.955 1652.955 0 0 
c16 1496.853 1496.853 -0.0002 -0.16 
c15 1326.747 1326.748 -0.0013 -1.01 






















Assigned fragment ions from CID of MeCP2 Knockout single mouse brain sample 










y49 5527 5527.006 -0.0057 -1.02 
  5527 5527.006 -0.0057 -1.02 
y47 5269.85 5269.857 -0.0069 -1.3 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.51 4773.52 -0.0096 -2 
y41 4626.45 4626.451 -0.0012 -0.25 
y40 4513.36 4513.367 -0.0071 -1.57 
y39 4384.32 4384.325 -0.0045 -1.03 
  4384.32 4384.325 -0.0045 -1.03 
y37 4171.22 4171.213 0.0068 1.64 
y34 3786.99 3787.001 -0.0111 -2.92 
y32 3616.89 3616.896 -0.0055 -1.53 
y31 3515.84 3515.848 -0.0079 -2.24 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y24 2630.39 2630.402 -0.0122 -4.63 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.03 1884.039 -0.0089 -4.72 
y16 1784.97 1784.971 -0.0005 -0.27 
  1784.97 1784.971 -0.0005 -0.27 
y15 1685.9 1685.902 -0.0021 -1.23 
y14 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 













y11 1210.62 1210.623 -0.0026 -2.16 
  1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.46 926.4629 -0.0029 -3.16 
y8 869.439 869.4415 -0.0025 -2.84 
y7 713.339 713.3404 -0.0014 -1.91 
y5 499.207 499.2086 -0.0016 -3.25 
b87 9613.48 9613.483 -0.0028 -0.29 
b86 9514.4 9514.414 -0.0144 -1.51 
b85 9415.34 9415.346 -0.006 -0.63 
b83 9169.32 9169.279 0.0415 4.52 
b71 7783.54 7783.537 0.003 0.39 
b69 7583.41 7583.421 -0.0109 -1.44 
b68 7512.38 7512.384 -0.0038 -0.51 
  7512.38 7512.384 -0.0038 -0.51 
  7512.38 7512.384 -0.0038 -0.51 
b63 6915.06 6915.06 -0.0004 -0.05 
  6915.06 6915.06 -0.0004 -0.05 
b62 6786.03 6786.018 0.0122 1.8 
b53 5772.37 5772.379 -0.0092 -1.59 
  5772.37 5772.379 -0.0092 -1.59 
b52 5643.33 5643.337 -0.0066 -1.17 
  5643.33 5643.337 -0.0066 -1.17 
b51 5514.29 5514.294 -0.004 -0.73 
b40 4370.62 4370.618 0.0024 0.54 
b39 4214.52 4214.517 0.0035 0.83 
b35 3718.19 3718.193 -0.0031 -0.84 
b31 3280.92 3280.918 0.0019 0.59 
b25 2640.53 2640.527 0.0027 1.03 
b23 2411.46 2411.457 0.0026 1.07 
  2411.46 2411.457 0.0026 1.07 
b19 1887.08 1887.078 0.0025 1.31 
b17 1593.92 1593.918 0.0025 1.56 
b15 1309.73 1309.721 0.0086 6.54 
b13 1181.66 1181.663 -0.0029 -2.43 













b11 996.547 996.5465 0.0005 0.55 
b10 939.524 939.525 -0.001 -1.05 
b9 826.441 826.4409 0.0001 0.08 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.325 641.3245 0.0005 0.76 
b6 584.303 584.303 0 -0.09 
b5 527.282 527.2816 0.0004 0.78 
b4 399.187 399.1866 0.0004 0.93 




















Assigned fragment ions from ECD of MeCP2 Knockout single mouse brain sample 










z101 11154.3 11154.32 -0.0216 -1.94 
  11154.3 11154.32 -0.0216 -1.94 
  11154.3 11154.32 -0.0216 -1.94 
z98 10884.2 10884.18 0.0224 2.06 
  10884.2 10884.18 0.0224 2.06 
z95 10642 10642.04 -0.0397 -3.73 
  10642 10642.04 -0.0397 -3.73 
z94 10513.9 10513.94 -0.0447 -4.25 
z93 10456.9 10456.92 -0.0233 -2.23 
  10456.9 10456.92 -0.0233 -2.23 
z92 10343.8 10343.84 -0.0392 -3.79 
z90 10158.7 10158.72 -0.0228 -2.24 
z89 10101.7 10101.7 -0.0013 -0.13 
z88 10044.7 10044.68 0.0201 2 
z87 9973.63 9973.643 -0.0128 -1.28 
z85 9689.44 9689.447 -0.0067 -0.69 
z79 8871.9 8871.907 -0.0068 -0.77 
  8871.9 8871.907 -0.0068 -0.77 
z78 8756.87 8756.88 -0.0099 -1.12 
  8756.87 8756.88 -0.0099 -1.12 
z76 8529.75 8529.753 -0.0029 -0.34 
z73 8231.58 8231.589 -0.0088 -1.06 
z70 7905.39 7905.393 -0.0034 -0.43 
z68 7721.27 7721.272 -0.0022 -0.28 
z67 7565.16 7565.171 -0.0111 -1.46 
z66 7409.06 7409.07 -0.01 -1.35 
z64 7224.94 7224.949 -0.0088 -1.22 
z63 7068.84 7068.848 -0.0077 -1.09 
z62 6912.74 6912.747 -0.0066 -0.95 
z61 6855.71 6855.725 -0.0151 -2.21 
z60 6798.69 6798.704 -0.0137 -2.01 
z59 6699.62 6699.635 -0.0153 -2.28 




















Mass Error  
(PPM) 
 
z58 6571.52 6571.54 -0.0203 -3.09 
  6571.52 6571.54 -0.0203 -3.09 
z57 6415.43 6415.439 -0.0092 -1.43 
z54 6158.29 6158.302 -0.0116 -1.89 
  6158.29 6158.302 -0.0116 -1.89 
z52 5932.13 5932.134 -0.0035 -0.59 
z51 5769.06 5769.07 -0.0102 -1.76 
  5769.06 5769.07 -0.0102 -1.76 
z50 5640.02 5640.028 -0.0076 -1.35 
z49 5510.98 5510.985 -0.005 -0.91 
z48 5409.93 5409.937 -0.0073 -1.35 
z43 4856.56 4856.567 -0.0073 -1.51 
z42 4757.5 4757.499 0.0011 0.23 
z39 4368.3 4368.304 -0.0039 -0.88 
z35 3886 3886.007 -0.0073 -1.89 
  3886 3886.007 -0.0073 -1.89 
z34 3770.98 3770.98 -0.0004 -0.11 
  3770.98 3770.98 -0.0004 -0.11 
z32 3600.87 3600.875 -0.0049 -1.36 
  3600.87 3600.875 -0.0049 -1.36 
z31 3499.83 3499.827 0.0028 0.8 
  3499.83 3499.827 0.0028 0.8 
z29 3235.71 3235.716 -0.0062 -1.91 
z28 3106.68 3106.674 0.0064 2.06 
z21 2286.17 2286.171 -0.0005 -0.2 
z15 1669.88 1669.881 -0.0014 -0.85 
z14 1506.82 1506.818 0.0019 1.27 
  1506.82 1506.818 0.0019 1.27 
z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 
z9 910.443 910.4423 0.0007 0.8 
z8 853.42 853.4208 -0.0008 -0.95 
c101 11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
  11241.3 11241.38 -0.0772 -6.87 
c81 9014.21 9014.22 -0.0101 -1.12 
c71 7800.56 7800.563 -0.0033 -0.43 
c70 7699.51 7699.516 -0.0057 -0.74 













c63 6932.08 6932.087 -0.0067 -0.97 
  6932.08 6932.087 -0.0067 -0.97 
  6932.08 6932.087 -0.0067 -0.97 
c60 6542.89 6542.892 -0.0016 -0.25 
c59 6443.82 6443.823 -0.0032 -0.5 
  6443.82 6443.823 -0.0032 -0.5 
c55 6046.54 6046.554 -0.0143 -2.37 
c54 5890.45 5890.453 -0.0032 -0.55 
  5890.45 5890.453 -0.0032 -0.55 
c53 5789.4 5789.406 -0.0055 -0.96 
c52 5660.36 5660.363 -0.003 -0.52 
  5660.36 5660.363 -0.003 -0.52 
c51 5531.32 5531.32 -0.0004 -0.07 
  5531.32 5531.32 -0.0004 -0.07 
c50 5368.25 5368.257 -0.007 -1.31 
c48 5142.08 5142.089 -0.0089 -1.73 
  5142.08 5142.089 -0.0089 -1.73 
c47 5085.06 5085.068 -0.0075 -1.47 
c45 4884.94 4884.951 -0.0114 -2.33 
c44 4728.84 4728.85 -0.0103 -2.17 
  4728.84 4728.85 -0.0103 -2.17 
  4728.84 4728.85 -0.0103 -2.17 
c41 4444.66 4444.665 -0.0054 -1.22 
  4444.66 4444.665 -0.0054 -1.22 
c40 4387.63 4387.644 -0.014 -3.18 
c39 4231.54 4231.543 -0.0029 -0.68 
  4231.54 4231.543 -0.0029 -0.68 
c38 4075.43 4075.442 -0.0117 -2.88 
c37 4004.4 4004.405 -0.0046 -1.16 
  4004.4 4004.405 -0.0046 -1.16 
c36 3891.31 3891.321 -0.0106 -2.72 
  3891.31 3891.321 -0.0106 -2.72 
c35 3735.21 3735.22 -0.0095 -2.54 
  3735.21 3735.22 -0.0095 -2.54 
  3735.21 3735.22 -0.0095 -2.54 
c34 3579.11 3579.118 -0.0084 -2.34 
  3579.11 3579.118 -0.0084 -2.34 
c30 3169.84 3169.85 -0.0095 -2.99 
c29 3068.79 3068.802 -0.0118 -3.84 













c27 2898.69 2898.696 -0.0063 -2.16 
c26 2770.63 2770.638 -0.0077 -2.78 
  2770.63 2770.638 -0.0077 -2.78 
c24 2543.51 2543.511 -0.0007 -0.27 
  2543.51 2543.511 -0.0007 -0.27 
c23 2428.48 2428.484 -0.0038 -1.55 
  2428.48 2428.484 -0.0038 -1.55 
c22 2272.38 2272.383 -0.0026 -1.17 
  2272.38 2272.383 -0.0026 -1.17 
c21 2159.3 2159.299 0.0014 0.65 
c19 1904.1 1904.104 -0.0039 -2.04 
c18 1748 1748.003 -0.0028 -1.58 
c17 1610.94 1610.944 -0.0039 -2.4 
  1610.94 1610.944 -0.0039 -2.4 
c16 1454.84 1454.843 -0.0027 -1.89 
c15 1326.75 1326.748 0.0022 1.67 
c14 1255.71 1255.711 -0.0007 -0.54 
c13 1198.69 1198.689 0.0008 0.65 
  1198.69 1198.689 0.0008 0.65 
c12 1141.66 1141.668 -0.0078 -6.8 
c10 956.548 956.5513 -0.0033 -3.49 
  956.548 956.5513 -0.0033 -3.49 
c9 843.467 843.4673 -0.0003 -0.33 
c8 786.445 786.4458 -0.0008 -1.04 
c7 658.35 658.3509 -0.0009 -1.3 
c6 601.328 601.3294 -0.0014 -2.33 
c5 544.306 544.3079 -0.0019 -3.56 












Assigned fragment ions from CID of MeCP2 Knockout single mouse brain sample 










y49 5527.01 5527.006 0.0043 0.79 
  5527.01 5527.006 0.0043 0.79 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.52 4773.52 0.0004 0.09 
y40 4513.36 4513.367 -0.0071 -1.57 
y39 4384.33 4384.325 0.0055 1.25 
y34 3787.01 3787.001 0.0089 2.36 
y32 3616.9 3616.896 0.0045 1.23 
y31 3515.85 3515.848 0.0021 0.61 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.6 2914.598 0.0018 0.6 
y24 2630.4 2630.402 -0.0022 -0.82 
y23 2502.3 2502.307 -0.0072 -2.88 
y22 2401.27 2401.26 0.0105 4.36 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.04 1884.039 0.0011 0.58 
y16 1784.97 1784.971 -0.0005 -0.27 
  1784.97 1784.971 -0.0005 -0.27 
y15 1685.9 1685.902 -0.0021 -1.23 
  1685.9 1685.902 -0.0021 -1.23 
y14 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.72 1338.718 0.0024 1.81 
y11 1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 




















Mass Error  
(PPM) 
 
y5 499.207 499.2086 -0.0016 -3.25 
b86 9528.44 9528.394 0.0464 4.87 
b84 9314.35 9314.298 0.0518 5.56 
b70 7696.51 7696.469 0.0415 5.39 
  7696.51 7696.469 0.0415 5.39 
b69 7597.43 7597.4 0.0299 3.93 
b68 7526.4 7526.363 0.037 4.92 
b53 5786.4 5786.358 0.0416 7.19 
  5786.4 5786.358 0.0416 7.19 
b52 5657.36 5657.316 0.0442 7.81 
  5657.36 5657.316 0.0442 7.81 
b39 4228.53 4228.496 0.0343 8.11 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.546 996.5465 -0.0005 -0.45 
  996.546 996.5465 -0.0005 -0.45 
b10 939.525 939.525 0 0.01 
b9 826.441 826.4409 0.0001 0.08 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.325 641.3245 0.0005 0.76 
b6 584.303 584.303 0 -0.09 
b5 527.282 527.2816 0.0004 0.78 
b4 399.187 399.1866 0.0004 0.93 














Assigned fragment ions from ECD of MeCP2 Knockout single mouse brain sample 










z101 11168.3 11168.3 -0.0008 -0.07 
z99 10955.2 10955.18 0.0218 1.99 
z98 10898.2 10898.16 0.0432 3.97 
z92 10357.8 10357.82 -0.0184 -1.78 
z89 10115.7 10115.68 0.0195 1.92 
z87 9987.63 9987.622 0.008 0.8 
  9987.63 9987.622 0.008 0.8 
z81 9141.08 9141.092 -0.012 -1.31 
z79 8871.89 8871.907 -0.0168 -1.89 
z78 8756.86 8756.88 -0.0199 -2.27 
z76 8529.74 8529.753 -0.0129 -1.51 
z68 7721.26 7721.272 -0.0122 -1.58 
z67 7565.17 7565.171 -0.0011 -0.14 
z66 7409.06 7409.07 -0.01 -1.35 
z63 7068.84 7068.848 -0.0077 -1.09 
z59 6699.64 6699.635 0.0047 0.71 
z58 6571.54 6571.54 -0.0003 -0.04 
z54 6158.3 6158.302 -0.0016 -0.26 
z51 5769.07 5769.07 -0.0002 -0.03 
z47 5253.84 5253.836 0.0038 0.72 
z43 4856.56 4856.567 -0.0073 -1.51 
z42 4757.49 4757.499 -0.0089 -1.87 
z39 4368.3 4368.304 -0.0039 -0.88 
z32 3600.87 3600.875 -0.0049 -1.36 
z31 3499.82 3499.827 -0.0072 -2.06 
  3499.82 3499.827 -0.0072 -2.06 
z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 
c71 7814.56 7814.543 0.0175 2.23 
c70 7713.51 7713.495 0.0151 1.96 
c63 6946.09 6946.066 0.0241 3.47 
  6946.09 6946.066 0.0241 3.47 













c55 6060.56 6060.534 0.0265 4.37 
c51 5545.32 5545.3 0.0204 3.68 
c48 5156.09 5156.068 0.0219 4.24 
  5156.09 5156.068 0.0219 4.24 
c44 4742.85 4742.83 0.0205 4.33 
  4742.85 4742.83 0.0205 4.33 
c39 4245.54 4245.522 0.0179 4.23 
c36 3905.32 3905.3 0.0202 5.18 
c35 3749.22 3749.199 0.0213 5.69 
c34 3593.12 3593.098 0.0224 6.25 
c26 2784.64 2784.617 0.0231 8.3 
c15 1326.74 1326.748 -0.0078 -5.87 
c13 1198.69 1198.689 0.0008 0.65 


















Assigned fragment ions from CID of MeCP2 Knockout single mouse brain sample 










y63 7084.86 7084.868 -0.0084 -1.18 
y62 6928.79 6928.767 0.0228 3.28 
y50 5656.05 5656.048 0.0018 0.31 
y49 5527 5527.006 -0.0057 -1.02 
  5527 5527.006 -0.0057 -1.02 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.51 4773.52 -0.0096 -2 
y40 4513.36 4513.367 -0.0071 -1.57 
y39 4384.32 4384.325 -0.0045 -1.03 
y35 3902.03 3902.028 0.002 0.51 
y34 3787 3787.001 -0.0011 -0.28 
y32 3616.89 3616.896 -0.0055 -1.53 
y31 3515.84 3515.848 -0.0079 -2.24 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y24 2630.4 2630.402 -0.0022 -0.82 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.04 1884.039 0.0011 0.58 
y16 1784.97 1784.971 -0.0005 -0.27 
  1784.97 1784.971 -0.0005 -0.27 
y15 1685.9 1685.902 -0.0021 -1.23 
y14 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 























y11 1210.62 1210.623 -0.0026 -2.16 
  1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.46 926.4629 -0.0029 -3.16 
y5 499.207 499.2086 -0.0016 -3.25 
b100 11209.3 11209.34 -0.04 -3.57 
b99 11062.3 11062.27 0.0284 2.57 
b85 9457.37 9457.357 0.0135 1.43 
b74 8218.7 8218.701 -0.0011 -0.14 
b70 7724.49 7724.5 -0.0099 -1.28 
b68 7554.38 7554.394 -0.0143 -1.9 
b63 6957.08 6957.071 0.0091 1.31 
b62 6828.03 6828.028 0.0017 0.25 
b53 5814.39 5814.39 0.0003 0.04 
  5814.39 5814.39 0.0003 0.04 
b52 5685.35 5685.347 0.0028 0.5 
  5685.35 5685.347 0.0028 0.5 
b51 5556.31 5556.305 0.0054 0.98 
b40 4412.63 4412.628 0.0018 0.42 
b39 4256.53 4256.527 0.0029 0.69 
  4256.53 4256.527 0.0029 0.69 
b35 3760.2 3760.204 -0.0037 -0.97 
b31 3322.93 3322.929 0.0014 0.42 
b25 2682.54 2682.538 0.0022 0.81 
b24 2568.49 2568.495 -0.0049 -1.9 
  2568.49 2568.495 -0.0049 -1.9 
b23 2453.47 2453.468 0.002 0.84 
  2453.47 2453.468 0.002 0.84 
b19 1929.09 1929.088 0.0019 1 
b17 1635.93 1635.928 0.002 1.19 
  1635.93 1635.928 0.002 1.19 
b15 1309.73 1309.721 0.0086 6.54 
b12 1124.64 1124.641 -0.0014 -1.25 
b11 996.546 996.5465 -0.0005 -0.45 
b10 939.524 939.525 -0.001 -1.05 
  939.524 939.525 -0.001 -1.05 
b9 826.441 826.4409 0.0001 0.08 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 













b7 641.325 641.3245 0.0005 0.76 
b6 584.303 584.303 0 -0.09 
b5 527.282 527.2816 0.0004 0.78 
b4 399.187 399.1866 0.0004 0.93 























Assigned fragment ions from ECD of MeCP2 Knockout single mouse brain sample 










z101 11196.3 11196.33 -0.0321 -2.87 
z100 11139.3 11139.31 -0.0107 -0.96 
z99 10983.2 10983.21 -0.0096 -0.87 
  10983.2 10983.21 -0.0096 -0.87 
z95 10684 10684.05 -0.0502 -4.7 
z89 10143.7 10143.71 -0.0119 -1.17 
  10143.7 10143.71 -0.0119 -1.17 
z87 10015.6 10015.65 -0.0533 -5.32 
z85 9689.43 9689.447 -0.0167 -1.72 
z80 9028 9028.008 -0.0079 -0.88 
z79 8871.9 8871.907 -0.0068 -0.77 
  8871.9 8871.907 -0.0068 -0.77 
z78 8756.88 8756.88 0.0001 0.02 
  8756.88 8756.88 0.0001 0.02 
z76 8529.75 8529.753 -0.0029 -0.34 
  8529.75 8529.753 -0.0029 -0.34 
  8529.75 8529.753 -0.0029 -0.34 
z67 7565.14 7565.171 -0.0311 -4.11 
z66 7409.06 7409.07 -0.01 -1.35 
z65 7295.97 7295.986 -0.0159 -2.18 
z64 7224.94 7224.949 -0.0088 -1.22 
  7224.94 7224.949 -0.0088 -1.22 
z63 7068.84 7068.848 -0.0077 -1.09 
  7068.84 7068.848 -0.0077 -1.09 
z61 6855.71 6855.725 -0.0151 -2.21 
z59 6699.63 6699.635 -0.0053 -0.78 
  6699.63 6699.635 -0.0053 -0.78 
z58 6571.53 6571.54 -0.0103 -1.57 
  6571.53 6571.54 -0.0103 -1.57 
z54 6158.29 6158.302 -0.0116 -1.89 
z51 5769.06 5769.07 -0.0102 -1.76 
  5769.06 5769.07 -0.0102 -1.76 























z49 5510.98 5510.985 -0.005 -0.91 
z47 5253.83 5253.836 -0.0062 -1.18 
  5253.83 5253.836 -0.0062 -1.18 
z43 4856.56 4856.567 -0.0073 -1.51 
z42 4757.49 4757.499 -0.0089 -1.87 
z39 4368.3 4368.304 -0.0039 -0.88 
  4368.3 4368.304 -0.0039 -0.88 
z32 3600.87 3600.875 -0.0049 -1.36 
z31 3499.82 3499.827 -0.0072 -2.06 
  3499.82 3499.827 -0.0072 -2.06 
z29 3235.72 3235.716 0.0038 1.18 
z15 1669.88 1669.881 -0.0014 -0.85 
z14 1506.82 1506.818 0.0019 1.27 
z11 1194.6 1194.602 -0.002 -1.64 
z10 1038.5 1038.501 -0.0009 -0.82 
c91 10147.8 10147.8 0.0009 0.09 
c73 8106.67 8106.685 -0.0149 -1.84 
c55 6088.56 6088.565 -0.0049 -0.8 
c52 5702.37 5702.374 -0.0035 -0.61 
c47 5127.08 5127.078 0.002 0.39 
c44 4770.86 4770.861 -0.0008 -0.17 
c43 4642.76 4642.766 -0.0058 -1.26 
c41 4486.67 4486.676 -0.006 -1.33 
c40 4429.65 4429.655 -0.0045 -1.02 
c39 4273.55 4273.553 -0.0034 -0.8 
c37 4046.41 4046.415 -0.0052 -1.28 
c35 3777.23 3777.23 0 0 
c34 3621.13 3621.129 0.0011 0.3 
c26 2812.65 2812.648 0.0018 0.63 
  2812.65 2812.648 0.0018 0.63 
c24 2585.52 2585.521 -0.0012 -0.48 
  2585.52 2585.521 -0.0012 -0.48 
c23 2470.49 2470.494 -0.0043 -1.74 
c22 2314.39 2314.393 -0.0032 -1.38 
c21 2201.31 2201.309 0.0009 0.4 
c18 1790.01 1790.013 -0.0033 -1.85 
c17 1652.95 1652.954 -0.0044 -2.66 
  1652.95 1652.954 -0.0044 -2.66 
c16 1496.85 1496.853 -0.0033 -2.2 













c15 1326.75 1326.748 0.0022 1.67 
c14 1255.71 1255.711 -0.0007 -0.54 
  1255.71 1255.711 -0.0007 -0.54 
c13 1198.69 1198.689 0.0008 0.65 
  1198.69 1198.689 0.0008 0.65 
c12 1141.67 1141.668 0.0022 1.96 
c10 956.549 956.5513 -0.0023 -2.45 
c9 843.467 843.4673 -0.0003 -0.33 
c8 786.446 786.4458 0.0002 0.23 
c7 658.35 658.3509 -0.0009 -1.3 




















Assigned fragment ions from CID of MeCP2 Knockout single mouse brain sample 










y49 5527 5527.006 -0.0057 -1.02 
  5527 5527.006 -0.0057 -1.02 
y43 4872.59 4872.588 0.002 0.41 
y42 4773.51 4773.52 -0.0096 -2 
y40 4513.36 4513.367 -0.0071 -1.57 
y32 3616.89 3616.896 -0.0055 -1.53 
y30 3352.78 3352.785 -0.0045 -1.35 
y29 3251.73 3251.737 -0.0069 -2.11 
y28 3122.69 3122.694 -0.0043 -1.36 
  3122.69 3122.694 -0.0043 -1.36 
y27 2985.63 2985.635 -0.0053 -1.79 
y26 2914.59 2914.598 -0.0082 -2.83 
y24 2630.4 2630.402 -0.0022 -0.82 
y23 2502.31 2502.307 0.0028 1.11 
y22 2401.26 2401.26 0.0005 0.2 
y21 2302.19 2302.191 -0.0011 -0.49 
y20 2201.14 2201.143 -0.0034 -1.56 
y19 2130.1 2130.106 -0.0063 -2.97 
y18 1999.06 1999.066 -0.0058 -2.92 
y17 1884.04 1884.039 0.0011 0.58 
y16 1784.97 1784.971 -0.0005 -0.27 
  1784.97 1784.971 -0.0005 -0.27 
y15 1685.9 1685.902 -0.0021 -1.23 
y14 1522.84 1522.839 0.0013 0.82 
y13 1451.8 1451.802 -0.0016 -1.13 
y12 1338.72 1338.718 0.0024 1.81 
y11 1210.62 1210.623 -0.0026 -2.16 
y10 1054.52 1054.522 -0.0015 -1.43 
y9 926.461 926.4629 -0.0019 -2.08 
y8 869.44 869.4415 -0.0015 -1.69 
y5 499.207 499.2086 -0.0016 -3.25 
b85 9471.38 9471.336 0.0443 4.68 























b69 7639.45 7639.411 0.0394 5.15 
b53 5828.41 5828.369 0.0411 7.04 
  5828.41 5828.369 0.0411 7.04 
b52 5699.36 5699.326 0.0336 5.9 
  5699.36 5699.326 0.0336 5.9 
b35 3774.22 3774.183 0.0371 9.84 
b11 996.546 996.5465 -0.0005 -0.45 
b10 939.525 939.525 0 0.01 
b9 826.441 826.4409 0.0001 0.08 
b8 769.42 769.4195 0.0005 0.69 
  769.42 769.4195 0.0005 0.69 
b7 641.325 641.3245 0.0005 0.76 
b5 527.282 527.2816 0.0004 0.78 



















Assigned fragment ions from ECD of MeCP2 Knockout single mouse brain sample 










z101 11210.33 11210.35 -0.0178 -1.59 
z85 9703.46 9703.462 -0.002 -0.2 
  9703.46 9703.462 -0.002 -0.2 
z84 9566.397 9566.403 -0.0062 -0.65 
  9566.397 9566.403 -0.0062 -0.65 
z79 8871.898 8871.907 -0.0093 -1.05 
z78 8756.877 8756.88 -0.0033 -0.38 
z76 8529.745 8529.753 -0.0081 -0.95 
z68 7721.268 7721.272 -0.0039 -0.5 
z66 7409.07 7409.07 -0.0003 -0.04 
z64 7224.953 7224.949 0.0045 0.62 
z63 7068.859 7068.848 0.0112 1.58 
z59 6699.649 6699.635 0.0138 2.06 
z54 6158.3 6158.302 -0.0019 -0.3 
z51 5769.071 5769.07 0.0008 0.14 
z43 4856.566 4856.567 -0.001 -0.2 
z42 4757.505 4757.499 0.0061 1.28 
z39 4368.305 4368.304 0.0013 0.31 
z32 3600.871 3600.875 -0.0037 -1.03 
z31 3499.819 3499.827 -0.0079 -2.24 
z14 1506.817 1506.818 -0.0013 -0.84 
z11 1194.603 1194.602 0.0014 1.16 
z10 1038.501 1038.501 0 0.02 
c101 11297.37 11297.4 -0.0359 -3.18 
  11297.37 11297.4 -0.0359 -3.18 
  11297.37 11297.4 -0.0359 -3.18 
  11297.37 11297.4 -0.0359 -3.18 
c100 11240.35 11240.38 -0.0362 -3.22 
c63 6988.107 6988.113 -0.0065 -0.93 
c60 6598.904 6598.918 -0.0138 -2.09 
c52 5716.381 5716.389 -0.0081 -1.41 
c51 5587.336 5587.347 -0.011 -1.97 























c24 2599.529 2599.537 -0.0079 -3.03 
c23 2484.503 2484.51 -0.0068 -2.75 
c18 1790.011 1790.013 -0.002 -1.09 
c17 1652.952 1652.955 -0.0021 -1.27 
c16 1496.85 1496.853 -0.0032 -2.14 























Assigned fragment ions from CID of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 408 m/z).  The list shows ions corresponding to 










y22 2314.435 2314.443 -0.0085 -3.66 
  2314.435 2314.443 -0.0085 -3.66 
y18 1916.197 1916.204 -0.007 -3.65 
  1916.197 1916.204 -0.007 -3.65 
  1916.197 1916.204 -0.007 -3.65 
y17 1859.177 1859.183 -0.0056 -3 
y15 1674.062 1674.066 -0.0039 -2.34 
  1674.062 1674.066 -0.0039 -2.34 
y14 1617.042 1617.045 -0.0029 -1.82 
y13 1503.956 1503.961 -0.005 -3.32 
  1503.956 1503.961 -0.005 -3.32 
  1503.956 1503.961 -0.005 -3.32 
y12 1446.935 1446.939 -0.0041 -2.83 
y11 1318.837 1318.844 -0.0068 -5.18 
  1318.837 1318.844 -0.0068 -5.18 
  1318.837 1318.844 -0.0068 -5.18 
y10 1261.816 1261.823 -0.0072 -5.75 
y6 849.5627 849.5681 -0.0053 -6.27 
y5 712.5024 712.5092 -0.0067 -9.42 
y4 556.4058 556.408 -0.0022 -3.99 
y3 386.2623 386.2661 -0.0038 -9.86 
b12 1124.638 1124.641 -0.0031 -2.75 
  1124.638 1124.641 -0.0031 -2.75 
b11 996.5446 996.5465 -0.0019 -1.93 
b10 939.5226 939.525 -0.0024 -2.52 
b9 826.4417 826.441 0.0008 0.92 
b8 769.4174 769.4195 -0.0021 -2.68 
  769.4174 769.4195 -0.0021 -2.68 
b7 641.3248 641.3245 0.0003 0.41 
b5 527.2812 527.2816 -0.0005 -0.85 





Assigned fragment ions from CID of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 408 m/z).  The list shows ions corresponding to 










y18 1902.182 1902.188 -0.0063 -3.29 
y15 1660.047 1660.05 -0.003 -1.84 
y14 1603.026 1603.029 -0.0029 -1.83 
y13 1489.94 1489.945 -0.0045 -3.02 
y12 1432.919 1432.923 -0.0045 -3.12 
y11 1304.823 1304.829 -0.0056 -4.28 
  1304.823 1304.829 -0.0056 -4.28 
y6 835.5473 835.5524 -0.005 -6.03 
y4 542.3899 542.3923 -0.0024 -4.42 
y3 386.2623 386.2661 -0.0038 -9.86 
b22 2255.36 2255.356 0.0032 1.44 
b12 1124.638 1124.641 -0.0031 -2.75 
  1124.638 1124.641 -0.0031 -2.75 
b11 996.5446 996.5465 -0.0019 -1.93 
b10 939.5226 939.525 -0.0024 -2.52 
b9 826.4417 826.441 0.0008 0.92 
b8 769.4174 769.4195 -0.0021 -2.68 
  769.4174 769.4195 -0.0021 -2.68 
b7 641.3248 641.3245 0.0003 0.41 
b5 527.2812 527.2816 -0.0005 -0.85 













Assigned fragment ions from ECD of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 408 m/z).  The list shows ions corresponding to 










z22 2298.396 2298.422 -0.0268 -11.64 
  2298.396 2298.422 -0.0268 -11.64 
z21 2241.376 2241.401 -0.0252 -11.23 
z20 2085.276 2085.3 -0.0234 -11.23 
z19 2028.256 2028.278 -0.0224 -11.04 
z16 1786.12 1786.14 -0.0207 -11.6 
z15 1658.026 1658.045 -0.019 -11.47 
z14 1601.007 1601.024 -0.0171 -10.7 
z12 1430.903 1430.919 -0.0154 -10.79 
z10 1245.788 1245.802 -0.0139 -11.17 
z9 1188.768 1188.781 -0.0128 -10.78 
z8 1117.731 1117.744 -0.0123 -11.02 
z7 989.6377 989.6485 -0.0109 -10.97 
z6 833.5375 833.5474 -0.0099 -11.91 
z5 696.4789 696.4885 -0.0096 -13.81 
c22 2286.373 2286.398 -0.0258 -11.28 
c21 2173.29 2173.314 -0.0239 -11 
c20 2074.223 2074.246 -0.0232 -11.2 
c19 1904.083 1904.104 -0.0214 -11.24 
  1904.083 1904.104 -0.0214 -11.24 
c18 1747.983 1748.003 -0.0196 -11.21 
c17 1610.927 1610.944 -0.0174 -10.78 
c16 1454.827 1454.843 -0.0154 -10.61 
c15 1326.733 1326.748 -0.015 -11.28 
c14 1255.696 1255.711 -0.0149 -11.88 
c11 1013.562 1013.573 -0.011 -10.86 




Assigned fragment ions from ECD of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 408 m/z).  The list shows ions corresponding to 













z15 1644.011 1644.03 -0.0183 -11.16 
c19 1904.083 1904.104 -0.0214 -11.24 
  1904.083 1904.104 -0.0214 -11.24 
c18 1747.983 1748.003 -0.0196 -11.21 
c17 1610.927 1610.944 -0.0174 -10.78 
c16 1454.827 1454.843 -0.0154 -10.61 
c15 1326.733 1326.748 -0.015 -11.28 
c14 1255.696 1255.711 -0.0149 -11.88 
c11 1013.562 1013.573 -0.011 -10.86 




















Assigned fragment ions from CID of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 490 m/z).  The list shows ions corresponding to 










y22 2314.441 2314.443 -0.0019 -0.81 
  2314.441 2314.443 -0.0019 -0.81 
y20 2101.318 2101.32 -0.0024 -1.14 
y18 1916.204 1916.204 0.0002 0.08 
  1916.204 1916.204 0.0002 0.08 
y17 1859.171 1859.183 -0.0116 -6.23 
  1859.171 1859.183 -0.0116 -6.23 
  1859.171 1859.183 -0.0116 -6.23 
y16 1802.159 1802.161 -0.0026 -1.44 
  1802.159 1802.161 -0.0026 -1.44 
y15 1674.064 1674.066 -0.002 -1.2 
  1674.064 1674.066 -0.002 -1.2 
  1674.064 1674.066 -0.002 -1.2 
y14 1617.035 1617.045 -0.0097 -6 
  1617.035 1617.045 -0.0097 -6 
  1617.035 1617.045 -0.0097 -6 
y13 1503.957 1503.961 -0.0033 -2.22 
  1503.957 1503.961 -0.0033 -2.22 
  1503.957 1503.961 -0.0033 -2.22 
y11 1318.842 1318.844 -0.0021 -1.63 
  1318.842 1318.844 -0.0021 -1.63 
y10 1261.819 1261.823 -0.0036 -2.88 
y6 849.5659 849.5681 -0.0022 -2.57 
  849.5659 849.5681 -0.0022 -2.57 
y5 712.5065 712.5092 -0.0026 -3.69 
b22 2269.372 2269.372 0.0001 0.07 
b19 1887.075 1887.078 -0.003 -1.6 
b17 1593.917 1593.918 -0.0008 -0.48 
b12 1124.641 1124.641 -0.0005 -0.42 
  1124.641 1124.641 -0.0005 -0.42 
b11 996.546 996.5465 -0.0005 -0.51 
  996.546 996.5465 -0.0005 -0.51 
b10 939.5246 939.525 -0.0004 -0.47 












     
  939.5246 939.525 -0.0004 -0.47 
b9 826.4405 826.441 -0.0004 -0.51 
b8 769.4191 769.4195 -0.0004 -0.53 
  769.4191 769.4195 -0.0004 -0.53 
b7 641.3246 641.3245 0.0001 0.16 
b6 584.303 584.3031 -0.0001 -0.22 
b5 527.2816 527.2816 0 0.04 
b4 399.1866 399.1867 -0.0001 -0.25 
b3 342.165 342.1652 -0.0002 -0.47 
 
 
Assigned fragment ions from CID of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 490 m/z).  The list shows ions corresponding to 










y18 1902.186 1902.188 -0.0021 -1.08 
  1902.186 1902.188 -0.0021 -1.08 
y15 1660.048 1660.05 -0.0022 -1.34 
  1660.048 1660.05 -0.0022 -1.34 
y14 1603.027 1603.029 -0.0016 -0.99 
y13 1489.938 1489.945 -0.0065 -4.35 
  1489.938 1489.945 -0.0065 -4.35 
  1489.938 1489.945 -0.0065 -4.35 
y11 1304.828 1304.829 -0.0009 -0.67 
  1304.828 1304.829 -0.0009 -0.67 
y6 835.5501 835.5524 -0.0023 -2.75 
y4 542.3904 542.3923 -0.0019 -3.54 
b19 1887.075 1887.078 -0.003 -1.6 
b17 1593.917 1593.918 -0.0008 -0.48 
b12 1124.641 1124.641 -0.0005 -0.42 
  1124.641 1124.641 -0.0005 -0.42 
b11 996.546 996.5465 -0.0005 -0.51 
  996.546 996.5465 -0.0005 -0.51 
b10 939.5246 939.525 -0.0004 -0.47 



















 Observed     













     
b9 826.4405 826.441 -0.0004 -0.51 
b8 769.4191 769.4195 -0.0004 -0.53 
  769.4191 769.4195 -0.0004 -0.53 
b7 641.3246 641.3245 0.0001 0.16 
b6 584.303 584.3031 -0.0001 -0.22 
b5 527.2816 527.2816 0 0.04 
b4 399.1866 399.1867 -0.0001 -0.25 





















Assigned fragment ions from ECD of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 490 m/z).  The list shows ions corresponding to 










y22 2314.441 2314.443 -0.0019 -0.81 
  2314.441 2314.443 -0.0019 -0.81 
y20 2101.318 2101.32 -0.0024 -1.14 
y18 1916.204 1916.204 0.0002 0.08 
  1916.204 1916.204 0.0002 0.08 
y17 1859.171 1859.183 -0.0116 -6.23 
  1859.171 1859.183 -0.0116 -6.23 
  1859.171 1859.183 -0.0116 -6.23 
y16 1802.159 1802.161 -0.0026 -1.44 
  1802.159 1802.161 -0.0026 -1.44 
y15 1674.064 1674.066 -0.002 -1.2 
  1674.064 1674.066 -0.002 -1.2 
  1674.064 1674.066 -0.002 -1.2 
y14 1617.035 1617.045 -0.0097 -6 
  1617.035 1617.045 -0.0097 -6 
  1617.035 1617.045 -0.0097 -6 
y13 1503.957 1503.961 -0.0033 -2.22 
  1503.957 1503.961 -0.0033 -2.22 
  1503.957 1503.961 -0.0033 -2.22 
y11 1318.842 1318.844 -0.0021 -1.63 
  1318.842 1318.844 -0.0021 -1.63 
y10 1261.819 1261.823 -0.0036 -2.88 
y6 849.5659 849.5681 -0.0022 -2.57 
  849.5659 849.5681 -0.0022 -2.57 
y5 712.5065 712.5092 -0.0026 -3.69 
b22 2269.372 2269.372 0.0001 0.07 
b19 1887.075 1887.078 -0.003 -1.6 
b17 1593.917 1593.918 -0.0008 -0.48 
b12 1124.641 1124.641 -0.0005 -0.42 
  1124.641 1124.641 -0.0005 -0.42 
b11 996.546 996.5465 -0.0005 -0.51 



















     
  939.5246 939.525 -0.0004 -0.47 
b9 826.4405 826.441 -0.0004 -0.51 
b8 769.4191 769.4195 -0.0004 -0.53 
  769.4191 769.4195 -0.0004 -0.53 
b7 641.3246 641.3245 0.0001 0.16 
b6 584.303 584.3031 -0.0001 -0.22 
b5 527.2816 527.2816 0 0.04 
b4 399.1866 399.1867 -0.0001 -0.25 
b3 342.165 342.1652 -0.0002 -0.47 
 
 
Assigned fragment ions from ECD of wild type single mouse brain sample digested with 
endo-proteinase Asp-N (precursor ion at 490 m/z).  The list shows ions corresponding to 










y18 1902.186 1902.188 -0.0021 -1.08 
  1902.186 1902.188 -0.0021 -1.08 
y15 1660.048 1660.05 -0.0022 -1.34 
  1660.048 1660.05 -0.0022 -1.34 
y14 1603.027 1603.029 -0.0016 -0.99 
y13 1489.938 1489.945 -0.0065 -4.35 
  1489.938 1489.945 -0.0065 -4.35 
  1489.938 1489.945 -0.0065 -4.35 
y11 1304.828 1304.829 -0.0009 -0.67 
  1304.828 1304.829 -0.0009 -0.67 
y6 835.5501 835.5524 -0.0023 -2.75 
y4 542.3904 542.3923 -0.0019 -3.54 
b19 1887.075 1887.078 -0.003 -1.6 
b17 1593.917 1593.918 -0.0008 -0.48 
b12 1124.641 1124.641 -0.0005 -0.42 
  1124.641 1124.641 -0.0005 -0.42 
b11 996.546 996.5465 -0.0005 -0.51 
  996.546 996.5465 -0.0005 -0.51 
b10 939.5246 939.525 -0.0004 -0.47 


























Mass Error  
(PPM) 
     
b9 826.4405 826.441 -0.0004 -0.51 
b8 769.4191 769.4195 -0.0004 -0.53 
  769.4191 769.4195 -0.0004 -0.53 
b7 641.3246 641.3245 0.0001 0.16 
b6 584.303 584.3031 -0.0001 -0.22 
b5 527.2816 527.2816 0 0.04 
b4 399.1866 399.1867 -0.0001 -0.25 
























 Annual RASOR Conference (November 2008).  Drymen, UK. 




 EMSG Symposium (September 2009).  Ardgour, UK. 




 Annual RASOR Conference (December 2009).  Stirling, UK. 
Poster:  Lactate is an Inhibitor of Histone De-Acetylation. 
 
Summer School in Mass Spectrometry for Biotechnology and Medicine (July 2010).  
Dubrovnik, Croatia. 
Poster and Oral Presentation:  Characterising Histone Modifications during senescence 
by FT-ICR MS. 
 
Edinburgh Physical Chemistry PhD Meeting (August 2010).  Firbush, UK. 




 EMSG Symposium (September 2010).  Ardgour, UK. 
Oral Presentation:   Characterising Histone Modifications in senescent cells by FT-ICR 
MS 
 
Mass Spectrometry for the Medical and Life Sciences:  The Role of High Field FT-ICR 











 ASMS Conference on Mass Spectrometry and Allied Topics (May 2011).  Denver, 
Colorado, USA. 
Poster:  Analysis of histone post-translational modifications specific to Rett syndrome by 
FT-ICR mass spectrometry. 
Poster:  Top-Down Precursor Acquisition Independent From Ion Count. 
 
Edinburgh Physical Chemistry PhD Meeting (August 2011).  Firbush, UK. 
Oral Presentation:  Fourier Transform Ion Cyclotron Resonance Mass Spectrometry of 




 EMSG Symposium (September 2011).  Ardgour, UK. 
Oral Presentation:  Fourier Transform Ion Cyclotron Resonance Mass Spectrometry of 
Histone Proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
 
 
 
 
 
 
 
 
 
 
Publication Reprints 
 
 
 
 
 
 
 
 
 
 
 
127 
 
 
 
